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 10 General introduction
Low back pain is a common disorder in industrialised countries, causing high expenses to 
society. The chance that someone may experience low back pain during her/ his life is 49 to 
70%(1). Reported one-year prevalences in the general population range from 14 to 55%(2-4). 
In the Netherlands alone, low back pain related expenses for medical care and work absen-
teeism were estimated in 1991 over four billion Euro(5). 
In most cases (80-95%) there is for low back pain no identiﬁ able pathophysiological origin, 
such as infection, inﬂ ammation, herniated nuclei pulposi, tumor or osteoporotic fracture(6). 
Such type of low back pain without a speciﬁ c cause is the main topic of this thesis and is 
often labelled as non-speciﬁ c low back pain. Characteristic symptoms of non-speciﬁ c low 
back pain are pain in the lumbar sacral region, possibly radiating to the legs, and decreased 
physical functioning. Other symptoms like decreased muscle strength, limited range of 
motion and stiffness correlate only modestly with low back pain(7). The prognosis for 
non-speciﬁ c low back pain is usually good, as complaints improve rapidly within weeks. 
However, recurrences are common(8). When speciﬁ c pathology can be excluded, the ﬁ rst 
step in the management of low back pain is to reassure that this condition is likely to 
resolve rapidly; advise to stay active and continue daily activities; if necessary, supported by 
prescribing analgesics. When complaints persist over 6 weeks, guided activating therapies, 
for example by a physiotherapis should be considered(9, 10). 
Health care workers are at increased risk for low back pain, with reported one-year preva-
lences ranging from 44 to 77%(11-13). This explains the availability of a variety of devices and 
treatments in this setting to prevent or relief low back pain, from patient lift to cherry stone 
bag. This thesis focuses on one preventive device in particular, lumbar supports, of which 
we studied its effectiveness in a population of home care workers. 
Lumbar supports are relatively unknown in the Netherlands, but are frequently used to 
prevent the onset of low back pain for example in the United States of America. Lumbar 
supports are anatomically contoured orthoses with hoop and loop fastening, available in 
different shapes and sizes. They resemble a corset. Figure 1 shows an example of a lumbar 
support. From systematic reviews it is known that lumbar supports are likely to be ineffec-
tive in preventing incident cases of low back pain(14, 15). However, in the preventive studies 
beneﬁ cial effects were reported for subgroups of workers with previous exacerbations of 
low back pain(16, 17). 
To aim at preventing the emergence of low back pain symptoms for people with a history 
of low back pain is called secondary prevention(18), also known as indicated prevention(19). 
This might be considered as a non-medical management option, before or in addition to 
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applying analgesics or therapeutic interventions. As valid evidence from studies geared 
toward this secondary preventive application of lumbar supports was lacking, the following 
primary objectives were stated:
- How effective are lumbar supports additionally to usual care, in reducing complaints and 
absence of work in home care workers with recurrent low back pain?
- What is the cost-effectiveness of the application of such a device? 
Secondary objectives of this thesis were: 
- How effective are NSAIDs and COX-2 inhibitors used to treat non-speciﬁ c low-back 
pain, and which type of NSAID is most effective? Prescribing medication is the most 
common treatment option for low back pain, which in 80% of the cases is an NSAID(20).
- Is it possible to explore the effect of lumbar supports on working postures of home care 
workers with ambulatory accelerometry? Potential biomechanical mechanisms of action 
of lumbar supports are still under debate.
- Which determinants explain why home care workers adhere to the use of a lumbar sup-
port? To target the use of lumbar supports on those patients who optimally can beneﬁ t 
from usage and to reduce barriers to enhance future adherence, one needs to know why 
people are adherent.  
Figure 1. Example of  a lumbar support.
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Thesis outline
This thesis describes ﬁ ve separately published or submitted articles. 
Chapter 2 describes a randomised controlled trial evaluating the effectiveness of lumbar 
supports in addition to the available primary and secondary care as usual, offered to home 
care workers with a history of low back pain episodes.
The low back pain related costs were monitored alongside the previous effectiveness trial. 
Chapter 3 focuses on the economical effects on a societal level of administering a lumbar 
support in addition to usual care. 
In Chapter 4 the effectiveness of NSAIDs for low back pain is examined in a systematic 
review. 
Chapter 5 describes the exploration of a possible biomechanical mechanism of the lum-
bar support, using an ambulatory measurement device. It was piloted if it was possible to 
observe differences in working postures caused by a lumbar support, during a working day 
of maternity nurses.
In Chapter 6 attitude, social support and self-efﬁ cacy determinants for prolonged adhe-
rence to a lumbar support usage is explored. 
The ﬁ nal Chapter 7 reﬂ ects on the highlights, limitations, practical implications, and impli-
cations for future research of the studies presented in this thesis, followed by a summary in 
both English and Dutch. 
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 16 Lumbar supports to prevent recurrent low back pain
Background: People use lumbar supports to prevent low back pain. Secondary analyses 
from primary preventive studies suggest benefi t among workers with previous low back pain, 
but defi nitive studies on the effectiveness of  supports for the secondary prevention of  low 
back pain are lacking.
Objective: To determine the effectiveness of  lumbar supports in the secondary prevention 
of  low back pain.
Design: Randomized, controlled trial.
Setting: Home care organization in the Netherlands.
Patients: 360 home care workers with self-reported history of  low back pain.
Intervention: Short course on healthy working methods, with or without patient-directed 
use of  1 of  4 types of  lumbar support.
Measurements: Primary outcomes were the number of  days of  low back pain and sick 
leave over 12 months. Secondary outcomes were average severity of  low back pain and func-
tion (Quebec Back Pain Disability scale) in the previous week.
Results: Over 12 months, participants in the lumbar support group reported an average 
of  -52.7 days (CI, -59.6 to -45.1 days) fewer days with low back pain than participants who 
received only the short course. However, the total sick days in the lumbar support group did 
not decrease (-5 days [CI, -21.1 to 6.8 days]). Small but statistically signifi cant differences in 
pain intensity and function favored lumbar support.
Limitations: Study participants were unblinded, and a substantial amount of  missing data 
required imputation. Objective data on sick days due to low back pain were not available.
Conclusions: Adding patient-directed use of  lumbar supports to a short course on healthy 
working methods may reduce the number of  days on which low back pain occurs, but not 
overall work absenteeism, among home care workers with previous low back pain. Further 
study of  lumbar supports is warranted.
ISRCTN registration number: ISRCTN73707379. 
Abstract
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Low back pain is a common problem that results in high medical expenses, work absentee-
ism, and disability(1). The reported 1-year prevalence ranges from 15% to 40% in a general 
population(2) and from 44% to 72% among home care workers(3, 4). Various ergonomic aids 
are marketed for the prevention of low back pain. Workers frequently use lumbar supports 
to prevent back pain(5), but the effectiveness of such supports remains unclear.
Recent systematic reviews of the sparse evidence on lumbar supports(6, 7) concluded that no 
evidence exists for the effectiveness of lumbar supports in the primary prevention of low 
back pain in the workplace, but 2 of the 4 included RCTs(8, 9) reported that lumbar sup-
ports might be effective in workers with a history of low back pain (secondary prevention). 
However, these ﬁ ndings were derived from subgroup analyses, and evidence from direct 
research on secondary prevention was not available.
In cohort studies, a history of low back pain proved to be a strong predictor for the inci-
dence of new episodes of low back pain(8, 10, 11). Home care workers with a history of low 
back pain may therefore be well suited to secondary preventive measures. In a previous 
uncontrolled feasibility study, we found that home care workers who had frequent episodes 
of low back pain reported compliance rates of 61% to 81% with lumbar supports and a 
45% decrease in pain intensity when using lumbar supports(12). We designed the current 
trial to evaluate the effectiveness of adding worker-directed use of lumbar supports to a 
short course on healthy working methods, to reduce low back pain and work absenteeism 
among home care workers with a history of low back pain.
Methods
Design
Our randomized, controlled trial included two groups. The control group received a short 
refresher course on healthy working methods provided by their employer at the start of 
their employment (Appendix); primary and secondary care for the management of low 
back pain was available as usual(13). The intervention group received a lumbar support in 
addition to usual care. The intervention and data collection continued for 12 months after 
enrollment. The Medical Ethical Committee of the Erasmus University Medical Center, 
Rotterdam, the Netherlands, approved the study.
Participants
All participants were recruited from employees of a large home care organization in Rot-
terdam. During staff meetings, all present team members completed a brief survey about 
study inclusion criteria that was distributed and collected by the team managers. We inclu-
ded persons who performed medical care or domestic tasks as a home care worker, were 
experiencing low back pain symptoms at the time of inquiry or had experienced 2 or more 
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episodes (on ≥2 consecutive days) of low back pain symptoms in the 12 months before 
the inquiry, did not have speciﬁ c low back pain (for example, due to rheumatoid arthritis or 
vertebral fractures), and were not pregnant at the start of the study. Because of a possible 
association between lumbar supports and increased blood pressure and heart rate, we ex-
cluded workers receiving medical treatment for high blood pressure(14). Employees who met 
the inclusion criteria received detailed information about the trial, and those who agreed to 
participate provided written consent.
Randomization
In the Netherlands, home care workers provide 1 of 8 functions, each of which requires 
different skills and tasks. To ensure a balance in workload and working conditions between 
the 2 study groups, we stratiﬁ ed randomization by these 8 functions. We also stratiﬁ ed 
randomization by low back pain experience at baseline (current pain vs. past pain). The 
randomization process used a computer-generated random number table with 16 strata 
(2 low back pain by 8 workplace functions), arranged in blocks of 8 within each stratum. 
After baseline measurements were completed, colleagues who were not otherwise involved 
in the study and who were blinded to participants’ baseline characteristics used the ran-
dom-number table to allocate each participant to 1 of the study groups.
Interventions
All participants in the intervention group were instructed to wear the lumbar supports on 
working days on which they had or expected they might develop low back pain. Partici-
pants could select 1 of 4 types of lumbar supports, supplied by Bauerfeind B.V., Haarlem, 
the Netherlands. LumboTrain and LumboTrain Lady are individually adjustable, hook-
and-loop fastening, fully elastic supports that are available in 5 sizes for men or women. 
LumboLoc and LordoLoc are more structured supports, with integrated stays in the back. 
LumboLoc and LordoLoc have individually adjustable hook-and-loop fastenings and are 
available in 6 sizes. Participants chose the lumbar support on the basis of ﬁ t and wearing 
comfort, and they were not given advice to direct their choice from among the 4 available 
supports. When measured by the researcher for the lumbar support, the participants were 
advised to wear the support for a few days in a row, regardless of low back pain, in order to 
become accustomed to it. The expected duration of wearability of the lumbar supports was 
1 year. The costs of the lumbar supports were €75 for LumboTrain and LumboTrain Lady, 
€56 for LumboLoc, and €50 for LordoLoc.
Outcome Measures
Our primary outcome measures were the number of days on which participants reported 
low back pain per month and the number of calendar days of sick leave that participants 
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took during the 12-month intervention period. Secondary outcome measures were average 
severity of low back pain in the previous week, rated on a scale of 0 to 10(15), and functio-
nal status in the previous week, measured by using a Dutch translation of the Quebec Back 
Pain Disability Scale (on which 0 corresponds to no disablement and 100 corresponds to 
fully disabled)(16, 17).
Participants used a calendar to record the days per month on which they experienced low 
back pain. The intervention group was also asked to record on the calendar whether they 
had worn the lumbar support; thus, the calendars also served as a monitor for adherence 
to therapy. The calendars were collected for review after 1, 3, 6, 9, and 12 months. The 
number of calendar days of sick leave was derived from the staff register and was provided 
by the home care organization at the end of the study; this information covered 15 months, 
from 3 months before the start of the study until the end of the intervention period. We 
could gather only general data on sick leave because employees are not obliged to specify 
their illness for the employer when they report themselves ill, and registration by a compa-
ny doctor starts from 6 consecutive weeks of sick leave. We collected information on self-
reported low back pain–related sick leave; however, this was not a predetermined outcome, 
and the results should be interpreted cautiously.
We administered a questionnaire at baseline to obtain information on the secondary 
outcome measures and demographic characteristics; history of low back pain; job charac-
teristics (among others, the Job Content Questionnaire, Dutch translation(18)); and other 
possible confounders, such as additional work (hours per week and type), preference for 
study group assignment, conﬁ dence in pain reduction with use of the lumbar support (scale 
of 0 to 10), and conﬁ dence in improved functioning (scale of 0 to 10). Follow-up question-
naires were administered at 3, 6, 9, and 12 months to measure the secondary outcomes; in 
the intervention group, these questionnaires also measured the general satisfaction with the 
lumbar support (scale of 0 to 10), several items on comfort of wearing (5-point Likert scale) 
and adherence to use of the lumbar support (7-point Likert scale). We recorded spontane-
ously reported side events and asked participants about side effects in the questionnaires.
Statistical Analysis
We estimated that with a power of 80%, a signiﬁ cance level of 0.05, and an SD of 20 days, 
we would need 140 participants in each study group to demonstrate a difference of 7 days 
of low back pain per year or sick leave per year between the 2 groups. To prevent inade-
quate power because of participant withdrawal or low adherence to therapy, we sought to 
enroll 400 home health care workers.
We used a longitudinal marginal model with generalized estimating equation estimates 
to analyze the data, according to intention-to-treat principles. For the primary outcomes 
(number of days of low back pain and number of days of sick leave), we used a 
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negative-binomial count data model with a log-link and an exchangeable correlation struc-
ture. Covariates (history of low back pain, body mass index, additional work, and pregnan-
cy during follow-up) were added to the model separately and were used in the ﬁ nal model 
if they statistically signiﬁ cantly contributed to the model (P < 0.05). The scale scores of the 
secondary outcomes were analyzed by using a normal distributed model and an exchange-
able correlation structure.
To investigate model misspeciﬁ cation and the effect of missing data, we performed sensiti-
vity analyses in which we used various structures for the working correlation to estimate the 
models and used multiple imputation techniques to analyze 5 imputed data sets for missing 
data (19). For all analyses, we used SAS, version 9.1.3 (SAS Institute, Cary, North Carolina).
Role of  the Funding Source
ZonMw is the national health council appointed by the Ministry of Health and the Nether-
lands Organization for Scientiﬁ c Research to promote quality and innovation in the ﬁ eld of 
health research and care. The ZonMw Thuiszorgtechnologie Fonds funded this study. Lum-
bar supports were supplied free of charge by Bauerfeind B.V., Haarlem, the Netherlands. 
ZonMw and Bauerfeind B.V. played no role in the design, conduct, or analysis of this study 
or in the decision to submit the manuscript for publication.
Results
Participants
Between May and October 2003, 96 team managers returned 1355 inquiry forms. On 
these forms, 811 (60%) home care workers reported an episode of low back pain in the 
previous week or at least 2 episodes of low back pain in the past year. Of the 708 eligible 
home care workers, 360 (51%) completed the baseline questionnaire; 183 were randomly 
allocated to the intervention group and 177 to the control group (Figure 1). All participants 
completed the 12-month intervention period by the end of November 2004.
Table 1 shows baseline characteristics of the sample. Except for sick leave in the 3 months 
before the start of the intervention, the 2 study groups did not differ substantially at base-
line. During the 12-month intervention, 66 participants (18%) withdrew from the 
self-reported measures, and data on sick leave registration were lost for 13 persons (4%) 
(12 were dismissed, and 1 died).
Figure 1 shows the distribution of the participants and reasons for withdrawal. In total, 
327 persons (91%) returned calendars reporting the number of days of low back pain per 
month. On average, information was received for 8.7 calendar months (SD 4.2; median, 
11; range, 0 to 12). The mean registration period for sick leave after the randomization was 
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1355 home care workers 
addressed by team managers
Excluded (n= 995) 
No LBP (n= 544) 
Not meeting inclusion criteria (n= 103)
Unwilling to participate (n= 308) 
Other reasons (n= 40)
Allocated to control (n= 177)
Received usual care (n= 177 )
Allocated to intervention (n= 183)
Received lumbar support (n= 180)
Did not receive lumbar support (n= 3)
Abandoned participation due to other health
complaints (n= 1)
Participation too much effort (n= 2)
Lost to follow-up (n=42)
Participation too much effort (n= 4)
Personal circumstances (n= 2)
Other health complaints (n= 10)
Unknown (n= 11)
Pregnant * (n= 2)
Lumbar support uncomfortable and no 
experienced benefit * (n= 3)
Therapist advised against support * (n= 1)
Dismissal from job (n= 8)
Deceased (n= 1)
Discontinued intervention (n=16)
Pregnant (n= 8)
Lumbar support uncomfortable and no 
experienced benefit (n= 6)
Lost lumbar support (n= 1)
Other health complaints (n= 1)
Lost to follow-up (n=24)
Participation too much effort (n= 4)
Personal circumstances (n= 2)
Other health complaints (n= 5)
Unknown (n= 8)
Bought lumbar support privately * (n= 1)
Dismissal from job (n= 4)
Discontinued usual care (n=2)
Bought lumbar support privately (n=2)
Randomized (n= 360)
Analyzed
Days LBP per month (n= 183) †
Sick leave (n= 183) ‡
LBP previous week (n= 183) §
Functional status previous week (n= 183) §
Analyzed
Days LBP per month (n= 177) †
Sick leave (n= 177) ‡
LBP previous week (n= 177) §
Functional status previous week (n= 177 ) §
A
llo
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n
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llo
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Figure 1. Study fl ow diagram.
LBP = low back pain. 
* Participants also cited “too much effort” and “unwilling to fi ll in questionnaires.” 
† 25% missing data. 
‡ 1% missing data. 
§ 20% missing data.
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11.9 months (SD, 0.7; median, 12; range, 5 to 12). For the follow-up questionnaires, the 
average response rate was 80% (84% at 3 months, 79% at 6 months, 77% at 9 months, 
and 79% at 12 months). The baseline characteristics of persons lost to follow-up did not 
differ statistically signiﬁ cant from those who completed the study.
Table 1. Baseline Characteristics of  Participants in Intervention and Control Groups
Characteristic Lumbar Support Group Control Group
  (n = 183) (n = 177)
Mean age (SD, range), y 41.8 (9.7, 19–62) 41.5 (9.8, 20–60)
Women, n (%) 180 (98) 172 (97)
Mean BMI (SD), kg/m2 26.6 (5.6) 27.1 (5.4)
Dutch/Caucasian ethnicity, n (%) 133 (73) 123 (70)
Mean time spent working (SD), h/wk 25.3 (7.9) 24.4 (8.4)
Employed with current home care  52 (29) 53 (30)
organization <3 years, n (%)
Home care function, n (%)   
 Domestic care A 60 (33) 59 (33)
 Domestic care B 42 (23) 40 (23)
 Nursing C 23 (13) 26 (15)
 Nursing D 16 (9) 15 (8)
 Medical nursing E 6 (3) 3 (2)
 Medical nursing F 9 (5) 9 (5)
 Ambulatory care 11 (6) 11 (6)
 Maternity care 16 (9) 14 (8)
Mean additional time spent working (SD), h/wk 1.2 (4.1) 0.6 (2.7)
Have had LBP episodes for >1 year, n (%) 166 (91) 159 (90)
LBP in the past 12 months, n (%)  
 1–2 episodes 28 (15) 32 (18)
 3–5 episodes 43 (24) 33 (19)
 >5 episodes 65 (35) 52 (29)
 Continuous 47 (26) 52 (29)
Mean severity of LBP  4.7 (2.5) 4.7 (2.6)
in the previous week (SD)†
Mean functional status  29.6 (16.6) 30.7 (17.6)
in the previous week (SD)‡
LBP with radiation, n (%) 44 (24) 39 (22)
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Consulted a physician for LBP  114 (62) 110 (62)
in past 12 months, n (%)
Mean calendar days of sick leave  3.7 (13.5) 1.5 (6.1)
in the 3 months before baseline (SD), n
Mean calendar days of maternity leave  6.9 (37) 1.4 (13)
during follow-up (SD), n
Previous experience with lumbar support, n (%) 8 (4) 6 (3)
Preference for lumbar support group, n (%) 136 (74) 142 (79)
Expected increased functioning  137 (75) 135 (76)
with lumbar support, n (%)
Expected reduction of pain  130 (71) 132 (76)
with lumbar support, n (%)
LBP = low back pain.
† Numeric rating scale on which 0 = no pain and 10 = worst pain.
‡ Score on the Quebec Back Pain Disability Scale, on which 0 = no disability and 
100 = completely disabled.
Primary Outcomes
Days of Low Back Pain per Month
Overall, participants experienced low back pain for an average of 8.6 days per month (SD, 
7.7; range, 0 to 30.3 days per month). The mean difference between the 2 groups was esti-
mated in the generalized estimating equation model to be −53.7 days of low back pain per 
year (95% CI, −85.2 to −28.7 days per year; P < 0.001) in favor of the intervention group 
(Figure 2). In Figure 2, the low estimates in the ﬁ rst month are due to incomplete measures 
(mainly caused by delays in the in-company postal service and delays in measuring for the 
lumbar support). For the estimates per month, we back-calculated the difference from the 
log-linear parameters by using the sample’s mean values for the covariate proﬁ le. The sum 
of the separate monthly estimates was used to calculate the yearly estimates. No statisti-
cally signiﬁ cant time effects were observed. Other statistically signiﬁ cant covariates in the 
ﬁ nal model were age, body mass index, functional status in the previous week, severity of 
low back pain in the previous week, maternity leave prevalence, and sick leave prevalence 
before the study period. The yearly estimate from the analyses on the multiple imputed 
data set was −52.7 days (CI, −59.6 to −45.1 days) (Table 2). In a post-hoc “worst-case” 
sensitivity analysis, in which we replaced missing calendar data from the lumbar support 
group with 16 days of low back pain, the difference was still statistically signiﬁ cant in favor 
of the intervention group (−17 days per year [CI, −35 to −1.3 days per year]).
Proefschrift Binnen_2.indd   23 28-12-2009   17:52:06
 24 Lumbar supports to prevent recurrent low back pain
Absenteeism
The prevalence of general sick leave was 45 calendar days per year (SD, 67; range, 0 to 
335 days per year). In the generalized estimating equation model, the groups did not dif-
fer for the estimated number of days of sick leave (−5.0 days [CI, −21.1 to 6.8 days]; P = 
0.45) (Table 2). Signiﬁ cant covariates in the multivariate model were age, body mass index, 
maternity leave prevalence, sex, and sick leave prevalence before the study period. Figure 2 
shows the group estimates over time. The monthly and yearly estimates were calculated in 
the same manner as the estimates for days of low back pain.
Table 2. Group Estimates for Outcome Measures
Outcome Measure Lumbar Control  Difference P Value
  Support  Group (95% CI)
  Group
Primary    
Mean calendar days of LBP, n 71.7 124.4 −52.7 (−59.6 to −45.1)† < 0.001
Mean calendar days of sick leave, n 38.5 43.5 −5.0 (−21.1 to 6.8)‡ 0.45
Secondary    
Mean severity of LBP  4.0 4.6 −0.6 (−1.0 to −0.1) 0.020
in the previous week§
Mean functional status  26.2 30.3 −4.1 (−7.5 to −0.8) 0.017 
in the previous week||
Mean calendar days of self-reported 3.2 8.0 −4.8 (−6.2 to −2.2) 0.003
LBP-related sick leave, n
LBP = low back pain.
† Adjusted for age, body mass index, functional status in the previous week, severity of  low back pain in the 
previous week, maternity leave prevalence, and sick leave prevalence before the study period.
‡ Adjusted for age, body mass index, maternity leave prevalence, sex, and sick leave prevalence before the 
study period.
§ Numeric rating scale on which 0 = no pain and 10 = worst pain.
|| Score on the Quebec Back Pain Disability Scale, on which 0 = no disability and 100 = completely disabled.
Secondary Outcomes
Severity of experienced low back pain in the previous week and functional status in the 
previous week (Quebec Back Pain Disability Scale) were the secondary outcomes of 
interest. We found small but statistically signiﬁ cant differences in favor of the intervention 
group for pain intensity (−0.6 points [CI, −1.0 to −0.1 points]; P = 0.020) and functional 
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Figure 2. Average number of  days of  low back pain per month (top) 
and general sick leave per month (bottom). 
Estimates and 95% CIs were calculated from the model and are shown for the “mean covariate profi le”: 
a Dutch woman 41.7 years of  age with a body mass index of  26.9 kg/m2, a score for functional status in 
the previous week of  30.1, a score for severity of  low back pain in the previous week of  4.7, a prevalence 
of  sick leave before the study period of  2.6 days per month, and a prevalence of  maternity leave during 
follow-up of  4.2 days.
Proefschrift Binnen_2.indd   25 28-12-2009   17:52:06
 26 Lumbar supports to prevent recurrent low back pain
status (−4.1 points [CI, −7.5 to −0.8 points]; P = 0.017) (Table 2). The number of days of 
low back pain–related sick leave was estimated to differ by −4.8 days per year in favor of 
the lumbar support group (CI, −6.2 to −2.2 days per year; P = 0.003) (Table 2).
Lumbar Supports
At baseline, 4% of the sample was familiar with lumbar supports, and fewer than 1% of 
participants had recently used one but was no longer using it; 73% expected that a lumbar 
support would reduce pain, 76% expected that a lumbar support would increase functioning, 
and 77% would have preferred to participate in the intervention group. One person chose 
LumboTrain, 47 chose LumboTrain Lady, 30 chose LumboLoc, and 102 chose LordoLoc. 
Three intervention group participants left the study before the lumbar support was ﬁ tted. Du-
ring the intervention phase, 3 control group participants purchased their own lumbar support. 
In the intervention group, 78% of participants wore the lumbar support for at least one third 
of the total number of days on which they reported low back pain. On average, participants 
wore the supports on 5.5 days per month (SD, 6.1; range, 0 to 27.3 days per month), which 
was 90% of the mean number of days with low back pain per month.
Nine persons (6%) said that the support was too uncomfortable to wear. Some practical 
disadvantages (for example, the support was “sweaty” on warm days), but no adverse 
events, were reported. In general, 74% of the sample was satisﬁ ed with the lumbar sup-
port, 66% reported that their low back pain was more bearable with the support, and 78% 
said that the support made them more aware of their working posture.
In post hoc analyses, we explored possible inﬂ uences of adherence and the different types 
of supports on effectiveness. In the analyses of participants who adhered to use of lumbar 
support, we found stronger differences on all outcome measures, such as days of low back 
pain (−65 days [CI, −77 to −50 days] and sick leave (−13 days [CI, −25 to 3.3 days]. In 
contrast, participants who did not adhere to use of lumbar support did not differ from con-
trol participants for these variables. The various lumbar supports did not differ statistically 
signiﬁ cantly for any outcome.
Discussion
This randomized, controlled trial demonstrates that the addition of lumbar supports to 
education about healthy work behaviors may prevent low back pain in home health care 
workers with previous low back pain. We observed almost 5 fewer days of low back pain 
per month among workers assigned to use a lumbar support, which is a clinically relevant 
reduction of 45% compared with the control group. All outcomes favored the lumbar sup-
port group, although not all reached statistical signiﬁ cance, and the effects were robust in 
sensitivity analyses.
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Disappointingly, use of lumbar supports did not seem to signiﬁ cantly decrease total work 
absenteeism. Although workers assigned to lumbar supports had 53 days fewer with low 
back pain per year, the number of sick days was similar in both groups. However, our 
power calculations did not anticipate the observed average of 45 sick days per year (SD, 
67), and this high prevalence did not differ from the general prevalence of sick leave in 
the home care organization in which this trial was performed. In an exploratory post hoc 
analysis, we found a difference in self-reported sick leave due to low back pain with lumbar 
supports. Further investigation of the relation between the low back pain–related secondary 
outcomes and sick leave resulted in Pearson correlation coefﬁ cients of 0.07 and 0.23 bet-
ween sick days and low back pain severity and function, respectively; these values suggest 
that low back pain contributed only modestly to absenteeism in total in our study sample.
In the intervention group, the secondary outcomes of severity of low back pain in the 
previous week and functional status in the previous week’ statistically signiﬁ cant improved 
(by 13% and 14%, respectively) compared with the control group. The clinical relevance 
of these observed effects is uncertain. Clinically relevant within-participant decreases of 2 
points for pain on an 11-point numeric rating scale and more than 10 points on the total 
functional status scale represent great improvement in patients with acute and chronic low 
back pain(20-22). However, low back pain ﬂ uctuates over time, with frequent recurrences or 
exacerbations(23), and we arbitrarily measured at 4 predeﬁ ned points, regardless of whether 
participants had an exacerbation. We therefore consider our ﬁ ndings for secondary outco-
mes to support the ﬁ ndings for the primary outcomes.
The overall good adherence (78%) in our study underscores the earlier observed feasibility 
of using a lumbar support as a secondary preventive measure in home care situations(12). 
The experienced beneﬁ t, therefore, most likely outweighs the discomfort of the device.
Similar to other studies of the effect of wearing a lumbar support, we could not include a 
placebo lumbar support group. Consequently, the control group was not blinded, which 
increases the chance of measurement bias, especially when self-reported measures are 
used. The magnitude of this possible bias is unclear, but given that participants had positive 
expectations of the lumbar supports, an overestimation of the effect would be the more 
obvious direction for bias (that is, persons who were not initially assigned to receive a lum-
bar support may have overreported their problems because they were disappointed to not 
be included in the intervention group).
The lack of blinding, the missing calendar data, and the limited ability to draw deﬁ nitive 
conclusions about work absenteeism given the high prevalence of absenteeism in the 
study population are limitations of our study. In addition, we studied a predominantly 
female population of Dutch home care workers. The efﬁ cacy of lumbar supports should 
be investigated in different working populations and settings and with different co-inter-
ventions. Positive secondary preventive effects were reported for warehouse workers and 
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freight personnel in subgroup analyses of 2 primary preventive trials(9, 24). Better insight into 
determinants of adherence is needed, as is greater knowledge of possible mechanisms of 
action, especially in working situations, so that lumbar supports can be offered to targeted 
groups (25). Nevertheless, low back pain remains a major problem in industrialized countries, 
and lumbar supports may be a valuable addition to secondary prevention strategies in the 
workplace.
Acknowledgments: The authors thank the study participants and managers at Thuiszorg 
Rotterdam, Rotterdam, the Netherlands, for their contribution.
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Appendix: Short Refresher Course on Healthy Working Methods
The yearly short refresher course on healthy working methods was not an intervention 
from our research group. Rather, it is part of the health and safety policy from the home 
care organization, as regulated by national legislation. All employees from the home care 
organization received this education, which was taught by the in-house health and safety 
executive. The course consisted of 2 hours of practical training and a theoretical compo-
nent. During the practical training, participants learned the ergonomics of common tasks, 
such as cleaning the domestic environment/ patients, transferring patients, or putting on 
elastic stockings, and practiced these tasks. The theoretical component consisted of a leaﬂ et 
and playing board games that were developed to refresh and discuss knowledge on healthy 
working methods. The course was taught in group settings and was geared towards the 
speciﬁ c functions. In the Dutch home care setting, this course is considered part of usual 
care; in other settings, however, this might not be the case.
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Design: Economic evaluation from a societal perspective alongside a 12-month randomized 
controlled trial.
Objective: To determine the cost-effectiveness of  wearing a lumbar support for home care 
workers with recurrent low back pain (secondary prevention).
Summary of  Background Data: Low back pain is a large medical and economical burden. 
Evidence on the secondary preventive use of  lumbar supports is sparse. 
Methods: 360 home care workers with a self-reported history of  low back pain were ran-
domly assigned to usual care or usual care plus wearing a lumbar support on working days 
with low back pain, during a one-year period. Primary clinical outcome measures were the 
average number of  self-reported days with low back pain, number of  calendar days sick leave 
in general, and quality of  life. Direct and indirect costs were measured by means of  cost 
diaries. Differences in mean costs between groups, cost-effectiveness, and cost-utility ratios 
were evaluated and cost-effectiveness planes and acceptability curves presented by applying 
non-parametric bootstrapping techniques.
Results: During the intervention period, the home care workers using a lumbar support in 
addition to usual care reported on average 54 fewer days with low back pain (95% CI -85 to -
29). The estimated mean difference in sick leave was not statistically signifi cant (-5.0 days per 
year in favour of  the lumbar support group; 95% CI -21.1 to 6.8). There was no statistically 
signifi cant difference in quality of  life. Direct costs were € 235 (US$ 266) lower in the lumbar 
support group (95% CI -386 to -79). Indirect costs were €255 (US$ 288) lower, but this was 
not statistically signifi cant (95% CI -879 to 299). 
Conclusion: Lumbar support seem a cost-effective addition to usual care for home care 
workers with recurrent low back pain. For estimating the low back pain related indirect costs 
it would be more precise when an objective measure for low back pain related sick leave 
would have been available. There is a need for more evidence to confi rm these fi ndings, also 
in other working populations. 
ISRCTN registration number: ISRCTN73707379.
 
Abstract
Proefschrift Binnen_2.indd   34 28-12-2009   17:52:07
 Cost-effectiveness of  lumbar supports to prevent recurrent low back pain 35
Introduction
Low back pain (LBP) is a major medical and economical problem. In 1998, the annual 
prevalence of low back pain in the Dutch working population was 44%(1) while the costs of 
low back pain to society in the Netherlands in 1991 were estimated over four billion Euro(2). 
This is an economic burden of 269 Euro per inhabitant and although comparing is difﬁ cult, 
similar costs were found in Sweden and the United Kingdom(3). 
In order to prevent low back pain, lumbar supports are widely used(4), but there is moderate 
evidence that lumbar supports are ineffective for primary prevention(5, 6). The recently issued 
European guidelines for prevention in low back pain even advised against the use of lumbar 
supports(7). For workers already suffering from low back pain however, positive effects have 
been reported for warehouse workers and freight personnel in subgroup analyses of two 
primary preventive trials(8, 9). Evidence from randomized trials directly addressing this form 
of secondary prevention was lacking(6) until recently. 
Among home care workers the prevalence of low back pain is relatively high, with reported 
annual prevalences of 44 – 72%(10, 11). The use of lumbar supports as secondary preventive aid 
has shown to be feasible in this group(12). Therefore we performed a RCT investigating the ef-
ﬁ cacy of lumbar supports for home care workers with low back pain(13). During the 
12 month intervention period, the home care workers using a lumbar support in addition 
to usual care reported on average 54 fewer days with low back pain (95% CI -85 to -29). The 
estimated mean difference in total sick leave (also not back pain related) was not statistically 
signiﬁ cant (-5.0 days per year in favor of the lumbar support group; 95% CI -21.1 to 6.8). 
As high quality economic evaluations are needed to provide relevant information to policy 
makers, health care providers and patients on cost-effectiveness of treatments for low back 
pain(14), we also conducted an economic evaluation alongside this RCT(13) to evaluate the 
cost-effectiveness of using lumbar supports in addition to usual care for home care workers 
with recurrent low back pain.
Methods
Subjects 
The home care workers were recruited by 96 team managers at staff meetings between 
May and October 2003, and they were all employed in a large home care organization in 
Rotterdam. Home care workers who met the selection criteria received detailed information 
about the procedures of the trial and were enrolled after giving written consent. 
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The inclusion criteria were: performing medical care and/or domestic tasks as a home care 
worker; reporting low back pain at the moment of recruitment, or reporting two or more 
episodes of low back pain in the 12 months prior to recruitment. Exclusion criteria were: 
suffering from speciﬁ c low back pain e.g. due to rheumatoid arthritis or vertebral fractures; 
pregnant at the start of the study; receiving medical treatment for high blood pressure(15). 
The Medical Ethical Committee of the Erasmus University Medical Center, Rotterdam 
approved the study. 
Intervention
After completing the baseline measurement, the participants were allocated to either the 
intervention or the control group using a computer-generated random number table. 
Treatment allocation was concealed, because independent persons, who were not involved 
in this study and were blinded for the baseline characteristics of the participants, performed 
the randomisation. In the intervention group the home care workers received additionally 
to usual care a lumbar support, which had to be worn on those working days that they 
experienced low back pain or expected to experience low back pain. There were four types 
of lumbar supports available (LumboTrain®, LumboTrain® Lady, Lumboloc®, Lordoloc®) 
in different sizes. The home care worker’s choice of model was based on ﬁ t and wearing 
comfort. The intervention period was 12 months. Home care workers in the control group 
received usual care. This was an annual short refresher course on healthy working methods 
provided by their employer from the start of their appointment; primary and secondary care 
for the management of low back pain was available as usual.
Economic evaluation
This economic evaluation was conducted from a societal perspective. The aim of the 
economic evaluation was to determine and compare the total costs of home care workers 
receiving a lumbar support in addition to usual care with usual care only, and to relate these 
costs to the effects. The volumes of relevant categories of resource utilisation were asses-
sed over the 12-month intervention period with 4 cost diaries covering periods of three 
months each. Direct healthcare costs, direct non-healthcare costs and indirect costs due 
to low back pain were used as economic indicators. Direct healthcare costs included the 
costs of the lumbar supports, additional visits to a healthcare provider (GP, physiotherapist, 
medical specialist/outpatient care, other healthcare professionals), prescribed medication, 
professional home care, diagnostic interventions and hospitalisation. Direct non-healthcare 
costs included out-of-pocket expenses (i.e. over-the-counter medication), costs of paid and 
unpaid help. Indirect costs of loss of production due to absence from work were also inclu-
ded. The direct healthcare and direct non-healthcare costs, as presented in table 1, were 
estimated according to the Dutch guidelines for cost analysis in healthcare research(16-18). 
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Visits to other health care professionals, acupuncturist or homeopath were estimated on the 
basis of fees or prices charged by the professional organisations. The costs of medication 
were estimated on the basis of prices charged by the Royal Dutch Society for Pharmacy(19). 
Indirect costs of loss of production due to low back pain for both paid and unpaid labour 
were calculated. For paid labour, these costs were calculated according to the human 
capital approach(20, 21), based on function and the corresponding salary scale in the collective 
labour agreement of the home care organisation(22), with a correction for the partial work 
factor. For unpaid labour (e.g. voluntary work or household work), the indirect costs were 
estimated using a shadow price of €8.40 per hour(16). Costs presented in US$ are based on 
the averaged 2003 exchange rate(23).
Table 1. Overview of  costs applied in economic evaluation of  
treatments home care workers with LBP
  Costs
  €  
Direct health care costs  
Lumbar support (mean price) 56.40 
Over the counter medication 3.25 
Prescribed medication 4.61 
General practitioner (<= 20 min. visit) 20.44 
Physiotherapist (<= 30 min. visit) 23.02 
(Manual therapist (<= 45 min. visit)) 31.83 
Cesar or Mensendieck exercise therapist (per visit) 23.27 
Medical specialist (outpatient care) 99.16 
  
Direct non-health care costs  
Alternative therapist (per visit) 51.25 
Thermal pillow 5.50 
Help from partner/friends (per hour) 8.40 
  
Indirect costs  
Absenteeism from paid work (per day) - * 
Absenteeism from unpaid work (per hour) 8.40
 
* Valuation by function scale salary  
Proefschrift Binnen_2.indd   37 28-12-2009   17:52:08
 38 Cost-effectiveness of  lumbar supports to prevent recurrent low back pain
Primary outcomes were the number of days per month that home care workers reported 
having low back pain, the number of calendar days they were on sick leave during the 
12-month intervention period, and quality of life (QoL). The number of low back pain 
days per month was registered daily using a calendar. All participants were asked to tag 
those days they experienced low back pain. The number of calendar days being on sick 
leave were provided by the home care organization at the end of the study, and covered a 
15 month period (i.e. 3 months prior to the start until the end of the intervention period). 
The registration of sick leave was irrespective of the underlying reason, and could be back 
pain related or not. For measuring QoL the EuroQol(24) was used, expressed as utility values 
ranging from 0 to 1 (1 represents perfect health). Data on clinical outcomes were collected 
through questionnaires at 3, 6, 9 and 12 months. 
Statistical analysis
The analyses were carried out according to the intention-to-treat (ITT) principle. The home 
care workers remained in the group they were allocated to at baseline, regardless if they 
did or did not wear the lumbar support. In the cost-effectiveness analyses, 14 women who 
went on maternity leave were left out of the analyses, as we lacked an accurate registra-
tion of the actual period they were not at risk because of maternity leave. Maternity leave, 
in the Netherlands normally a period of 16 to 18 weeks which should not be considered 
as illness, was assimilated in the sick-leave data and therefore wrongfully creating indirect 
expenses. The clinical outcomes, number of days low back pain per month and calendar 
days sick leave per year, were included in the cost-effectiveness analysis. A cost-utility ana-
lysis was also performed, in which the effects were expressed as quality adjusted life year 
(QALY). 11% of the workers did not return any cost diary (25 intervention, 15 control). 
Missing cost estimates were imputed according to the expectation-maximization method(25). 
A complete case analysis and an analysis including the 14 women on maternity leaver were 
performed as sensitivity analyses. Bootstrapping (2000 replications) was used for pair-wise 
comparison of the mean costs between the two study groups and for obtaining 95% con-
ﬁ dence intervals for the mean differences in costs (26). The effects were expressed as mean 
differences between the two study groups. The cost-effectiveness and cost-utility ratios 
were also calculated with bootstrapping (5000 replications), according to the bias corrected 
percentile method(27). The bootstrapped cost-effect pairs were graphically represented on a 
cost-effectiveness plane. Acceptability curves were calculated, which show the probability 
that a treatment is cost-effective at a speciﬁ c ceiling ratio(28, 29).  
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Results
Subjects
A total of 360 home care workers were included in the trial, of which 183 were randomised 
to the intervention group, and 177 to the control group. The last participants completed 
the 12-month intervention period in November 2004. Table 2 summarises the baseline cha-
racteristics of the study population. Except for sick leave 3 months prior to the intervention, 
there were no substantial differences between the baseline characteristics of the two study 
groups. During the 12-month follow-up period 66 participants (18%) withdrew from the 
study, and of 13 (4%) sick leave data were not available for the complete follow-up period. 
The baseline characteristics of persons lost to follow-up did not differ signiﬁ cantly from 
those who completed the study. Figure 1 shows the ﬂ ow chart of the study with reasons for 
withdrawal. In total, 327 persons (91%) returned calendars reporting the number of days 
with low back pain per month. Data covered an average of 8.7 calendar months (SD 4.2, 
median 11, range 0 to 12). The mean registration period for sick leave after randomisation 
was 11.9 months (SD 0.7, median 12, range 5 to 12). Regarding the cost diaries, on 
average information was received for 9.5 months (SD 4.2, median 12, range 0 to 12). 
Table 2. Baseline characteristics of  the study population.
Factor Lumbar support Control Total
  (n= 183) (n= 177) (n=360)
Age, years, mean  41.8 41.5 41.7
(SD, range) (9.7, 19-62)  (9.8, 20- 60)  (9.7, 19- 62)
Gender, female  180 172 352
(%) (98) (97)  (98)
BMI, mean  26.6 27.1 26.9
(SD) (5.6) (5.4) (5.5)
Ethnicity, Dutch/Caucasian  133 123 256
(%) (73)  (70)  (71)
Working hours/ week, mean  25.3 24.4 24.8
(SD) (7.9)  (8.4)  (8.1)
Employment in current home 52 53 105
care organisation, <3 years, (%) (29)  (30)  (29)
Activities
predominantly domestic, (%) 102 (56) 99 (56) 201 (56)
predominantly personal care 45 (25) 44 (25) 89 (25)
specialised care 36 (19) 34 (19) 70 (19)
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LBP since, >1 year ago 166 159 325
(%)  (91)  (90)  (90)
LBP frequency past 12 months
1-2, (%) 28 (15) 32 (18) 60 (17)
3-5 43 (24) 33 (19) 76 (21)
>5  65 (35) 60 (34) 125 (34)
continuous 47 (26) 52 (29) 99 (28)
LBP previous week,  4.7 4.7 4.7
Numeric Rating Scale (0= no pain,  (2.5) (2.6) (2.5)
10= worst pain) mean, (SD)  
Functional status previous week,  29.6 30.7 30.1
QBPDS (0 = no disability,  (16.6) (17.6) (17.1)
100= completely disabled), mean, (SD)  
LBP with radiation  44 39 83
(%)  (24)  (22)  (23)
Consulted physician for LBP  114 110 224
in past 12 months, (%)  (62)  (62)  (62)
Sick leave 3 months prior to baseline,  3.7 1.5 2.6
calendar days, mean (SD)   (13.5) (6.1)  (10.6)
Utility, EuroQol (0.13–1;  0.75 0.77 0.76
1 represents perfect health), mean, (SD) (0.16) (0.19) (0.18)
Clinical outcomes
In the total study population low back pain was experienced on average 8.6 days per 
month (SD 7.7, range 0 to 30.3); the mean difference between the two groups was estima-
ted in a GEE-model at -54 days low back pain per year (95% CI -85.2 to -28.7, p< .0001) 
in favour of the intervention group (Table 3). There were no statistically signiﬁ cant time 
effects. Other statistically signiﬁ cant covariates in the ﬁ nal model were: age, body mass in-
dex, functional status in the previous week, severity of low back pain in the previous week, 
maternity leave prevalence and sick leave prevalence prior to the study period(13). 
The general sick leave prevalence was 45 calendar days per year (SD 67, range 0 to 335). 
There was no statistically signiﬁ cant difference between the two groups in the GEE model 
for the estimated number of days sick leave (-5.0 days; 95% CI -21.1 to 6.8; Table 3). 
Statistically signiﬁ cant covariates in the multivariate model, were: age, body mass index, 
gender, maternity leave prevalence, and sick leave prevalence prior to the study period. 
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Figure 1. Flow diagram of  the study population. 
* Participants also cited too much effort/ unwilling to fi ll in questionnaires
1355 home care workers 
addressed by team managers
Excluded (n= 995)
No LBP (n=544)
Not meeting inclusion criteria (n= 103)
Unwilling to participate (n= 308)
Other reasons (n= 40)
Allocated to control (n= 177)
Received usual care (n= 177 )
Allocated to intervention (n= 183)
Received lumbar support (n= 180)
Did not receive lumbar support (n= 3)
Abandoned participation due to other health
complaints (n= 1)
Participation too much effort (n= 2)
A
llo
ca
tio
n
Lost to follow-up (n=42)
Participation too much effort (n= 4)
Personal circumstances (n= 2)
Other health complaints (n= 10)
Unknown (n= 11)
Pregnant * (n= 2)
Lumbar support uncomfortable and no 
experienced benefit * (n= 3)
Therapist advised against support * (n= 1)
Dismissal from job (n= 8)
Deceased (n= 1)
Discontinued intervention (n=16)
Pregnant (n= 8)
Lumbar support uncomfortable and no 
experienced benefit (n=6) 
Lost lumbar support (n= 1)
Other health complaints (n= 1)
Lost to follow-up (n=24)
   Participation too much effort (n= 4)
   Personal circumstances (n= 2)
   Other health complaints (n= 5)
   Unknown (n= 8)
   Bought lumbar support privately * (n= 1)
   Dismissal from job (n= 4)
Discontinued usual care (n=2)
   Bought lumbar support privately (n=2)
Fo
llo
w
-u
p
En
ro
lm
en
t
Randomized (n= 360)
Analyzed
Days LBP per month (n= 183)
Sick leave (n= 183)
   Quality of life (n= 183)
   Cost data (n= 183)
Analyzed
Days LBP per month (n= 177) 
Sick leave (n= 177)
   Quality of life (n= 177)
   Cost data (n= 177)
A
na
ly
si
s
Proefschrift Binnen_2.indd   41 28-12-2009   17:52:09
 42 Cost-effectiveness of  lumbar supports to prevent recurrent low back pain
Self-reported low back pain related sick leave, a secondary outcome measure, was 
statistically signiﬁ cantly lower in the lumbar support group (-4.8 days; 95%CI -6.2 to -2.2; 
Table 3)(13). 
Regarding QoL (mean 0.76, SD 0.16, range -0.02 to 1) there was no statistically signiﬁ cant 
difference between the two groups in the GEE model (0.01 points; 95% CI -0.02 to 0.04; 
Table 3). Age, body mass index, gender, maternity leave prevalence, and sick leave pre-
valence prior to the study period were statistically signiﬁ cant covariates in the multivariate 
model. 
Table 3. Outcome measures of  effi cacy of  lumbar support; cost-effect ratios; 
mean costs (€) and differences in costs (€).
  Lumbar  Control Mean   Cost-
  support mean difference    effect
  mean     Ratio 
Outcome measures    lower upper 
Effects      
Days LBP per month# 5.5 10.0 -4.5 -7.1 -2.4 109
Total sick leave#  38.5 43.5 -5.0 -21.1 6.8 51
(calendar days)
Utility, EQ (-0.13 to 1),  0.76 0.75 0.01 -0.02 0.04 25500
1 represents a perfect health      
LBP related sick leave# ** 3.2 8.0 -4.8 -6.2 -2.2 77
Costs      
Direct  491 726 -235 -386* -79* 
Indirect  1635  1890  -255 -879* 299* 
Total  2126  2616 -490 -1104* 169* 
      
Indirect LBP related** 166 302 -136 -237 -28 
Total LBP related** 657 1028 -371 -580 -117 
LBP – low back pain; EQ – EuroQol
# Group estimates GEE model, controlled for age, body mass index, maternity leave prevalence, 
sex, and sick leave prevalence prior to the study period
* Obtained by bias corrected and accelerated bootstrapping
** Self-reported sick leave due to low back pain
      95% conﬁ dence
interval mean
difference
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Table 4. Overview utilisation of  healthcare resources. 
  Utilisation 
  mean (SD)
  Lumbar support Usual care
Direct health care costs    
Lumbar support (no.) 0.98 (0.13) 0.02 (0.13)
Over the counter medication (no. purchased) 3.83 (4.14) 4.26 (4.13)
Prescribed medication (no. prescribed) 1.80 (3.18) 1.62 (3.01)
General practitioner (no. of visits) 1.23 (3.55) 1.25 (2.27)
Physiotherapist (no. of treatment sessions) 2.94 (7.61) 4.60 (10.8)
Manual therapist (no. of treatment sessions) 0.99 (4.21) 0.59 (2.47)
Cesar or Mensendieck exercise therapist  0.11 (1.43) 0.23 (1.42)
(no. of treatment sessions)
Medical specialist (no. of outpatient appointments) 0.07 (0.39) 0.33 (1.23)
    
Direct non-health care costs    
Alternative therapist (no. of treatment sessions) 0.03 (0.29) 0.06 (0.52)
Thermal pillow (no. purchased) 0.05 (0.27) 0.10 (0.45)
Help from partner/friends (hours) 10.1 (26.0) 18.8 (40.5)
    
Indirect costs    
Absenteeism from paid work (days) 38.5 (46.0) 39.3 (46.7)
Absenteeism from unpaid work (hours) 23.4 (52.7) 34.4 (61.2)
Utilisation of  healthcare resources
In the total study population 67% had used medication for their low back pain complaints, 
of which 37% had used prescribed medication and 30% over-the-counter medication. 
A general practitioner was consulted by 38% on average 1.2 times. 25% received treat-
ment from a physiotherapist, 9% from a manual therapist and 2% from other paramedics. 
7% paid a visit to outpatient care from a specialist. Alternative therapies, like acupuncture, 
were used less than 3%. One third received help from family/ friends for their low back 
pain. The utilisation of the main healthcare resources for low back pain is summarised per 
group in table 4. 
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Costs
Table 4 presents the mean (SD) costs per patient for the two groups. The mean direct costs 
in the intervention group were statistically signiﬁ cantly lower than in the control group 
(€ -235; 95% CI -386 to -79; US$ -266; 95%CI -437 to -89). There was no statistically sig-
niﬁ cant difference in the mean indirect costs between the two groups (mean € -255; 95% 
CI -879 to 299; US$ -288; 95%CI -994 to 338), nor in the mean total costs (€ -490; 95% 
CI -1104 to 169; US$ -554; 95%CI -1248 to 191). 
Cost-effectiveness and cost-utility ratios
The cost-effectiveness and cost-utility ratios (mean difference in total costs / mean differen-
ce in effect) are presented in table 3. All ratios were dominant, because the ratios represent 
on average lower costs with a favourable difference in effect. In ﬁ gure 2, 3 and 4 the cost-
effectiveness planes are shown for days low back pain per month, absenteeism and quality 
of life respectively. The planes represent 5000 bootstrap replications of the cost-effecti-
veness ratios. The planes show the difference in effect on the x-axis and the difference in 
costs on the y-axis. Consequently, ratios in the northeast quadrant of the plane show that 
the lumbar supports are associated with higher costs and more effects compared with usual 
care only; ratios in the southeast with less costs and more effects, when comparing to usual 
care only; ratios in the southwest with less costs and less effects; and ratios in the northwest 
quadrant with more costs and less effects.
For days low back pain per month 94% of the ratios are located in the southeast (SE) 
quadrant and 6% in the northeast (NE) quadrant. This reﬂ ects the ﬁ nding that effects in the 
lumbar support group are statistically signiﬁ cantly larger than in the usual care only group 
and there is no statistically signiﬁ cant difference in total costs. Figure 3 shows that lumbar 
supports are more cost-effective than usual care regarding days of sick leave, because there 
was no difference in effect, but costs were statistically signiﬁ cantly lower. In this plane the 
costs on the y-axis represent direct costs, because sick-leave is included as effect and there-
fore not as cost. Lumbar supports are not more cost-effective compared to usual care regar-
ding QALYs (Figure 4). The acceptability curve for calendar days low back pain per month 
(Figure 5) shows that at a ceiling ratio of zero, the probability is 94% that the secondary 
preventive use of lumbar supports was cost-effective. 
Secondary analysis
When the secondary measure, self-reported low back pain is used for calculating the 
indirect costs, total costs are €371 lower in the intervention group (95%CI -580 to -117; 
US$ -420; 95%CI -656 to -132; Table 3). In the cost-effectiveness plane, the ratio’s are 
dominantly cost-effective (Figure 6). 
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Figure 2. Cost-effectiveness plane for days LBP per month
Sensitivity analyses
Firstly an additional complete case analysis was performed (data not shown), reproducing 
similar results. Secondly the analyses repeated with 14 women (n=10 intervention; n= 4 
control) that went on maternity leave (data not shown), also reproducing similar result with 
slightly broader conﬁ dence intervals. 
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Figure 4. Cost-effectiveness plane EQ-5D
Figure 3. Cost-effectiveness plane calendar days sick-leave
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Figure 6: Cost-effectiveness plane for days LBP per month, LBP related indirect costs.
Figure 5: Acceptability curve for calendar days LBP per month.
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Discussion
Besides reducing the number of calendar days suffering from low back pain with 54 days 
per year, the secondary preventive use of lumbar supports in addition to usual care also 
appears to be less costly for home care workers with recurrent low back pain. In this 
prospective cost-effectiveness study alongside a randomised controlled trial, the direct 
costs were statistically signiﬁ cantly lower in the lumbar support group (€ -235; US$ -266). 
There was no statistically signiﬁ cant difference in indirect costs based on the total sick leave 
data. When the self-reported low back pain related sick leave was used to calculate indirect 
costs, these costs were statistically signiﬁ cantly lower in the lumbar support group (€ -136; 
US$ -154). Although this self-reported sick leave due to low back pain was not a primary 
objective, these results support our ﬁ ndings of small ﬁ nancial beneﬁ ts with less low back 
pain complaints. 
There were no differences in QoL. This could be due to ﬁ ndings that the EuroQol may 
not be sensitive enough in low back pain populations. Even when other outcomes (pain 
and functioning) ﬁ nd clinical important changes, the EuroQol does not show a difference 
in effect(30). 
There is a potential hazard for an overestimation of the clinical effect, because of potential 
measurement bias in the self-reported outcomes. The home care workers were not blinded, 
since in a pragmatic trial like this, it is not possible to use sham lumbar supports. On the 
other hand, the external validity of cost-effectiveness ﬁ ndings is considered to be high in 
a pragmatic design, as the intervention is examined more closely to conditions of daily 
practice(31). 
However, we have to be somewhat cautious, as this is only the ﬁ rst trial designed to study 
the secondary preventive effect and cost-effectiveness of wearing a lumbar support. It was 
conducted in a predominantly female population and a speciﬁ c setting where the use of 
lumbar supports is feasible(12). Therefore, the efﬁ cacy and cost-effectiveness of lumbar sup-
ports in the secondary prevention of low back pain should also be investigated in different 
working populations and settings. 
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Background: Non-steroidal anti-infl ammatory drugs (NSAIDs) are the most frequently 
prescribed medications worldwide and are widely used for patients with low-back pain. 
Selective COX-2 inhibitors are currently available and used for patients with low-back pain. 
Objectives: The objective was to assess the effects of  NSAIDs and COX-2 inhibitors in the 
treatment of  non-specifi c low-back pain and to assess which type of  NSAID is most effective. 
Search strategy: We searched the MEDLINE and EMBASE databases and the Cochrane 
Central Register of  Controlled Trials up to and including June 2007 if  reported in English, 
Dutch or German. We also screened references given in relevant reviews and identifi ed trials. 
Selection criteria: Randomised trials and double-blind controlled trials of  NSAIDs in 
non-specifi c low-back pain with or without sciatica were included. 
Data collection & analysis: Two review authors independently extracted data and asses-
sed methodological quality. All studies were also assessed on clinical relevance, from which 
no further interpretations or conclusions were drawn. If  data were considered clinically ho-
mogeneous, a meta-analysis was performed. If  data were lacking for clinically homogeneous 
trials, a qualitative analysis was performed using a rating system with four levels of  evidence 
(strong, moderate, limited, no evidence). 
Main results: In total, 65 trials (total number of  patients = 11,237) were included in 
this review. Twenty-eight trials (42%) were considered high quality. Statistically signifi cant 
effects were found in favour of  NSAIDs compared to placebo, but at the cost of  statistically 
signifi cant more side effects. There is moderate evidence that NSAIDs are not more effective 
than paracetamol for acute low-back pain, but paracetamol had fewer side effects. There is 
moderate evidence that NSAIDs are not more effective than other drugs for acute low-back 
pain. There is strong evidence that various types of  NSAIDs, including COX-2 NSAIDs, are 
equally effective for acute low-back pain. COX-2 NSAIDs had statistically signifi cantly fewer 
side-effects than traditional NSAIDs. 
Reviewers’ conclusions: The evidence from the 65 trials included in this review suggests 
that NSAIDs are effective for short-term symptomatic relief  in patients with acute and chro-
nic low-back pain without sciatica. However, effect sizes are small. Furthermore, there does 
not seem to be a specifi c type of  NSAID which is clearly more effective than others. 
The selective COX-2 inhibitors showed fewer side effects compared to traditional NSAIDs 
in the RCTs included in this review. However, recent studies have shown that COX-2 
inhibitors are associated with increased cardiovascular risks in specifi c patient populations. 
Abstract
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Background
Low-back pain is a major health problem among populations in western industrialized 
countries and a major cause of medical expenses, absenteeism and disablement(1, 2). 
Although low-back pain is usually a benign and self-limiting disease which tends to improve 
spontaneously over time(3), a wide variety of therapeutic interventions is available for 
treatment(4-6). However, the effectiveness of most of these interventions has not yet been 
demonstrated beyond doubt and consequently, the therapeutic management of low-back 
pain varies widely. A major challenge for researchers is to provide evidence of which treat-
ment, if any, is of most beneﬁ t for (sub-groups of) patients with low-back pain.
Non-steroidal anti-inﬂ ammatory drugs (NSAIDs) are the most frequently prescribed medi-
cations worldwide and are widely used for patients with low-back pain. The rationale for 
the treatment of low-back pain with NSAIDs is based both on their analgesic potential and 
their anti-inﬂ ammatory action.
Guidelines for the management of low-back pain in primary care have been published in 
various countries around the world(7-10). All these guidelines recommend the prescription of 
NSAIDs as one option for symptomatic relief in the management of low-back pain. In most 
guidelines, NSAIDs are recommended as a treatment option after paracetamol has been 
tried. In addition to symptomatic relief, facilitating early return to normal activities is a goal 
of NSAID therapy.
In recent years, the selective cyclooxygenase-2 (COX-2) inhibiting NSAIDs have become 
available as an alternative to traditional NSAIDs. The putative advantage of the COX-2 
inhibitors is lower risk of gastro-intestinal side effects as compared with the traditional 
NSAIDs. However, recently there has been substantial debate on their cardiovascular safety. 
A few randomised clinical trials have evaluated the efﬁ cacy of selective COX-2 inhibitors for 
low-back pain and will be included in this updated systematic review.
Objectives
The objective of this systematic review was to determine if NSAIDs are more efﬁ cacious 
than various comparison treatments for non-speciﬁ c low-back pain and if so, which type of 
NSAID is most efﬁ cacious.
Comparisons of NSAIDs with reference treatments that were investigated are NSAIDs 
versus placebo, NSAIDs versus acetaminophen/paracetamol, NSAIDs versus other drugs 
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(e.g. narcotic analgesics or muscle relaxants), NSAIDs versus NSAIDs (e.g. traditional 
NSAIDs versus selective COX-2 inhibitors), NSAIDs versus NSAIDs plus muscle relaxant, 
NSAIDs versus NSAIDs plus B vitamins, and NSAIDs versus non-drug treatment.
Criteria for considering studies for this review
Types of  studies
Randomised trials (double-blind, single-blind and open-label) and double-blind controlled 
trials were included.
Types of  participants
Subjects age 18 years or older, treated for non-speciﬁ c low-back pain with or without 
sciatica, were included. Subjects with speciﬁ c low-back pain caused by pathological entities 
such as infection, neoplasm, metastasis, osteoporosis, rheumatoid arthritis, or fractures 
were excluded. Both acute (12 weeks or less) and chronic (more than 12 weeks) low-back 
pain patients were included.
Types of  interventions
One or more types of NSAIDs were included. Additional interventions were allowed if there 
was a contrast for NSAIDs in the study. For example, studies comparing NSAIDs plus mus-
cle relaxants versus muscle relaxants alone were included, while studies comparing NSAIDs 
plus muscle relaxants versus paracetamol were not.
Types of  outcome measures
Primary outcome measures were (in hierarchical order): 1) pain intensity (e.g. Visual Analog 
Scale or Numerical Rating Scale), 2) global measure (e.g. overall improvement, proportion 
of patients recovered), 3) back pain-speciﬁ c functional status (e.g. Roland Disability Questi-
onnaire, Oswestry Scale), 4) return to work (e.g. return to work status, number of days off 
work), and 5) side effects (proportion of patients experiencing side effects). Physiological 
outcomes (e.g. range of motion, spinal ﬂ exibility, degrees of straight leg raising or muscle 
strength) and generic functional status (e.g. SF-36, Nottingham Health Proﬁ le, Sickness 
Impact Proﬁ le) were considered secondary outcomes. Other symptoms such as health care 
consumption were also considered.
Search strategy for identiﬁ cation of studies
All relevant RCTs meeting our inclusion criteria were identiﬁ ed by:
A) a computer-aided search of the MEDLINE (from 1966 to June 2007) and EMBASE (from 
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1988 to June 2007) databases using the search strategy recommended by the Cochrane 
Back Review Group(11). RCTs published in English, Dutch and German were included be-
cause the review authors who conducted the methodological quality assessment and data 
extraction were able to read papers published in these languages.
B) a search in CENTRAL, the Cochrane Library 2007, issue 2.
C) screening references given in relevant reviews and identiﬁ ed RCTs.
The intervention speciﬁ c search contained MeSH-headings (explode ‘anti-inﬂ ammatory 
agents, non-steroidal’) and textwords in title, keywords and abstracts (‘nsaid’, ‘non-steroi-
dal anti-inﬂ ammatory drug’). The complete search strategy is presented in additional Table 
01; Table 02; Table 03.
Methods of the review
Study selection
Two review authors independently selected the trials to be included in the systematic review 
according to the inclusion criteria. Consensus was used to resolve disagreements concerning 
inclusion of RCTs.
Methodologic quality assessment
The criteria list recommended by the Cochrane Back Review Group (Table 04) was used for 
assessing the methodological quality of the included studies(11). All items were scored as po-
sitive or negative. Unclear scores were not included, because we had decided not to contact 
the authors for additional information.
The methodologic quality of the RCTs was independently assessed by two review authors. 
Consensus was used to resolve disagreements and a third review author was consulted if 
disagreements persisted. If the article did not contain information on the methodologic cri-
teria, these criteria were scored as ‘negative’. Because 31 of the 64 studies included in this 
review were published before 1990, we decided not to contact the authors for additional 
information.
We deﬁ ned high quality studies as RCTs which fulﬁ lled six or more of the validity criteria, 
but also performed sensitivity analyses exploring the results when high quality was deﬁ ned 
as fulﬁ lling ﬁ ve or more or seven or more of the 11 validity criteria. We also explored the 
results if high quality was deﬁ ned as having adequate concealment of treatment allocation. 
Analyses were performed separately for traditional NSAIDs and selective COX-2 NSAIDs, 
(sub)acute low-back pain (12 weeks or less) and chronic low-back pain (more than 12 
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weeks), short-term follow-up (less than six months after randomization) and long-term 
follow-up (six months or more), and low-back pain with and without sciatica.
Data extraction
Two review authors independently extracted the data (using a standardized form). Data 
were extracted on type and dose of NSAIDs, type of reference treatment, follow-up, 
presence or absence of sciatica, duration of current symptoms, and the outcomes described 
above.
Data analysis
The quantitative analysis (statistical pooling) was limited to clinically homogeneous studies 
for which the study populations, interventions and outcomes were considered by the 
review authors to be similar (see comparisons). We included a test for homogeneity of 
the Relative Risk (RR) of the RCTs. If studies were clinically and statistically homogeneous, 
Mean Differences, RRs and 95% CI were presented using the ﬁ xed-effect model. If studies 
were clinically homogeneous but statistically heterogeneous, the random-effects model 
was used. For Mean Differences, the Weighted Mean Difference (WMD) was presented if 
all studies reported an identical scale for an outcome measure (e.g. 100 mm VAS for Pain 
Intensity); otherwise the Standardized Mean Difference (SMD) was presented (e.g. 100 mm 
VAS and 5-point scale for Pain Intensity).
A qualitative analysis was performed if relevant data enabling statistical pooling were 
lacking. In the qualitative analysis, a rating system of levels of evidence was used to sum-
marize the results of the studies in terms of strength of the scientiﬁ c evidence. The rating 
system consisted of four levels of scientiﬁ c evidence based on the quality and the outcome 
of the studies:
- Strong evidence - consistent ﬁ ndings among multiple high quality RCTs
- Moderate evidence - consistent ﬁ ndings among multiple low quality RCTs and/or one 
high quality RCT
- Limited evidence - one low quality RCT
- Conﬂ icting evidence - inconsistent ﬁ ndings among multiple RCTs
- No evidence from trials - no RCTs or CCTs
Clinical relevance
In order to give an indication for clinical relevance, all included studies were checked on the 
following criteria(12):
- Are the patients described in detail so that you can decide whether they are comparable 
to those that you see in your practice?
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- Are the interventions and treatment settings described well enough so that you can 
provide the same for your patients?
- Were all clinically relevant outcomes measured and reported?
- Is the size of the effect clinically important?(13)
- Are the likely treatment beneﬁ ts worth the potential harms? 
Note that when studies comparing two or more medications determined that the medi-
cations were equally effective, the effects were considered negative with respect to the 
effectivenss of the intervention medication. All scores were added to the Characteristics of 
included studies Table, but no further conclusions were drawn from these results.
Description of studies
The updated search resulted in 125 additional references from MEDLINE, 566 from EM-
BASE and 55 from the Cochrane Central Register of Controlled Trials. After ﬁ ltering for 
duplicates, 467 references were left for assessment. During the ﬁ rst selection based on 
titles, keywords and abstracts, the two review authors agreed that 23 articles should be 
included, they were uncertain about ﬁ ve studies and rejected 439 studies. Assessment of 
the 28 full papers resulted in four more studies being rejected. One study reported on two 
trials(14). Six studies that had been included earlier in the review were also rejected, as two 
of these papers only described the onset of pain relief(15, 16), and four papers did not meet 
language criteria(17-20). Three papers were considered to contain additional information for 
earlier reported studies(21-23).
Consequently, 15 new studies were included.
The previous search had resulted in 53 selected studies for this review. Three of these 
studies were excluded, one of them because the efﬁ cacy of a muscle relaxant instead of 
an NSAID was evaluated(24), the second only investigated different dosage regimes of the 
same NSAID(25) and the third because the study population consisted of back and neck pain 
patients(26).
Finally, 65 studies were included in this update, 59 of which were published in English and 
six in German:
- sixteen studies compared one or more types of NSAIDs with a placebo(14, 27-41);
- seven studies compared one or more types of NSAIDs with paracetamol(42-48);
- nine studies compared one or more types of NSAIDs to other drugs(29, 42, 49-55);
- four studies compared some type of NSAIDs with non-drug treatment(47, 56-58);
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- 33 studies compared different types of NSAIDs(14, 28, 30, 33, 42, 48, 59-85);
- three studies compared NSAIDs with NSAIDs plus muscle relaxants(29, 86, 87); and
- three studies compared NSAIDs with NSAIDs plus B vitamins(88-90). 
Twenty-ﬁ ve studies included a homogeneous population of low-back pain patients without 
sciatica(27, 31-33, 36, 39, 44, 45, 47, 48, 51-54, 58, 60, 64, 66, 67, 70, 74, 76, 77, 85, 87); six studies included a homogene-
ous population of low-back pain patients with sciatica(14, 34, 38, 40, 41, 49), while the other studies 
either did not specify whether or not the patients had sciatica, or included a mixed popula-
tion of patients with and without sciatica.
Thirty-seven studies reported exclusively on acute low-back pain(14, 27, 29, 33, 34, 37, 39, 41, 42, 44, 45, 
47-50, 53-55, 57-60, 62-64, 68-70, 74-77, 79, 83, 84, 87, 89); nine studies reported exclusively on chronic low-back 
pain(30-32, 36, 43, 51, 66, 80, 85), while the other studies reported either on a mixed population of 
(sub)acute and chronic low-back pain, or did not adequately specify if patients with acute 
or chronic low-back pain were included (e.g. by reporting the mean and standard devia-
tion of the duration of back pain in the population). Studies from this last category were 
included in the analyses for acute or chronic low-back pain if the authors stated somewhere 
in the article that it was about acute or chronic low-back pain, even if they did not provide 
data on the duration (e.g. mean (SD) number of days of low-back pain episode).
Eight studies evaluated the efﬁ cacy of selective COX-2 inhibitors. Three versus placebo(31, 32, 
36) and ﬁ ve versus traditional NSAIDs(14, 67, 76, 83, 85).
Methodological quality of included studies
Twenty-eight studies (43%) were considered high quality(14, 28, 30-34, 36, 39-41, 43, 44, 51, 55, 62, 63, 71, 
73, 74, 76, 77, 83-86, 89, 90). The most prevalent methodologic shortcomings, which were identiﬁ ed 
in more than half of the trials, were that the randomization procedure and concealment of 
treatment allocation were inadequate, that measures were not taken in the study design to 
avoid co-interventions, that compliance was unsatisfactory and that the length of follow-up 
was inadequate.
Results
NSAIDs versus placebo
Acute low-back pain
Eleven studies comparing NSAIDs with placebo for acute low-back pain were included in 
our meta-analysis. Seven of these studies were high quality(14, 28, 33, 34, 39-41) and four low 
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quality(27, 29, 35, 37). Three studies reported on low-back pain without sciatica(27, 33, 39), four on 
sciatica(14, 34, 40, 41), and the other four on a mixed population.
Six of these eleven studies reported sufﬁ cient data on pain intensity to enable statistical 
pooling(14, 27, 28, 33, 39, 41). The Chi-square value for homogeneity of the weighted mean dif-
ference (WMD) was 16.18 (P < 0.01), indicating statistical heterogeneity among these 
studies.
Potential explanations for this heterogeneity were explored. The meta-analysis was split 
into studies reporting on low-back pain without sciatica or a mixed population and studies 
reporting on low-back pain with sciatica only. The studies that reported on non-sciatic/
mixed acute low-back pain were statistically homogeneous (Chi-square 3.47; P > 0.1), 
and using the ﬁ xed-effect model, the pooled WMD was -8.39 (95% CI -12.68 to -4.10), 
indicating a statistically signiﬁ cant effect in favour of NSAIDs compared to placebo (graph 
01.01). The sciatica-only studies were still heterogeneous (Chi-square 7.25; P < 0.01) and 
there was no statistical difference in effect between NSAIDs and placebo (WMD -0.16; 
95% CI -11.92 to 11.52).
Graph 01.01 
Graph 01.02
Comparison: 01 NSAIDs versus placebo for acute LBP                                                                        
Outcome: 01 Change in Pain Intensity from baseline on 100mmVAS. Follow-up <=3 weeks.                                   
Study  NSAID  Placebo  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Amlie 1987             134    -76.00(35.00)        132    -68.00(35.00)     25.99     -8.00 [-16.41, 0.41]    
Babej-Dolle 1994        86    -46.80(67.00)         82    -23.40(67.00)      4.48    -23.40 [-43.67, -3.13]   
Szpalski 1994           33    -68.00(17.00)         35    -64.00(17.00)     28.14     -4.00 [-12.08, 4.08]    
Dreiser 2003           122    -48.00(26.00)        121    -38.00(27.00)     41.40    -10.00 [-16.67, -3.33]   
Total (95% CI)    375                         370 100.00     -8.39 [-12.68, -4.10]
Test for heterogeneity: Chi² = 3.47, df = 3 (P = 0.32), I² = 13.6%
Test for overall effect: Z = 3.84 (P = 0.0001)
 -100  -50  0  50  100
 Favours NSAIDs  Favours control
Comparison: 01 NSAIDs versus placebo for acute LBP                                                                        
Outcome: 02 Proportion of patients experiencing global improvement. Follow-up <=3 weeks.                               
Study  NSAID  Placebo  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Goldie 1968               14/25              16/25          6.60      0.88 [0.56, 1.38]        
 Jacobs 1968               23/55              11/55          4.54      2.09 [1.13, 3.86]        
 Weber 1980                 6/28               3/29          1.22      2.07 [0.57, 7.49]        
 Basmajian 1989            31/39              30/41         12.06      1.09 [0.85, 1.39]        
 Szpalski 1994             23/35              23/35          9.48      1.00 [0.71, 1.40]        
 Dreiser 2001             139/181            121/180        50.03      1.14 [1.00, 1.30]        
 Dreiser 2003              53/113             39/113        16.08      1.36 [0.99, 1.87]        
Total (95% CI) 476                478 100.00      1.19 [1.07, 1.33]
Total events: 289 (NSAID), 243 (Placebo)
Test for heterogeneity: Chi² = 8.39, df = 6 (P = 0.21), I² = 28.5%
Test for overall effect: Z = 3.28 (P = 0.001)
 0.2  0.5  1  2  5
 favours placebo  favours NSAID
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Seven of the eleven studies which compared NSAIDs with placebo for acute low-back pain 
reported dichotomous data on global improvement(14, 29, 33-35, 39, 41). The Chi-square value 
for homogeneity of the RR was 8.39 (P > 0.1), indicating statistical homogeneity among 
these studies. The pooled RR for global improvement after one week, using the ﬁ xed-effect 
model, was 1.19 (95% CI 1.07 to 1.33), indicating a statistically signiﬁ cant effect in favour 
of NSAIDs compared to placebo (graph 01.02).
Ten of the eleven studies which compared NSAIDs with placebo for acute low-back pain 
reported data on side effects. The Chi-square value for homogeneity of the RR for side ef-
fects was 5.45 (P > 0.5), indicating homogeneity among the studies. Using the ﬁ xed-effect 
model, the pooled RR for side effects was 1.35 (95% CI 1.09 to 1.68), indicating statisti-
cally signiﬁ cantly fewer side effects in the placebo group (graph 01.03).
Graph 01.03 
Graph 01.04
Comparison: 01 NSAIDs versus placebo for acute LBP                                                                        
Outcome: 03 Proportion of patients experiencing side effects. Follow-up <=3 weeks.                                     
Study  NSAID  Placebo  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Goldie 1968                8/25               5/25          4.39      1.60 [0.61, 4.22]        
 Jacobs 1968               28/55              20/55         17.55      1.40 [0.91, 2.16]        
 Weber 1980                 0/29               0/28                Not estimable         
 Lacey 1984                18/148             14/150        12.20      1.30 [0.67, 2.52]        
 Amlie 1987                24/138             18/140        15.68      1.35 [0.77, 2.38]        
 Weber 1993                22/94              13/120        10.02      2.16 [1.15, 4.06]        
 Babej-Dolle 1994           4/88               2/86          1.78      1.95 [0.37, 10.39]       
 Szpalski 1994              1/35               0/35          0.44      3.00 [0.13, 71.22]       
 Dreiser 2001              29/171             24/180        20.52      1.27 [0.77, 2.09]        
 Dreiser 2003              16/124             20/126        17.41      0.81 [0.44, 1.49]        
Total (95% CI) 907                945 100.00      1.35 [1.09, 1.68]
Total events: 150 (NSAID), 116 (Placebo)
Test for heterogeneity: Chi² = 5.45, df = 8 (P = 0.71), I² = 0%
Test for overall effect: Z = 2.74 (P = 0.006)
 0.1  0.2  0.5  1  2  5  10
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Comparison: 01 NSAIDs versus placebo for acute LBP                                                                        
Outcome: 04 Additional analgesic use. Follow-up <=3 weeks.                                                             
Study  NSAID  Placebo  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Weber 1980                 3/28               8/29          3.12      0.39 [0.11, 1.32]        
 Amlie 1987                49/134             62/132        24.81      0.78 [0.58, 1.04]        
 Weber 1993                51/120             48/94         21.38      0.83 [0.62, 1.11]        
 Dreiser 2001             105/180            128/181        50.69      0.82 [0.71, 0.96]        
Total (95% CI) 462                436 100.00      0.80 [0.71, 0.91]
Total events: 208 (NSAID), 246 (Placebo)
Test for heterogeneity: Chi² = 1.59, df = 3 (P = 0.66), I² = 0%
Test for overall effect: Z = 3.44 (P = 0.0006)
 0.1  0.2  0.5  1  2  5  10
 Favours NSAID  Favours placebo
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Four of the eleven studies which compared NSAIDs with placebo for acute low-back pain 
reported data on the need for additional analgesic use(14, 27, 40, 41). The Chi-square value for 
homogeneity of the RR was 1.59 (df = 3; P > 0.5), indicating statistical homogeneity. Using 
the ﬁ xed-effect model, the pooled RR for analgesic use was 0.80 (95% CI 0.71 to 0.91), 
indicating signiﬁ cantly less use of analgesics in the NSAIDs group (graph 01.04). Analgesics 
were not permitted in three trials(34, 35, 39). 
Chronic low-back pain
All four studies which compared NSAIDs with placebo for chronic low-back pain repor-
ted sufﬁ cient data on pain intensity to enable statistical pooling. The Chi-square value for 
homogeneity of the weighted mean difference (WMD) was 1.82 (P > 0.5), indicating sta-
tistical homogeneity among these studies. Using the ﬁ xed-effect model, the pooled WMD 
was -12.40 (95% CI -15.53 to -9.26), indicating a statistically signiﬁ cant effect in favour of 
NSAIDs compared to placebo (graph 02.01).
Graph 02.01 
The four studies also reported data on side effects. The Chi-square value for homogeneity 
of the RR for side effects was 1.01 (df = 3; P > 0.5), indicating homogeneity among the 
studies. Using the ﬁ xed-effect model, the pooled RR for side effects was 1.24 (95% CI 1.07 
to 1.43), indicating statistically signiﬁ cantly fewer side effects in the placebo group (graph 
02.02).
NSAIDs versus paracetamol/acetaminophen
Six studies, one high quality study(43) and ﬁ ve low quality studies(42, 45-48), compared some 
type of NSAID with paracetamol or acetaminophen. There is moderate evidence that 
NSAIDs are equally effective for pain relief and global improvement compared with para-
cetamol for acute low-back pain(42, 45, 47, 48); pooled SMD -0.21 (95% CI -0.43 to 0.02; N 
= 309); pooled RR 1.23 (95% CI 0.88 to 1.73; N = 128) (43, 45, 46) (graphs 03.01 and 
03.02). One low quality study in a mixed population of acute and chronic low-back pain 
Comparison: 02 NSAIDs versus placebo for chronic LBP                                                                      
Outcome: 01 Change in Pain Intensity from baseline on 100mm VAS. Follow up  <=12 weeks.                                
Study  NSAID  Placebo  WMD (fixed)  Weight  WMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Berry 1982              37    -11.00(32.50)         37      9.00(32.50)      4.49    -20.00 [-34.81, -5.19]   
Birbara 2003            99    -10.50(23.00)        105      0.00(23.00)     24.67    -10.50 [-16.82, -4.18]   
Katz 2003              228    -45.50(24.90)        223    -32.00(24.90)     46.57    -13.50 [-18.10, -8.90]   
Coats 2004             148    -40.80(27.70)        143    -30.00(27.70)     24.28    -10.80 [-17.17, -4.43]   
Total (95% CI)    512                         508 100.00    -12.40 [-15.53, -9.26]
Test for heterogeneity: Chi² = 1.82, df = 3 (P = 0.61), I² = 0%
Test for overall effect: Z = 7.75 (P < 0.00001)
 -100  -50  0  50  100
 Favours NSAID  Favours placebo
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Graph 02.02
Graph 03.01 
Graph 03.02
Graph 03.03 
Comparison: 02 NSAIDs versus placebo for chronic LBP                                                                      
Outcome: 02 Proportion of patients experiencing side effects. Follow up <=12 weeks.                                    
Study  NSAID  Placebo  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Berry 1982                18/37              16/37          8.20      1.13 [0.69, 1.85]        
 Birbara 2003              60/101             51/107        25.38      1.25 [0.97, 1.61]        
 Katz 2003                112/233             93/228        48.18      1.18 [0.96, 1.45]        
 Coats 2004                52/148             35/143        18.24      1.44 [1.00, 2.06]        
Total (95% CI) 519                515 100.00      1.24 [1.07, 1.43]
Total events: 242 (NSAID), 195 (Placebo)
Test for heterogeneity: Chi² = 1.01, df = 3 (P = 0.80), I² = 0%
Test for overall effect: Z = 2.95 (P = 0.003)
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Comparison: 03 NSAIDs versus paracetamol                                                                                  
Outcome: 01 Pain Intensity on various scales. Follow-up <=3 weeks.                                                     
Study  NSAID  Paracetamol  SMD (fixed)  Weight  SMD (fixed)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
Evans 1980              30     -0.23(0.49)          30      0.00(0.49)      19.09     -0.46 [-0.98, 0.05]     
Wiesel 1980             15     27.07(10.69)         15     41.40(32.46)      9.37     -0.58 [-1.31, 0.16]     
Nadler 2002            106     -0.06(0.67)         113      0.00(0.67)      71.54     -0.09 [-0.35, 0.18]     
Total (95% CI)    151                         158 100.00     -0.21 [-0.43, 0.02]
Test for heterogeneity: Chi² = 2.70, df = 2 (P = 0.26), I² = 25.8%
Test for overall effect: Z = 1.80 (P = 0.07)
 -1  -0.5  0  0.5  1
 Favours NSAIDs  Favours paracetamol
Comparison: 03 NSAIDs versus paracetamol                                                                                  
Outcome: 02 Proportion of patients experiencing global improvement. Follow-up <=3 weeks.                               
Study  NSAID  Paracetamol  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Hickey 1982               13/16               7/14         26.23      1.63 [0.92, 2.89]        
 Muckle 1986                7/25               8/25         28.10      0.88 [0.37, 2.05]        
 Milgrom 1993              16/24              13/24         45.67      1.23 [0.77, 1.96]        
Total (95% CI) 65                 63 100.00      1.23 [0.88, 1.73]
Total events: 36 (NSAID), 28 (Paracetamol)
Test for heterogeneity: Chi² = 1.51, df = 2 (P = 0.47), I² = 0%
Test for overall effect: Z = 1.22 (P = 0.22)
 0.2  0.5  1  2  5
 favours paracetamol  favours NSAID
Comparison: 03 NSAIDs versus paracetamol                                                                                  
Outcome: 03 Proportion of patients experiencing side effects. Follow-up <=3 weeks.                                     
Study  NSAID  Paracetamol  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Evans 1980                20/30              13/30         68.76      1.54 [0.95, 2.49]        
 Hickey 1982                2/16               1/14          5.64      1.75 [0.18, 17.29]       
 Nadler 2002               11/106              5/113        25.60      2.35 [0.84, 6.53]        
Total (95% CI) 152                157 100.00      1.76 [1.12, 2.76]
Total events: 33 (NSAID), 19 (Paracetamol)
Test for heterogeneity: Chi² = 0.60, df = 2 (P = 0.74), I² = 0%
Test for overall effect: Z = 2.45 (P = 0.01)
 0.1  0.2  0.5  1  2  5  10
 Favours NSAID  Favours paracetamol
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patients also found no differences(46). One high quality study(43) found limited evidence that 
NSAIDs are more effective for pain relief than paracetamol in patients with chronic low-
back pain.
NSAIDs were associated with more side effects compared to paracetamol (RR 1.76; 95% CI 
1.12 to 2.76, N = 309) (graph 03.03).
NSAIDs versus other drugs
Nine studies(29, 42, 49-55) were identiﬁ ed that compared NSAIDs with some other kind of 
drug. Two of these studies were considered to be of high methodologic quality(51, 55). Seven 
studies reported on acute low-back pain, ﬁ ve of which, including one high quality study, 
did not ﬁ nd any statistical differences between NSAIDs and narcotic analgesics or muscle 
relaxants(29, 49, 50, 54, 55). Because of clinical heterogeneity, the pooled RR was not estimated 
(graph 04.01). There is moderate evidence that NSAIDs are not more effective than other 
drugs for acute low-back pain.
For chronic low-back pain, one high quality study(51) reported equal effectiveness for an 
NSAID (dolotefﬁ n) compared to a herbal medicine (Harpagophytum procumbens).
One study did not specify if patients with acute and/or chronic low-back pain were inclu-
ded and data extraction was not possible from this study(52).
Side effects are plotted in Graph 04.02.
NSAIDs versus non-drug treatments
Four low quality studies were identiﬁ ed comparing NSAIDs with non-drug treatments 
such as spinal manipulation, physiotherapy and bed rest. There is conﬂ icting evidence that 
NSAIDs are more effective than bed rest for acute low-back pain, as one study(57) reported 
a positive outcome and one study did not ﬁ nd a signiﬁ cant difference(56). However, the 
latter study also showed a larger improvement in the NSAID group, and the small number 
in the bed rest group (N = 29) may have caused a lack of power to detect a statistically 
signiﬁ cant difference. Two studies found no differences between NSAIDs and physiotherapy 
or spinal manipulation in acute low-back pain(56, 58), therefore, there is moderate evidence 
that NSAIDs are not more effective than physiotherapy or spinal manipulation for acute 
low-back pain. One study may have lacked power because of the small groups(58). One 
low quality study comparing NSAIDs to a heat-wrap for patients with acute low-back pain, 
found a statistically signiﬁ cant difference in favour of the heat-wrap. So, there is limited 
evidence that NSAIDs are less effective than a heat-wrap for acute low-back pain.
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Graph 04.01 
Graph 04.02
Comparison of  different types of  NSAIDs
Thirty-three trials compared at least two or more different types of NSAIDs. Two trials 
compared two types of NSAIDs (diclofenac versus dipyrone and diclofenac versus etofena-
mat, respectively) administered by intramuscular injection(28, 79). One compared intramuscu-
lar diclofenac with intravenous meloxicam(64), one compared an intramuscular injection of 
tenoxicam with tenoxicam tablets(72), one compared ibuprofen tablets with felbinac foam(70), 
and one compared diclofenac gel with indomethacin plaster(81).
One study reported on acute and chronic low-back pain separately, and consequently a to-
tal of 20 studies included acute low-back pain patients, four chronic low-back pain patients, 
and eight an unspeciﬁ ed or mixed population of acute and chronic low-back pain patients.
Six studies on acute low-back pain reported differences between the NSAIDs and ﬁ fteen 
found no differences. Eleven studies on acute low-back pain were of high quality(14, 28, 33, 
62, 63, 71, 74, 76, 77, 83, 84). One of the high quality studies compared two types of NSAIDs admi-
nistered by intramuscular injection and reported better results for dipyrone compared to 
diclofenac(28). None of the other high quality studies evaluating NSAIDs capsules found any 
differences.
Comparison: 04 NSAIDs versus other drug treatment                                                                         
Outcome: 01 Proportion of patients experiencing global improvement. Follow-up <=3 weeks.                               
Study  NSAID  Other drug  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Brown 1986                16/19              17/21         12.65      1.04 [0.78, 1.38]        
 Sweetman 1987             33/39              33/41         25.21      1.05 [0.86, 1.29]        
 Basmajian 1989            31/44              37/43         20.04      0.82 [0.65, 1.03]        
 Innes 1998                50/62              52/60         41.43      0.93 [0.80, 1.09]        
 Chrubasik 2003             4/44               5/44          0.66      0.80 [0.23, 2.78]        
 0.2  0.5  1  2  5
 favours other drug  favours NSAID
Comparison: 04 NSAIDs versus other drug treatment                                                                         
Outcome: 02 Proportion of patients experiencing side effects. Follow-up <=3 weeks.                                     
Study  NSAID  Other drug  RR (random)  Weight  RR (random)
or sub-category  n/N  n/N  95% CI  %  95% CI
 Ingpen 1969                7/20              13/20          8.88      0.54 [0.27, 1.06]        
 Evans 1980                20/30              19/30         20.34      1.05 [0.73, 1.53]        
 Videman 1984a             19/35              23/35         19.44      0.83 [0.56, 1.22]        
 Brown 1986                 3/19               5/21          2.86      0.66 [0.18, 2.41]        
 Sweetman 1987              9/39              16/41          8.66      0.59 [0.30, 1.18]        
 Innes 1998                21/62              38/59         18.92      0.53 [0.35, 0.78]        
 Metscher 2001             13/81              22/79         10.45      0.58 [0.31, 1.06]        
 Chrubasik 2003            14/44              14/44         10.45      1.00 [0.54, 1.84]        
 0.1  0.2  0.5  1  2  5  10
 Favours NSAID  Favours other drug
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Graph 05.01
There seems to be no difference in the reported number and severity of side effects for the 
various types of NSAIDs. Only three low quality studies reported statistically signiﬁ cant dif-
ferences in side effects(60, 67, 69).
Although 33 studies compared different types of NSAIDs, it was only possible to state that 
there is moderate evidence based on two trials that the relative effectiveness of meloxicam 
is equal to diclofenac for acute low-back pain(14, 64). None of the other studies compared the 
same two NSAIDs for acute or chronic low-back pain.
COX-2 NSAIDs versus traditional NSAIDs
Five studies compared COX-2 NSAIDs with traditional NSAIDs (meloxicam versus diclo-
fenac(14); nimesulide versus diclofenac(67); nimesulide versus ibuprofen(76); valdecoxib versus 
diclofenac(83); etoricoxib versus diclofenac(85)). Statistical pooling of three studies(14, 76, 83) 
found no statistically signiﬁ cant differences for pain relief for acute low-back pain (graph 
05.01). The fourth study showed similar results.
The ﬁ fth, a high quality study, found moderate evidence that there were no differences in 
pain relief between COX-2 and traditional NSAIDs for chronic low-back pain(85).
COX-2 NSAIDs had statistically signiﬁ cantly fewer side-effects (RR 0.83 ; 95% CI 0.70 to 
0.99) (graphs 05.02, 05.03, 05.04).
Comparison: 05 NSAIDs selective COX-2 inhibition versus non selective                                                     
Outcome: 01 Change in Pain Intensity from baseline on 100mmVAS.                                                        
Study  Selective  Nonselective  WMD (random)  Weight  WMD (random)
or sub-category N Mean (SD) N Mean (SD)  95% CI  %  95% CI
01 Acute low back pain
Pohjolainen 2000        52    -45.00(21.00)         50    -38.00(21.00)     16.64     -7.00 [-15.15, 1.15]    
Dreiser 2001b          164    -57.00(26.00)        162    -57.00(26.00)     31.50      0.00 [-5.64, 5.64]     
Ximenes 2007           167    -41.00(19.00)        166    -41.00(19.00)     51.86      0.00 [-4.08, 4.08]     
Subtotal (95% CI)    383                         378 100.00     -1.17 [-4.67, 2.33]
Test for heterogeneity: Chi² = 2.43, df = 2 (P = 0.30), I² = 17.8%
Test for overall effect: Z = 0.65 (P = 0.51)
02 Chronic low back pain
Zerbini 2005           222    -33.00(21.00)        218    -35.00(21.00)    100.00      2.00 [-1.92, 5.92]     
Subtotal (95% CI)    222                         218 100.00      2.00 [-1.92, 5.92]
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
 -100  -50  0  50  100
 Favours selective  Favours nonselective
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NSAIDs versus NSAIDs plus muscle relaxants
Three studies, one high quality and two low quality RCTs, compared some type of NSAID 
with NSAIDs plus muscle relaxants for acute low-back pain. In all three studies, the authors 
reported the combination of an NSAID with a muscle relaxant to be better than the NSAID 
alone, although there were no statistically signiﬁ cant differences. In two trials, side effects 
were more frequent in the combination groups(86, 87). The review authors concluded that no 
differences were shown in any of the three trials and therefore, there is moderate evidence 
that muscle relaxants do not provide any additional effect to NSAIDs alone for acute low-
back pain.
NSAIDs versus NSAIDs plus B vitamins
Three studies compared diclofenac with the addition of B vitamins for low-back pain, two 
of which were high quality(89, 90). All three studies were published in German. Two studies 
included patients with acute low-back pain(88, 89); one included patients with degenerative 
changes(90). The authors of all three studies reported positive results for the combination 
therapy, although there were no statistically signiﬁ cant differences reported in two of 
these(88, 90). The review authors concluded that there is conﬂ icting evidence that an NSAID 
(diclofenac) plus B vitamins are more effective than diclofenac alone for acute low-back 
pain, and limited evidence that B vitamins do not provide additional effect to an NSAID for 
chronic degenerative low-back pain.
Graph 05.02 
Comparison: 05 NSAIDs selective COX-2 inhibition versus non selective                                                     
Outcome: 02 Proportion of patients experiencing side effects                                                           
Study  COX-2 selective  Non selective  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Acute low back pain
 Pohjolainen 2000           7/52              11/50          6.09      0.61 [0.26, 1.45]        
 Dreiser 2001b             42/164             45/162        24.58      0.92 [0.64, 1.32]        
Subtotal (95% CI) 216                212  30.67      0.86 [0.62, 1.20]
Total events: 49 (COX-2 selective), 56 (Non selective)
Test for heterogeneity: Chi² = 0.74, df = 1 (P = 0.39), I² = 0%
Test for overall effect: Z = 0.89 (P = 0.37)
02 Sub-acute/ chronic LBP
 Famaey 1998               26/93              41/98         21.67      0.67 [0.45, 1.00]        
Subtotal (95% CI) 93                 98  21.67      0.67 [0.45, 1.00]
Total events: 26 (COX-2 selective), 41 (Non selective)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.05)
03 Chronic low back pain
 Zerbini 2005              79/222             87/218        47.66      0.89 [0.70, 1.13]        
Subtotal (95% CI) 222                218  47.66      0.89 [0.70, 1.13]
Total events: 79 (COX-2 selective), 87 (Non selective)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 531                528 100.00      0.83 [0.70, 0.99]
Total events: 154 (COX-2 selective), 184 (Non selective)
Test for heterogeneity: Chi² = 2.26, df = 3 (P = 0.52), I² = 0%
Test for overall effect: Z = 2.03 (P = 0.04)
 0.1  0.2  0.5  1  2  5  10
 Fav. COX-2 selective  Fav. non selective
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Graph 05.03
Graph 05.04
Comparison: 05 NSAIDs selective COX-2 inhibition versus non selective                                                     
Outcome: 03 Proportion of patients experiencing gastrointestinal side effects                                          
Study  COX-2 selective  Non selective  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Acute low back pain
 Dreiser 2001b             17/164             19/162        30.10      0.88 [0.48, 1.64]        
Subtotal (95% CI) 164                162  30.10      0.88 [0.48, 1.64]
Total events: 17 (COX-2 selective), 19 (Non selective)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
02 Chronic low back pain
 Zerbini 2005              30/222             44/218        69.90      0.67 [0.44, 1.02]        
Subtotal (95% CI) 222                218  69.90      0.67 [0.44, 1.02]
Total events: 30 (COX-2 selective), 44 (Non selective)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
Total (95% CI) 386                380 100.00      0.73 [0.52, 1.04]
Total events: 47 (COX-2 selective), 63 (Non selective)
Test for heterogeneity: Chi² = 0.53, df = 1 (P = 0.47), I² = 0%
Test for overall effect: Z = 1.74 (P = 0.08)
 0.1  0.2  0.5  1  2  5  10
 Fav. COX-2 selective  Fav. non selective
Comparison: 05 NSAIDs selective COX-2 inhibition versus non selective                                                     
Outcome: 04 Proportion of gastrointestinal side effects                                                                
Study  COX-2 selective  Non selective  RR (fixed)  Weight  RR (fixed)
or sub-category  n/N  n/N  95% CI  %  95% CI
01 Acute low back pain
 Pohjolainen 2000           3/52               9/50         12.69      0.32 [0.09, 1.12]        
 Ximenes 2007              19/167             27/166        37.46      0.70 [0.41, 1.21]        
Subtotal (95% CI) 219                216  50.16      0.60 [0.37, 0.99]
Total events: 22 (COX-2 selective), 36 (Non selective)
Test for heterogeneity: Chi² = 1.27, df = 1 (P = 0.26), I² = 21.2%
Test for overall effect: Z = 2.00 (P = 0.05)
02 Sub-acute/ chronic LBP
 Famaey 1998               23/93              37/98         49.84      0.66 [0.42, 1.01]        
Subtotal (95% CI) 93                 98  49.84      0.66 [0.42, 1.01]
Total events: 23 (COX-2 selective), 37 (Non selective)
Test for heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.06)
Total (95% CI) 312                314 100.00      0.63 [0.45, 0.87]
Total events: 45 (COX-2 selective), 73 (Non selective)
Test for heterogeneity: Chi² = 1.30, df = 2 (P = 0.52), I² = 0%
Test for overall effect: Z = 2.76 (P = 0.006)
 0.1  0.2  0.5  1  2  5  10
 Fav. COX-2 selective  Fav. non selective
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Discussion
Effi cacy
The results of the 65 RCTs which were included in this review suggest that NSAIDs are 
slightly effective for short-term global improvement in patients with acute and chronic low-
back pain without sciatica.
The placebo-controlled studies suggest that NSAIDs are effective in improving global 
improvement in patients with acute low-back pain, but effects are only small. Quantitative 
analysis, in which the results of individual RCTs were statistically pooled, indicate statistically 
signiﬁ cant effects in favour of NSAIDs compared to placebo for populations with acute 
and chronic low-back pain without sciatica. Besides the effectiveness of NSAIDs compared 
to placebo, the NSAIDs group with acute low-back pain used less additional analgesics, 
but there was a statistically signiﬁ cantly higher number of patients with side-effects in the 
NSAIDs group.
The studies regarding chronic low-back pain also showed statistically signiﬁ cantly more 
side-effects in the NSAIDs group compared with placebo. In addition, in all newly added 
studies assessing NSAIDs for chronic low-back pain, a so called “ﬂ are design” was used, in 
which patients who were already responding well to NSAIDs are only included when they 
show a large worsening in low-back pain complaints during a wash-out period. This may 
have caused favourable results of the investigated NSAIDs, expressed in an overestimation 
of the effects and an underestimation of the side-effects due to the selection of the study 
population, and certainly decreases the external validity for daily practice.
Whether NSAIDs are more effective than other drugs or non-drug therapies for acute low-
back pain still remains unclear. There is conﬂ icting evidence that NSAIDs are more effec-
tive than simple analgesics or bed rest, and moderate evidence that NSAIDs are not more 
effective than other drugs, physiotherapy or spinal manipulation for acute low-back pain. 
NSAIDs in combination with muscle relaxants or B vitamins do not seem to provide more 
beneﬁ ts than NSAIDs alone. However, except for the B vitamin studies, the group sizes in 
these studies were smaller than 65 and therefore, these studies simply may have lacked 
power to detect a statistically signiﬁ cant difference. Sample size calculations have shown 
that 65 patients are needed per group to detect a clinically relevant difference of 25% with 
a power of 0.80 and an alpha of 0.05. There is little evidence on the most effective way of 
administration, i.e. intramuscular injections, capsules or a combination of both, or gel, as 
only a few studies evaluated injections or gel.
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There is strong evidence that various types of NSAIDs are equally effective for acute low-
back pain.
The efﬁ cacy of NSAIDS for patients with sciatica has not been shown in the studies inclu-
ded in this review. Even compared to placebo, the favourable effects of NSAIDs could not 
be demonstrated in this important subgroup of patients.
Side effects
There is no clear difference in the reported number or severity of side-effects between the 
different types of NSAIDs in the studies included in this review. Numerous articles have 
reported on the side-effects of NSAIDs, especially gastrointestinal events. In the studies pre-
sented in this review, side-effects were also frequently reported, including abdominal pain, 
diarrhea, edema, dry mouth, rash, dizziness, headache, tiredness, etc. According to the 
authors of the studies, most side-effects were considered to be mild to moderately severe. 
However, the sample sizes of most of the studies were relatively small and therefore, no 
clear conclusion can be drawn from these studies regarding the risks for gastrointestinal and 
other side effects of NSAIDs. Statistical pooling of all side effects of NSAIDs compared to 
placebo for acute low-back pain indeed showed an increased RR, indicating the additional 
risk of using NSAIDs. The comparison of several COX-2 selective NSAIDs with traditional 
NSAIDs showed a decreased RR of side-effects associated with COX-2 NSAIDs but more 
extended analyses of the separate risks of upper and lower gastrointestinal side-effects 
and central nervous system side effects are needed. In this respect, the recent insights and 
debate on the increased risk for cardiovascular events associated with the use of selective 
COX-2 inhibitors are of importance. These increased risks of COX-2 NSAIDs (as compared 
with placebo) have been shown in large randomized clinical trials. These ﬁ nding have lead 
to the removal of some selective COX-2 inhibitors from the market. The current question 
is whether the increased risk holds for all selective COX-2 inhibitors and perhaps for the 
traditional NSAIDs as well. But in order to validly answer this question, more valid data 
are needed from large epidemiologic studies of NSAID side effects. These data should also 
consider the dose, frequency and duration of the NSAID intake. It might well be, that in the 
majority of patients with low-back pain, the intake is of short duration and might not reach 
the level associated with increased cardiovascular risks.
Henry(91) reported the results of a meta-analysis of controlled epidemiological studies on 
the relative risks of serious gastrointestinal complications due to NSAIDs. The authors con-
cluded that ibuprofen was associated with the lowest relative risk of serious gastrointestinal 
complications. However, this was mainly attributable to the low doses of ibuprofen used in 
clinical practice. Because there are no important differences in efﬁ cacy between the 
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different types of NSAIDs, Henry recommended using the lowest effective doses of drugs 
that seem to be associated with a comparatively low risk of serious gastrointestinal compli-
cations.
Methodological quality
This review shows that many RCTs examining the efﬁ cacy of NSAIDs in low-back pain have 
methodological shortcomings. The randomization procedure was not described in most stu-
dies, making it impossible for the reader of the article to determine whether adequate pro-
cedures were used to exclude bias. In many studies, no measures were taken in the study 
design to avoid co-interventions, so it remains unclear if a reported difference of effect was 
due to the NSAID alone, or to a co-intervention (vice versa, if there was no difference in 
effect, this may be due to co-interventions in the control group). Compliance was often not 
measured and reported or was not satisfactory, leaving it uncertain if the prescribed medi-
cation was actually taken and leaving it unclear if the effect (or lack of effect) was due to 
the prescribed regimen. The length of follow-up was considered inadequate in more than 
half of the trials, because there was no long-term follow-up. Since international guidelines 
set prevention of disability as one of the main goals of early management and NSAIDs play 
a role in establishing this goal, one would be interested to know if NSAIDs also have any 
long-term beneﬁ ts. In post hoc sensitivity analyses, we repeated the meta-analyses without 
the low quality studies, but these did not alter the direction of any of the conclusions.
Although not related to the internal validity or methodological quality of the RCTs, the 
small size of the study populations in many RCTs indicates that these studies may lack 
statistical power to detect clinically relevant differences in effects. Statistical pooling may 
be a way to overcome this problem, but as was shown in this review, pooling is not always 
feasible. Smaller sample sizes may also lead to an imbalance of important prognostic factors 
between the study groups after randomisation, which may lead to biased outcomes if, by 
chance, patients in one group had a more favourable prognosis.
The reported methodologic ﬂ aws are not unique for RCTs evaluating the efﬁ cacy of 
NSAIDs, but have been reported to be a general problem in low-back pain trials(92). On 
average, trials of drug therapy for low-back pain even have a higher methodologic quality 
than non-drug trials(6). However, there is still a need to improve the development, conduct 
and reporting of RCTs in the ﬁ eld of back pain.
Limitations of  the study
It is possible that the effectiveness of NSAIDs is overestimated in this review because of 
publication bias. The language criteria we used for including studies in this review might 
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even have enlarged this risk, as positive results are more likely to be published in English. 
However we were not able to estimate the impact it might have had on our results, as the 
number of studies per comparison was small.
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Reviewers’ conclusions
Implications for practice
The evidence from the 65 RCTs included in this review suggests that NSAIDs are effective 
for short-term global improvement in patients with acute and chronic low-back pain wit-
hout sciatica, although the effects are small. It is still unclear if NSAIDs are more effective 
than simple analgesics and other drugs. Furthermore, there does not seem to be a speciﬁ c 
type of NSAID which is clearly more effective than others, nor is there any evidence to 
recommend another route of administration besides oral capsules or tablets. NSAIDs plus 
muscle relaxants or B vitamins do not seem to be more effective than NSAIDs alone. For 
patients with sciatica, there is no evidence that NSAIDs are more effective than placebo.
Implications for research
There is a need for RCTs, which meet the current high methodological standards, to evalu-
ate the effectiveness of NSAIDs for treating patients with acute low-back pain with sciatica 
and for treating patients with chronic low-back pain with sciatica. It also seems useful to 
evaluate the most effective dose with the comparatively lowest risk of (serious) side effects.
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Characteristics of included studies
Study Aghababian 1986
Methods RCT, open-label. Randomization procedure not described.
Participants 56 Patients.
 Inclusion criteria: mild to moderate acute LBP, 18 to 60 years of age.
 Exclusion criteria: taking analgesics, chronic back pain, pain longer than 72 hours, history of blee-
ding disorders, high blood pressure, heart, kidney, liver or ulcer disease, pregnant or breast feeding, 
allergic reactions to analgesics or NSAIDs.
Interventions NSAID (i): diﬂ unisal capsules, 1000 mg initially, 500 mg every 8 to 12 hrs, 2 wks (N=16).
 NSAID (ii): naproxen capsules, 500 mg initially, 250 mg every 6 to 8 hrs, 2 wks (N=17).
Outcomes No. of patients (%) reporting no pain (on a ordinal 4-point scale) after 2 weeks (i) 81% (ii) 41%. 
No signiﬁ cance tests reported. No adverse experiences were reported by the patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions -; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 1.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
+ beneﬁ ts/ harms +
 
Study Agrifoglio 1994
Methods RCT; single-blind. Randomization procedure not described.
Participants 100 Patients from 5 centers, 60 men and 40 women, aged 19 to 68 years.
 Inclusion criteria: acute lumbago, less than 48 hours, age 18 to 70 years, pain intensity at least 50 
mm on VAS.
 Exclusion criteria: any disorder which might interfere with the study drug, anticoagulants or other 
drugs which may interfere with the assessment of treatment, pregnancy, breastfeeding or hormonal 
contraception.
Interventions NSAID (i): Aceclofenac 150 mg intramuscular b.i.d. for 2 days + 100 mg tablets b.i.d. for 5 days + 1 
placebo tablet for 5 days (N=50).
 NSAID (ii): Diclofenac 75 mg intramuscular b.i.d. for 2 days + 50 mg tablets t.i.d. for 5 days (N=50).
Outcomes Mean improvement in pain intensity (VAS) after 8 days: (i) 65 (ii) 62. Global improvement good/
very good in (i) 87% and (ii) 79% of patients. Side effects: (i) 1 (ii) 8 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 2.
 Clinical relevance:patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
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Study Amlie 1987
Methods RCT, double-blind, placebo controlled. Randomization procedure not described.
Participants 282 Patients.
 Inclusion criteria: acute LBP lees than 48 hours, free from LBP for 3 months, age 18 to 60 years.
 Exclusion criteria: radicular symptoms, ankylosing spondylitis, rheumatoid arthritis, history of peptic 
ulcer or severe dyspepsia, hypersensitivity to aspirin or other NSAIDs, pregnancy or lactation, any 
other hematologic, hepatic, renal, pulmonary, cardiac or systemic disease.
Interventions NSAID (i): piroxicam 20 mg capsules, twice per day ﬁ rst two days, one per day next 5 days, 7 days 
(N=140).
 Reference treatment (ii): placebo capsules (N=142).
Outcomes (i) More pain relief than (ii) measured with visual analogue scale after 3 days. After 7 days no 
signiﬁ cant differences. Side effects similar (i) 18 (13%) (ii) 24 (17%).
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Aoki 1983
Methods RCT; double-blind. Randomization procedure not described.
Participants 237 Patients.
 Inclusion criteria: adults presenting at clinical centers with principal complaint LBP.
 Exclusion criteria: history of gastrointestinal, hepatic or renal disease, those with complications 
or requiring surgery, history of drug allergy, anticoagulants, abnormal baseline laboratory values, 
pregnancy, nursing mothers and women with childbearing potential.
Interventions NSAID (i): piroxicam 20 mg capsules, once per day, 14 days (N=116).
 NSAID (ii): indomethacin 25 mg capsules, three times per day, 14 days (N=114).
Outcomes No. of patients (%) who are (very much) improved after 1 and 2 weeks assessed by a physician 
(i) 49%, 70% (ii) 46%, 58%. Patients assessment after 2 weeks (very) good (i) 69% (ii) 62%. No 
signiﬁ cant differences. Side effects similar (i) 11% (ii) 13%.
Notes -Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Proefschrift Binnen_2.indd   80 28-12-2009   17:52:16
 Non-steroidal anti-infl ammatory drugs for low back pain 81
Study Babej-Dolle 1994
Methods RCT; observer-blind, multicenter study. Randomization using a random number generator. Drugs 
were randomized and provided by pharmaceutical company in individualized patient’s kits, which 
were assigned by the investigator according to the patients order of entry to the study.
Participants 260 patients aged over 18 years with lumbago or sciatic pain, 134 men, 126 women.
 Exclusion criteria: hypersensitivity to drugs or drug related malfunction of liver or kidney, polyneu-
ropathy, previous disk surgery or vertebral fractures, psychiatric disease, alcohol and drug abuse, 
pregnancy or lactation.
Interventions NSAIDs (i): dipyrone intramuscular, 5 ml (= 2.5 G) 1 to 2 injections, 1 to 2 days (N=88).
 NSAIDs (ii): diclofenac intramuscular, 3 ml (= 75 mg), 1to 2 injections, 1-2 days (N=86).
 Reference treatment (iii): placebo, 5 ml isotonic saline, 1to 2 injections, 1-2 days (N=86).
Outcomes Mean (SD) pain intensity (VAS) at baseline and after 6 hours: (i) 80.2 (15.4), 33.4 (25.5); (ii) 79.2 
(14.5), 41.7 (25.9); (iii) 78.2 (14.8), 54.8 (25.3). (i) signiﬁ cantly better than (ii) and (iii). No. (%) of 
patients recovered after 2 days (5-point NRS): (i) 27 (32%); (ii) 10 (12%); (iii) 7 (9%). Mean (SD) 
ﬁ nger-toe distance at baseline and after 2 days: (i) 29.0 (15.3), 12.0 (13.3); (ii) 28.9 (15.2), 16.3 
(14.3); (iii) 29.7 (15.7), 21.1 (14.7). Side effects: (i) 4 patients, (ii) 1 patient, (iii) 2 patients.
Notes Methodological quality: randomization +; treatment allocation +; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance 
+; baseline similarity -; follow-up -. Total score = 9.
 Clinical relevance: patients description - intervention description + outcome measures + effect size + 
beneﬁ ts/ harms +
 
Study Bakshi 1994
Methods RCT; double-blind, multicenter study. Randomization procedure not described.
Participants 132 patients, 62 men, 70 women.
 Inclusion criteria: acute back pain less than 1 week, moderate to severe pain (> 50 mm on VAS), 
at least 2 objective signs of lumbosacral pathology (tenderness, limited ROM or SLR < 75 degrees), 
LBP due to mechanical cause.
 Exclusion criteria: hypersensitivity to aspirin or NSAIDs, gastroduodenal ulcer, history of gastroin-
testinal bleeding, severe cardiac, hepatic or renal insufﬁ ciency, severe hypertension, history of 
maemopoietic or bleeding disorders, pregnancy, sensory or motor deﬁ cits in lower extremities, 
and infective, inﬂ ammatory, neoplastic, metabolic or structural cause.
Interventions NSAIDs (i): diclofenac 75 mg b.i.d., 14 days (N=66).
 NSAIDs (ii): piroxicam 20 mg b.i.d. 2 days plus once a day for 12 days (N=66).
Outcomes Mean pain intensity at rest (VAS) at baseline and after 4, 8 and 15 days: (i) 70.0, 43.3, 30.6, 22.7; 
(ii) 67.1, 44.5, 27.8, 21.0; mean ﬁ nger tip to ﬂ oor distance: (i) 28.6, 20.3, 17.8, 14.7; (ii) 29.4, 
21.5, 16.9, 14.9. No. (%) of patients improved after 14 days: (i) 54 (82%), 58 (88%). 
Not signiﬁ cant. Side effects (i) 13 patients (1 withdrawal), (ii) 12 patients (4 withdrawals).
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Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Basmajian 1989
Methods RCT; double-blind, multicenter. Randomization procedure not described.
Participants 175 Patients from 18 clinics.
 Inclusion criteria: acute incidence of trauma or musculoskeletal strain, rigid criteria of clinical pain 
and spasm for the previous 7 days were required.
Interventions NSAID (i): diﬂ unisal capsules 500 mg twice per day (N=44).
 NSAID plus muscle relaxant (ii): diﬂ unisal capsules 500 mg + 5 mg cyclobenzaprine twice per day 
(N=43).
 Muscle relaxant (iii): cyclobenzaprine (ﬂ exeril) capsules 5 mg twice per day (N=43).
 Reference treatment (iv): placebo capsules twice per day (N=45).
Outcomes No. of patients reporting marked improvement after 2, 4 and 7 days: (i) 10, 14, 24 (ii) 10, 14, 31 
(iii) 8, 18, 30 (iv) 10, 14, 20. Group (ii) signiﬁ cantly better after 4 days (based on total distribution). 
No other signiﬁ cant differences. No signiﬁ cant side effects were reported.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 5.
 Unclear presentation of results.
 Clinical relevance: patients description - intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Berry 1982
Methods RCT; double-blind, cross-over.
 Randomization procedure not described.
Participants 37 Patients, 24 women and 13 men, aged 32 to 79 years, median duration of back pain 3 years.
 Inclusion criteria: adult patients with chronic back pain (> 3 months) due to spondylosis, degenera-
tive disease, sciatica, or nonspeciﬁ c pain.
 Exclusion criteria: malignancy, infection, spondylolisthesis, abnormal alkaline phosphatase level, ESR 
> 25 mm/hr.
Interventions NSAID (i): naproxen sodium 275 mg capsules, 2 times 2 capsules per day, 14 days (N=37 in cross-
over design).
 NSAID (ii): diﬂ unisal 250 mg capsules, 2 times 2 capsules per day, 14 days (N=37 in cross-over 
design).
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 Reference treatment (iii): placebo capsules (N=37 in cross-over design).
Outcomes Decrease in pain by visual analogue scale. Group (i) reduction of pain (ii) no change (iii) increase 
of pain. Data in graphs. Group (i) signiﬁ cantly better than (iii) and somewhat better than (ii). Side 
effects similar in the three groups (i) 18 (ii) 18 (iii) 16.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
+ beneﬁ ts/ harms +
 
Study Berry 1988b
Methods RCT; double-blind, multicenter study. Randomization procedure not described.
Participants 105 patients, 58 men, 47 women, from seven general practitioners.
 Inclusion criteria: acute low back pain of at least moderate severity, recent onset, limitation of 
movement of the lumbar spine, age 18 to 65 years.
 Exclusion criteria: pregnancy or lactation, malignancy, osteoporosis, history of lumbar spine surgery, 
signiﬁ cant systemic disease, allergy or sensitivity to study drugs, rheumatic diseases.
Interventions NSAIDs (i): ibuprofen 400 mg plus placebo tid, 7 days (N=54).
 Reference treatment (ii): ibuprofen 400 mg plus tizanidine 4 mg tid, 7 days (N=51).
Outcomes Mean (SD) changes in pain at rest (VAS) between baseline and day 3 and baseline and day 7: (i) 16 
(24.9), 33 (32.9); (ii) 18 (25.3), 29 (43.3). Number (%) of patient improved on functional status 
(restriction of movement) after 3 days: (i) 32 (60%), (ii) 32 (64%). No. (%) of patients improved 
according to physician after 3 and 7 days: (i) 36 (67%), 42 (81%); (ii) 39 (76%), 39 (85%). Not 
signiﬁ cant. Side effects: (i) 17 patients, (ii) 23 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 7.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Birbara 2003
Methods RCT; “ﬂ are design”; double-blind; double-dummy; multicentre. Randomised according to computer 
generated random allocation table
Participants 314 outpatients, 190 women, 124 men from 46 centres in USA.
 Inclusion criteria: age 18 to 75 years;
 LBP >= 3 months, usage NSAID or Acetaminophen >= 30 days; pain without radiation to an extre-
mity and without neurological signs or pain with radiation to an extremity, but not below the knee 
and without neurological signs; ﬂ are criteria after washout period.
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 Exclusion criteria: secondary cause of LBP; surgery for LBP in previous 6 months; symptomatic 
depression; drug abuse in past 5 years; usage opioids > 4 days in previous month; corticosteroid 
injection in previous 3 months
Interventions NSAIDs (i): Etoricoxib 60 mg/ day, 12 weeks (N=101).
 NSAIDs (ii): Etoricoxib 90 mg/ day, 12 weeks (N=106).
 Reference treatment (iii): placebo, daily, 12 weeks (N=107).
Outcomes Mean difference (95% CI) pain intensity scale (100 mm VAS) at 12 weeks; (i vs iii) -10.45 (-16.77 
to -4.14); (ii vs iii) -7.5 (-13.71 to -1.28)
 Mean difference (95% CI) LBP bothersomeness scale over 12 weeks (4-pt Likert, 0= not at all, 
4= extremely); (i vs iii) -0.38 (-0.62 to -0.14); (ii vs iii) -0.33 (-0.57 to -0.09)
 Mean difference (95% CI) RMDQ (0- 24 pt scale) over 12 weeks; (i vs iii) -2.42 (-3.87 to -0.98); 
(ii vs iii) -2.06 (-3.46 to -0.65)
 Side effects: (i) 60 patients (14 withdrew); (ii) 56 patients (17 withdrew); (iii) 51 patients 
(10 withdrew)
Notes Methodological quality: randomization +; treatment allocation +; withdrawals -; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up +. Total score = 7.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Blazek 1986
Methods RCT; double-blind. Randomization procedure not described.
Participants 28 Patients, 20 women and 8 men.
 Inclusion criteria: lumbo-ischialgia and femoralgia due to herniated disc.
 Exclusion criteria: gastrointestinal, hepatic or renal disease.
Interventions NSAID (i): diclofenac 25-mg capsules, four times per day ﬁ rst 4 days and three times per day next
 8 days, 12 days (N=14).
 NSAID (ii): biarison 300-mg capsules, four times per day ﬁ rst 4 days and three times per day next 
8 days, 12 days (N=14).
Outcomes Average improvement on ordinal 5-points scale (0= no response, 4=very good response) during and 
after the intervention period of 12 days according to physician and patient (i) 2.6 and 2.8 (ii) 2.8 
and 3. No signiﬁ cant differences in recovery rate. Side effects: mild side effects in three patients in 
each group.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
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Study Borenstein 1990
Methods RCT; open-label. Randomization procedure not described.
Participants 40 patients with acute low back pain referred to an orthopedist or rheumatologist, 28 men, 
12 women.
 Inclusion criteria: acute muscle spasm with mild to moderate back pain, duration 10 days or less, 
age 18 to 60 years.
 Exclusion criteria: severe pain, hypersensitivity to study drugs, history of peptic ulcer or bleeding dis-
orders, hypertension, hepatic, cardiovascular or renal disease, marked obesity, neurologic symptoms 
including sciatica history of back surgery, lactation or pregnancy.
Interventions NSAIDs (i): naproxen 500 mg initially plus 250 mg qid, 14 days (N=20).
 Reference treatment (ii): naproxen 500 mg initially plus 250 mg qid plus cyclobenzaprine 10 mg tid, 
14 days (N=20).
Outcomes Physical examination (Schober), days to resolution of pain, days to sit without pain, functional 
capacity after 14 days: (i) 5, 12.5, 7, 15; (ii) 5, 8.5, 5, 9. Side effects: (i) 4 patients, (ii) 12 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat +; compliance +; 
baseline similarity +; follow-up -. Total score = 5.
 Poor presentation of data. Only statistically signiﬁ cant results presented.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Braun 1982
Methods RCT. Randomization procedure not described.
Participants 37 patients with acute lubo-ischialgia.
Interventions NSAID (i): ketoprofen (Orudis) 200 mg intramuscular bid for 3 days plus 50 mg, 4 capsules plus 
100 mg drink for 5 days (N=?).
 Reference treatment (ii): combination (Phenylbutazon-Sodium, Carbamoylphenoxyacetose, 
Dexamethasone, Lydocaine- hydrochlorid, Cyanocobalamine) 1 intramuscular placebo injection, 
3 days plus 3 tablets for 5 days plus 1 placebo drink for 5 days (N=?).
Outcomes Mean pain intensity at baseline and after 4 and 9 days: (i) 68, 56, 42 and (ii) 68, 52, 39; Laseque: 
(i) 48, 65, 74 and (ii) 51, 51, 60; ﬁ ngertip-to-ﬂ oor distance: (i) 28, 25, 17 and (ii) 36, 30, 26. 
No signiﬁ cant differences. No adverse effects.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity -; follow-up -. Total score = 1.
 Clinical relevance: patients description - intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
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Study Brown 1986
Methods RCT; open-label. Randomization procedure not described.
Participants 47 Patients.
 Inclusion criteria: initial or recurrent mild to moderate acute LBP, age 18 to 59 years.
 Exclusion criteria: pregnant or nursing women, allergy to aspirin or other NSAIDs, history of peptic 
ulcer, gastrointestinal bleeding or bleeding disorders, hypertension, cardiovascular, renal or hepatic 
disease, recurrent chronic pain, neurologic signs or symptoms, fracture.
Interventions NSAID (i): diﬂ unisal (capsules), initial dose 1000 mg, 500 mg every 12 hrs, 15 days (N=19).
 Reference treatment (ii): acetaminophen 300 mg with codeine 50 mg, two capsules initially, one 
capsule every 4 hours, 15 days (N=21).
Outcomes Pain assessments by patient and investigator on 3-point ordinal scale show similar improvement 
curves (data in graphs). No. of patients rating drugs as excellent or very good (i) 9 (ii) 9. 
No signiﬁ cant differences. Side-effects: more side effects in (ii) 10 than in (i) 3.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity -; follow-up -. Total score = 2.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Bruggemann 1990
Methods RCT; double-blind, multicenter study. Randomization procedure not described.
Participants 418 ambulant patients.
 Inclusion criteria: acute low back pain, age 18 years and older.
 Exclusion criteria: acute disc problems, intolerance of study drugs, disorders or drugs which could 
interfere with the study.
Interventions NSAID (i): Diclofenac sodium, 25 mg 2 capsules t.i.d., 7-14 days (N=192).
 Reference treatment (ii): diclofenac sodium plus vitamin B1, B6, B12, 2 capsules t.i.d., 7 to 14 days 
(N=184).
Outcomes After 1 week 49% of (i) and 56,5% of (ii) no or weak pain and 25% in (i) and 29% in (ii) impro-
ved. Mean overall pain score at baseline and after 1 and 2 weeks: (i) 78.7, 37.7, 23.7, (ii) 83.7, 
34.4, 23.6. Tolerability good or very good in 90% (i) and 88% (ii). Side effects: (i) 7 patients 
(ii) 12 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
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Study Chrubasik 2003
Methods RCT; double-blind; double-dummy; single-centre. Allocated according to a random 
number, exact procedure not described.
Participants 88 patients, 64 women, 24 men
 Inclusion criteria: age 45 to 75 years;
 LBP >= 6 months not attributable to a speciﬁ c cause; exacerbation of complaints> 8 weeks, 
affecting rest and movement; pain>= 50 mm on 100 mm VAS; judged to require symptomatic 
treatment for 6 weeks
 Exclusion criteria: participation in other clinical study within 30 days; serious organic illness; drug/ 
alcohol abuse; requirement of psychotherapeutic agents; pregnancy/ lactation; allergies to medica-
tion; in patients over 50 constitutional symptoms.
Interventions NSAIDs (i): rofecoxib 12.5 mg/ day, 6 weeks (N=44).
 Reference treatment (ii): dolotefﬁ n 2400 mg/ day, 6 weeks (N=44).
Outcomes Number of patients pain free after 3 and 6 weeks: (i) 4, 7; (ii) 5, 10
 Side effects: (i) 14 patients (1 withdrew); (ii) 14 patients (6 withdrew)
Notes Methodological quality: randomization ?; treatment allocation ?; withdrawals +; co-interventions ?; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance 
?; baseline similarity +; follow-up +. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Coats 2004
Methods RCT; “ﬂ are design”; double-blind; multicentre. Randomised according to computer generated ran-
dom allocation table, exact procedure not described.
Participants 293 patients, 166 women, 127 men from 42 centres in USA and Canada.
 Inclusion criteria: age >=18 years;
 LBP >= 3 months, regular usage of analgesic medication; pain without radiation to an extremity 
and without neurological signs or pain with radiation to an extremity, but not below the knee and 
without neurological signs; ﬂ are criteria after washout period.
 Exclusion criteria: secondary cause of LBP; surgery for LBP in previous 4 weeks; usage opioids or 
corticosteroids in previous 90 days; pending workers compensation claims; (possible) pregnancy or 
breastfeeding
Interventions NSAIDs (i): valdecoxib 40-mg/ day, 4 weeks (N=148). 
 Reference treatment (ii): placebo tablets, once daily, 4 weeks (N=143).
Outcomes Data in graphs; Mean changed score on pain intensity scale (100 mm VAS) at 1 week and 4 weeks; 
(i) 29.2 and 41.9; (ii) 17.7 and 31.1; (i vs ii) all P< 0.001
 Side effects: (i) 52 patients (1 withdrew); (ii) 35 patients (3 withdrew)
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Notes Methodological quality: randomization +; treatment allocation ?; withdrawals -; co-interventions ?; 
patients blinded +; outcomes blinded +; care providers blinded ?; intention-to-treat -; compliance +; 
baseline similarity +; follow-up +. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 Unclear presentation of results.
 
Study Colberg 1996
Methods RCT; multicenter study (12 centers of orthopaedic surgeons, internal specialists and general practi-
tioners). Randomization procedure not described.
Participants 183 patients, 103 men, 80 women.
 Inclusion criteria: age 18 years or older, acute lumbago, onset within 48 hours prior to treatment.
 Exclusion criteria: chronic or recurrent LBP, disk prolapse, trauma, history of gastrointestinal ulcer, 
coagulation or bleeding disorders, hypersensitivity to analgesics or NSAIDs, pregnant or breast-
feeding women or women without adequate contraception.
Interventions NSAIDs (i): meloxicam intravenous 1.5 ml (= 15 mg) 1 injection day 1 plus 15 mg tablets once a 
day, 7 days (N=92).
 NSAIDs (ii): diclofenac intramuscular 3 ml (= 75 mg) 1 injection day 1 plus 100 mg tablets once a 
day, 7 days (N=91).
Outcomes Percentage of patients recovered after 8 days on pain intensity, overall improvement, functional sta-
tus and tolerance: (i) 91%, 89%, 67%, 96%; (ii) 88%, 91%, 54%, 98%. Side effects: (i) 6 patients 
(1 severe), (ii) 8 patients (1 severe).
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 3.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Davoli 1989
Methods RCT. Randomization procedure not described.
Participants 30 patients, 26 women and 4 men, mean age 62 years, range 45 to 80 years.
 Inclusion criteria: acute or recurrent low back pain, with or without radiation, degree of pain at least 
2 on a 5-point scale.
 Exclusion criteria: pregnant or lactating women, gastroduodenal ulcer, depression, severe hepatic, 
renal and/or cardiovascular insufﬁ ciency, severe alterations of blood chemistry, hypersensitivity or in-
tolerance to piroxicam, aspirin or other NSAIDS, use of NSAIDs or corticosteroids in previous 30 days.
Interventions NSAID (i): etodolac 200 mg bid, 7 days (N=15).
 NSAID (ii): piroxicam-beta-cyclodextrin one 20 mg tablet, 7 days (N=15).
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Outcomes Mean degree of pain at baseline and after 7 days: (i) 3.1, 0.8, (ii) 3.13, 0.3. No signiﬁ cant diffe-
rence. Side effects (i) 3 patients, (ii) 2 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 3.
 Very short-term follow-up, small sample size.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Dreiser 2001
Methods RCT; double-blind; double-dummy; multicentre.
 Randomisation procedure not described.
Participants 532 outpatients with acute sciatica, age mean (SD), 47 (14); 44% male, 56% female.
 Inclusion criteria: age >= 18; common sciatica; onset of pain within 3 days; pain 100 mm VAS >= 
50 mm; monoradiculagia (L5 or S1); positive straight-leg-raising test <=60 degrees; requirement 
of NSAID’s.
 Exclusion criteria: treatment with any NSAID previous 3 days; adverse events due to NSAIDs; 
hypersensitivity to analgesics, antipyretics, or NSAIDs; concomitant treatment with anti-coagulants, 
lithium, other NSAID, analgesic agents; previous or active peptic ulcer; former lumbar surgery; 
symptomatic sciatica during previous 6 months; cauda equina syndrome; paralysing sciatica; 
troncular sciatica; sciatica due to tumour; spindylodiscitis; known lumbar canal narrowing.
Interventions NSAID (i): Melocicam 7.5 mg/ day, 1 week (N=171).
 NSAID (ii): Melocicam 15 mg/ day, 1 week (N=181).
 Reference treatment (iii): placebo, daily, 1 week (N= 80).
Outcomes Pain mean changed score (SD), 100 mm VAS, after 7 days: (i) -46 (26); (ii) -45 (27); (iii) -40 (27); 
(i) vs (iii) and (ii) vs (iii) signiﬁ cantly lower (P< 0.05)
 Side effects: (i) 29 patients (2 withdrew); (ii) 35 patients (2 withdrew); (iii) 24 patients (3 withdrew)
Notes Methodological quality: randomization ?; treatment allocation ?; withdrawals +; co-interventions ?; 
patients blinded +; outcomes blinded +; care providers blinded ?; intention-to-treat +; compliance ?; 
baseline similarity +; follow-up +. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Dreiser 2001b
Methods RCT; double-blind; double-dummy; multicentre.
 Randomisation procedure not described.
Participants 489 outpatients with acute sciatica, age mean (SD), 45 (14); 53% male, 47% female.
 Inclusion criteria: age >= 18; common sciatica; onset of pain within 3 days; pain 100 mm VAS >= 
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50 mm; monoradiculagia (L5 or S1); positive straight-leg-raising test <=60 degrees; requirement 
of NSAID’s.
 Exclusion criteria: treatment with any NSAID previous 3 days; adverse events due to NSAIDs; 
hypersensitivity to analgesics, antipyretics, or NSAIDs; concomitant treatment with anti-coagulants, 
lithium, other NSAID, analgesic agents; previous or active peptic ulcer; former lumbar surgery; 
symptomatic sciatica during previous 6 months; cauda equina syndrome; paralysing sciatica; troncu-
lar sciatica; sciatica due to tumour; spindylodiscitis; known lumbar canal narrowing.
Interventions NSAID (i): Meloxicam 7.5 mg/ day, 14 days (N=164).
 NSAID (ii): Meloxicam 15 mg/ day, 14 days (N=163).
 NSAID (iii): diclofenac, daily, 14 days (N=162).
Outcomes Pain mean changed score (SD), 100 mm VAS, after 14 days: (i) -57 (26); (ii) -56 (26); (iii) -57 (26); 
 Side effects: (i) 42 patients (6 withdrew); (ii) 49 patients (6 withdrew); (iii) 45 patients (7 withdrew)
Notes Methodological quality: randomization ?; treatment allocation ?; withdrawals +; co-interventions ?; 
patients blinded +; outcomes blinded +; care providers blinded ?; intention-to-treat +; compliance ?; 
baseline similarity +; follow-up +. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Dreiser 2003
Methods RCT; double-blind; double-dummy parallel group; multicentre.
 Drugs were randomised according to a random scheme in blocks of 3, provided by pharmaceutical 
company; the lowest available randomisation number was assigned to the patients at each site 
when entering the study.
Participants 369 GP patients, 187 female, 182 male 
 Inclusion criteria: 18- 60 years, with untreated acute low back pain, onset within 2 days, pain>= 50 
mm on 100 mm VAS, not due to an associated radicalagia; not radiating below gluteal fold, pain 
intermittent/ constant and aggravated by mechanical factors.
 Exclusion criteria: hypersensitivity to diclofenac/ ibuprofen/ paracetamol/ aspirin, current disease 
status that could interfere with safety or efﬁ cacy of study medication, concomitant treatments, 
pregnant or nursing, sensory or motor deﬁ cits in lower extremities, previous episode of LBP within 3 
months, and infective, inﬂ ammatory, neoplastic, metabolic or structural cause.
Interventions NSAID (i): diclofenac-K 12 mg, initial dose 2 tablets, 7 days ﬂ exible dose 4 to 6 tablets/ day 
(N=124)
 NSAID (ii): ibuprofen 200 mg, initial dose 2 tablets, days ﬂ exible dose 4 to 6 tablets/ day (N=122)
 Reverence treatment (iii): placebo, initial dose 2 tablets, 7 days ﬂ exible dose 4 to 6 tablets/day 
(N=126)
Outcomes Pain mean changed score (SD), 100 mm VAS, after 7 days: (i, N=122) -48 (26); (ii, N=119) -49 
(24); (iii, N=121) -38 (27); (i) vs (iii) and (ii) vs (iii) signiﬁ cantly lower (P< 0.001)
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 Roland-Morris Back Pain Questionnaire (0-24, no- maximal disability) mean changed score (SD) 
after 7 days: (i, N=119) -8.6 (5.7), (ii, N=118) -8.1 (5.2), (iii, N=116) -5.7 (5.3); (i) vs (iii) and (ii) vs 
(iii) signiﬁ cantly lower (P< 0.001)
 Side effects: (i) 16 patients (4 withdrew); (ii) 14 patients (4 withdrew); (iii) 20 patients (8 withdrew)
Notes Methodological quality: randomization ?; treatment allocation +; withdrawals +; co-interventions ?; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance 
+; baseline similarity +; follow-up +. Total score = 9.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
+ beneﬁ ts/ harms +
 
Study Driessens 1994
Methods RCT; double-blind, double-dummy, multiple-dose. Randomization procedure not described.
Participants 62 patients from 5 rheumatology centers, 29 men, 33 women, mean age (SD) 52.6 (14.3).
 Inclusion criteria: hospital outpatients, chronic back pain for at least 4 weeks.
 Exclusion criteria: acute or chronic infections, neoplasm or metastases, other severe intercurrent sy-
stemic disease, sciatica, referred pain, pregnancy or lactation, contraindications for NSAID therapy.
Interventions NSAID (i): ibuN=rofen sustained-release (SR) 800 mg bid plus placebo, 14 days (N=30).
 NSAID (ii): diclofenac SR 100 mg once per day plus placebo, 14 days (N=32).
Outcomes Mean (SD) improvement in pain intensity, global measure, physical examination (Schober), level of 
activity: (i) 2.0, 2.2 (1.5), 0.6 (0.6), 2.2 (ii) 2.3, 3.0 (1.7), 0.4 (0.6), 1.9. no signiﬁ cant differences. 
Side effects in (i) 4 patients, (ii) 16 patients. Signiﬁ cant.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Evans 1980
Methods RCT; single-blind, cross-over. Allocation according to a random list.
Participants 60 Ambulant outpatients.
 Inclusion criteria: suffering from acute exacerbations of LBP of moderate intensity.
 Exclusion criteria: pregnancy, sensitive to any of the trial drugs, suffering from concomitant disease.
Interventions NSAID (i): aspirin 300 mg, 3 capsules 4 times per day, week (N=30).
 NSAID (ii): indomethacin 50 mg, 3 times per day, 1 week (N=30).
 NSAID (iii): mefenamic acid 250 mg, 2 capsules 3 times per day, 1 week (N=30).
 NSAID (iv): phenylbutazone 100 mg, 3 times per day, 1 week (N=30).
 Reference treatment (v): dextropropoxyphene 32.5 mg and paracetamol 325 mg capsules, 
2 capsules 4 times per day, 1 week (N=30).
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 Reference treatment (vi): paracetamol 500 mg capsules, 2 capsules 4 times per day, 1 week (N=30).
Outcomes Mean daily pain index during intervention period (on 4-point ordinal scale) (i) 1.4 (ii) 1.5 (iii) 1.4 
(iv) 1.4 (v) 1.7 (vi) 1.7. (iii) Signiﬁ cantly different from (v) and (vi); (i) signiﬁ cantly different from (v). 
Side effects: more side effects in (i) 20 (ii) 19 and (v) 19 than in (iii) 12 (vi) 13 and (iv) 4.
Notes Methodological quality: randomization +; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat +; compliance +; 
baseline similarity -; follow-up -. Total score = 4.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms +
 
Study Famaey 1998
Methods Open label randomized trial, multicenter. Randomization procedure not described.
Participants 196 out-patients, 123 female 73 male, subacute/ chronic low back pain patients without a speciﬁ c 
diagnosis such as root entrapment syndromes, with at least severe pain at either rest, motion, stan-
ding or at night. Exclusion criteria: acute LBP; active/ previous history of gastric or duodenal ulcers, 
renal or hepatic diseases, history asprin/ NSAID intolerance; treatment with corticosteroids.
Interventions NSAIDs (i): nimesulide 100 mg, b.i.d., 4 weeks (N=95).
 Reference treatment (ii): diclofenac sodium 50 mg b.i.d., 4 weeks (N=101).
Outcomes Sum of patients with none, mild moderate/ sum of patients with severe, very severe pain at: rest, 
motion, night, standing. Data in graphs. No differences found between treatments. Side effects (i) 
26, (ii) 41; (i) vs (ii) P=0.05.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity +; follow-up +. Total score = 4.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms +
 
Study Goldie 1968
Methods RCT; Neither doctor, nurse or patient were aware of which treatment was given as the bottles in 
which the capsules were dispensed only had a number on the label the code of which was known 
only to the manufacturer.
Participants 50 Patients; 26 men and 24 women, all but 5 patients were hospitalized.
 Inclusion criteria: sciatica, acute back pain less than 3 weeks.
Interventions NSAID (i): indomethacin 25 mg capsules, three per day, course of 50 capsules (N=25).
 Reference treatment (ii): placebo capsules (N=25).
Outcomes No. of patients with complete relief of pain after 7 and 14 days (i) 7, 14 (ii) 9, 16. No signiﬁ cant 
differences. Side effects comparable (i) 8 (ii) 5.
Notes Methodological quality: randomization +; treatment allocation +; withdrawals +; co-interventions +; 
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patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 9.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Hickey 1982
Methods RCT; double-blind. Randomization was carried out prior to the trial by the ﬁ rm supplying the drugs, 
which were code-labelled and unknown to the investigator.
Participants 30 Patients, 26 women and 4 men.
 Inclusion criteria: chronic LBP. 
 Exclusion criteria: pain from intervertebral disc prolapse, suspected neoplastic disease, neurological 
disease, pregnancy, peptic ulceration, gastrointestinal haemorrhage, current treatment with systemic 
corticosteroids or anticoagulants, liver or kidney disease, haemopoietic disorders and history of 
sensitivity to salicylates or paracetamol, psychiatric problems.
Interventions NSAID (i): diﬂ unisal 500 mg capsules, twice per day, 4 weeks (N=16).
 Reference treatment (ii): paracetamol 1000 mg, four times per day, 4 weeks (N=13).
Outcomes No. of patients with none or mild low back pain after 2 and 4 weeks (i) 11, 13 (ii) 9, 7. Signiﬁ cantly 
more patients in (i) (10 out of 16) considered the therapy as good or excellent than in (ii) (4 out of 
12). Side effects similar (i) 2 (ii) 1.
Notes Methodological quality: randomization +; treatment allocation +; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 7.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
+ beneﬁ ts/ harms +
 
Study Hingorani 1970
Methods CCT; double-blind. Not randomized.
Participants 83 patients with acute low back pain warranting in-patient treatment, 59 men, 24 women.
 Inclusion criteria: pain in the lower back of acute or chronic onset.
 Exclusion criteria: neoplasms, myeloma, Paget’s disease, collagen disease, rheumatoid arthritis, 
ankylosing spondylitis and patients with contraindications to either drug.
Interventions NSAID (i): indomethacin 25 mg, qid, 7 days (N=40).
 NSAID (ii): oxyphenbutazone 100 mg, qid, 7 days (N=43).
Outcomes Total pain score (4-points scale) at baseline and after 3 and 7 days: (i) 52, 48, 39, (ii) 60, 47, 44; 
total physical examination score (ﬁ ngertip-ﬂ oor distance, inch): (i) 440, 384, 304, (ii) 530, 456, 380; 
total functional status score (movements; 4-point scale): 113, 105, 77, (ii) 142, 117, 99; paraceta-
mol use: after 3 and 7 days: (i) 7.4, 3.8, (ii) 7.7, 4.1. Only pain after 3 days signiﬁ cantly different. 
Side effects: (i) 5/40, (ii) 3/43.
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Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Hingorani 1975
Methods RCT; double-blind, cross-over. Randomization procedure not described.
Participants 50 patients, 32 men, 18 women, mean age 48.4 years.
 Inclusion criteria: age 20 to 70 years, acute backache necessitating a stay in hospital of at least 
3 weeks.
 Exclusion criteria: concomitant treatment with steroids, gold or mono-amine oxidase inhibitors, 
systemic cause of backache, history of peptic ulcer, possibility of pregnancy.
Interventions NSAIDs (i): azapropazone 300 mg qid, 1 week (N=?).
 NSAIDs (ii): ketoprofen 50 mg qid, 1 week (N=?).
Outcomes No data presented. Side effects: (i) 3 patients (1 severe), (ii) 14 patients (10 severe).
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 5.
 Clinical relevance: patients description - intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Hosie 1993
Methods RCT; double-blind, double-dummy, multicenter. Randomization procedure not described.
Participants 287 patients, 151 men, 136 women, aged 18 to 63 years.
 Inclusion criteria: acute LBP less than 1 month.
 Exclusion criteria: sciatica, 2 or more episodes of LBP in the previous 6 months, nerve root pressure, 
previous vertebral fractures, spinal stenosis, spondylolisthesis, marked scoliosis, ankylosing spon-
dylitis, osteoarthritis, Paget’s disease, metabolic bone disease, systemic connective tissue disorders, 
malignancy, infection, referred pain from intra-abdominal or intra-pelvic disease, pregnancy, lacta-
tion, allergy to NSAIDs, history of bronchial asthma or peptic ulcer, gastrointestinal, renal, hepatic, 
cardiovascular, metabolic, haematological or dermatological disease.
Interventions NSAID (i): ibuprofen capsules 400 mg three times per day + placebo foam 3 times d, 14 days 
(N=147).
 NSAID (ii): felbinac (foam 3%) 3 times daily + placebo capsules 3 times d, 14 days (N=140).
Outcomes Patients (%) reporting none or mild severity after 1 and 2 weeks (i) 84, 92 (ii) 76, 88. No signiﬁ cant 
differences between the groups. No. of side effects (i) 22 (ii) 26.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
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patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Ingpen 1969
Methods RCT; double-blind, cross-over. Paired bottles containing identical capsules were coded and 
randomized in groups of six.
Participants 20 patients with backache.
 Inclusion criteria: longstanding backache with X-ray conﬁ rmation of degenerative changes.
 Exclusion criteria: sciatica.
Interventions NSAID (i): indomethacin 25 mg tid, 4 days (N=20).
 Reference treatment (ii): dextropropoxyphene HCL, 150 mg tid, 4 days (N=20).
Outcomes Data extraction not possible. Side effects: (i) 7 patients (ii) 13 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Innes 1998
Methods RCT; double-blind; multicentre. Randomised according to computer generated random allocation 
table, exact procedure not described.
Participants 122 emergency department patients with acute LBP, age mean (SD), 34.5 (10); 96 male, 26 female.
 Inclusion criteria: age 18 - 60; weight >50 kg ;moderate/ severe LBP, well enough for discharge 
within 4 hours; onset of pain within 72 hours; requirement of oral analgesics.
 Exclusion criteria: treatment with investigational drug in previous 4 weeks; adverse events due 
to NSAIDs; hypersensitivity to analgesics, antipyretics, or NSAIDs; anti-coagulants use within 
4 weeks, concurrent treatment with other medications inﬂ uencing pain intensity evaluations;
active peptic ulcer within 6 months; conditions requiring treatment beyond analgesics; 
pregnancy or nursing; alcohol/ drug abuse; chronic LBP/ neurologic cause; interfering co-existing 
injury/ illness.
Interventions NSAID (i): Dose 1 to 4 per day Ketrolac tromethamine 10 mg/ 4 to 6 hours as needed; dose 5, 6 
per day acetaminophen 650 mg if needed; up to 7 days (N= 62).
 Reference treatment (ii): Dose 1 to 6 per day, acetaminophen 600 mg + codeine 60 mg/ 4 to 6 
hours as needed; up to 7 days (N= 60).
Outcomes Pain mean changed score (SD), 100 mm VAS, after 6 hours: (i, N=55) -6 (17); (ii, N=58) -5 (18), 
no signiﬁ cant differences; 
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 % patients reporting ‘a lot/ complete’ pain relief after 4 days: (i) 53 %; (ii) 55%, no signiﬁ cant 
differences; 
 % patients reporting ‘no/ mild’ impairment after 4 days: (i) 67 %; (ii) 62%, no signiﬁ cant differences.
 Side effects: (i) 21 patients (0 withdrew); (ii) 38 patients (7 withdrew)
Notes Methodological quality: randomization +; treatment allocation ?; withdrawals +; co-interventions ?; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance +; 
baseline similarity +; follow-up +. Total score = 8.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms +
 
Study Jacobs 1968
Methods RCT; double-blind. Patients were allotted the next serial number in their diagnostic category and 
given the appropriate numbered bottle.
Participants 110 patients with clinically diagnosed prolapsed intervertebral disc with or without radicular pain 
attending an outpatient clinic, maximum 60 years of age.
 Inclusion criteria: acute or chronic LBP, age < 60 years.
 Exclusion criteria: neoplastic, metabolic, or other bone disease, pregnancy, diabetes, epilepsy, 
peptic ulcer.
Interventions NSAID (i): indomethacin 25 mg capsules, 3 capsules per day for 2 days, 4 capsules per day next 
5 days (N=25 with nerve root pain, and N=30 without nerve root pain).
 Reference treatment (ii): placebo capsules (N=25 with nerve root pain, and N=30 without nerve 
root pain).
Outcomes Group (i) signiﬁ cantly more effective than (ii) only in patients with nerve root pain (data in graphs). 
Number of side effects (i) 38 (ii) 23.
Notes Methodological quality: randomization +; treatment allocation +; withdrawals -; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity -; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Jaffe 1974
Methods RCT; double-blind. Randomization procedure not described.
Participants 61 patients with low back pain with or without sciatica, 27 men, 34 women, 30 with acute onset 
and 31 with chronic pain.
 Exclusion criteria: peptic ulcer, renal or hepatic impairment, history of intolerance to study drugs, 
children.
Interventions NSAIDs (i): alclofenac 1 g tid, 7 days (N=15 acute; N=16 chronic).
 NSAIDs (ii): indomethacin 50 mg tid, 7 days (N=15 acute; N=15 chronic).
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Outcomes Mean (SEM) change score in pain intensity (5-point NRS), functional status (4-point NRS) and 
Lasegue after 7 days for acute LBP: (i) 1.46 (0.28), 1.80 (0.03), 1.50 (0.30); (ii) 1.45 (0.27), 1.53 
(0.23), 1.40 (0.23). Not signiﬁ cant. Mean (SEM) change score in pain intensity (5-point NRS), 
functional status (4-point NRS) and Lasegue after 7 days for chronic LBP: (i) 1.66 (0.62), 1.31 
(0.63), 1.21 (0.52); (ii) 1.01 (0.71), 1.00 (0.58), 0.87 (0.42). Not signiﬁ cant. Side effects: 
(i) 5 patients, (ii) 3 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 7.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Katz 2003
Methods RCT; “ﬂ are design”; double-blind; parallel group; multicentre.
 Drugs were randomised according to a random allocation scheme; when entering the study, the 
lowest available randomisation numbers were assigned to the patients with pre-study NSAID usage 
and the highest available numbers to patients that used other analgesics before the study.
Participants 690 patients from primary care practices or rheumatologists, 430 female, 260 male, 18 to 75 years, 
with chronic low back pain > 3 months, taking analgesics daily, ﬂ are criteria: pain > 40 mm and 
increase > 10 mm during washout period on 100 mm VAS, pain not radiating below the knee and 
without neurological signs.
 Exclusion criteria: CLBP due to known secondary causes, LBP surgery within 6 months, clinical 
depression within 2 years, drugs/ alcohol within 5 years, opioids > 4 days in previous month, corti-
costeroid injections previous 3 months.
Interventions NSAIDs (i): rofecoxib 25 mg/ day, 4 weeks (N= 233)
 NSAIDs (ii): rofecoxib 50 mg/ day, 4 weeks (N= 229)
 Reference treatment (iii): placebo, daily, 4 weeks (N= 228)
Outcomes Mean difference (95% CI) pain intensity scale (100 mm VAS) at 4 weeks; (i, N= 228 vs iii, N= 223) 
-13.5 (-18.1 to -8.9); (ii, N= 224 vs iii) -13.8 (-18.5 to -9.2)
 Mean difference (95% CI) LBP bothersomeness scale over 4 weeks (4-pt Likert, 0= not at all, 4= 
extremely); (i vs iii) -0.5 (-0.6 to -0.3); (ii vs iii) -0.5 (-0.7 to -0.3)
 Mean difference (95% CI) RMDQ (0- 24 pt scale) over 4 weeks; (i vs iii) -2.2 (-3.2 to -1.3); (ii vs iii) 
-2.3 (-3.3 to -1.3)
 Side effects: (i) 112 patients (10 withdrew); (ii) 106 patients (10 withdrew); (iii) 93 patients
(3 withdrew)
Notes Methodological quality: randomization +; treatment allocation +; withdrawals +; co-interventions ?; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance 
?; baseline similarity +; follow-up +. Total score = 9.
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 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Kuhlwein 1990
Methods RCT; double-blind. Randomization procedure not described.
Participants 122 patients , aged 18-65 years, 90 men, 32 women.
 Inclusion criteria: degenerative acute low back pain less than 3 days, strong functional limitations.
 Exclusion criteria: acute disc protrusion or disc prolapse, hypersensitivity for NSAIDs or vitamin 
B, peptic ulcer or gastrointestinal bleedings, malignancy, renal or hepatic disorders, anticoagulant 
treatment, pregnancy or lactation.
Interventions NSAIDs (i) diclofenac 25 mg t.i.d., 7 days (N=62).
 Reference treatment (ii): diclofenac 25 mg plus vitamins B1, B6, B12, t.i.d., 7 days (N=61).
Outcomes Mean (SD) pain intensity, physical examination (Laseque) at baseline and after 7 days: (i) 61.2 
(10.8), 15.6 (13.2); 48.69 (10.8), 76.36 (11.3) and (ii) 40 (12.6), 3.6 (4.2); 49.43 (12.5), 82.80 
(8.3). 35% in (i) and 78% in (ii) returned to work within 7 days (signiﬁ cant). 53% in (i) and 83% in 
(ii) success rate good or very good. Side effects: (i) 1 patient, (ii) 1 patient.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance +; 
baseline similarity +; follow-up -. Total score = 7.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Lacey 1984
Methods RCT; double-blind, placebo-controlled. Randomization procedure not described.
Participants 337 patients with acute back or sacroiliac pain (< 72 hours) from over 200 general practitioners. 
Age and sex ratio unknown.
Interventions NSAID (i): piroxicam 10 mg capsules, four times per day ﬁ rst two days, two time per day next 
12 days, 14 days (N=168).
 Reference treatment (ii): placebo capsules (N=169).
Outcomes Patient (%) improved after 1 week only in subgroups with initial moderate/severe pain (i) 
82%/49% (ii) 53%/38%. No differences for subgroup with mild initial pain. Results after 2 weeks 
not reported (no data presented on side-effects for subgroup with back pain; overall, including 
other musculoskeletal disorders, similar (i) 12 % (ii) 9%).
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity -; follow-up -. Total score = 3.
 Clinical relevance: patients description - intervention description + outcome measures + effect size + 
beneﬁ ts/ harms +
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Study Listrat 1990
Methods RCT; double-blind. Randomization procedure not described.
Participants 40 patients with low back pain, 22 men and 18 women, age unknown.
 Inclusion criteria: herniated or degenerative lumber disc with or without sciatica, pain on lateral 
bending > 40 mm on VAS.
Interventions NSAID (i): tenoxicam 20 mg intramuscular injection plus 1 placebo tablet, 4 days (N=20).
 NSAID (ii): tenoxicam 20 mg tablet plus intramuscular placebo injection (N=20).
Outcomes Mean (SD) pain intensity (VAS) before treatment and after 24 hours: (i) 55 (15), 34 (29), (ii) 50 
(13), 37 (13). Side effects: (i) 5 patients, (ii) 5 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity -; follow-up -. Total score = 3.
 Oral versus intramuscular administration, irrelevant timing of outcome assessment (24 hours).
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Matsumo 1991
Methods RCT; double-blind. Randomization procedure not described.
Participants 155 outpatients and inpatients all of whom had complained of chronic lumbago for more than 1 
month and had been diagnosed as having muscular pain, intervertebral disc disorders, spondylosis 
or sciatica, age and sex ratio unknown.
Interventions NSAID (i): ketoprofen 25 mg capsules, 150 mg per day, duration not given (N=77).
 NSAID (ii): diclofenac sodium 25 mg capsules, 75 mg per day, duration not given (N=78).
Outcomes No. of patients improved after 1, 2 weeks (i) 71%, 86% (ii) 62%, 79%. No signiﬁ cant differences. 
Side effects similar in both groups (i) 18% (ii) 21%.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Metscher 2001
Methods RCT; double-blind, multicentre. Randomization procedure not described.
Participants 193 patients, age 18- 70 years, acute low back pain; pain 100 mm VAS >= 50 mm; onset within 48 
hours; not indicated for other than analgesic treatment
Interventions NSAID (i): dexketorofen-trometamol 25 mg t.i.d., 7 days (N=97).
 NSAID (ii): tramadolhydrochlorid 50 mg t.i.d., 7 days (N=95).
Outcomes Pain difference mean changed score, 100 mm VAS, after 7 days: (i, N=81) vs (ii, N=79) -6 (4 (P< 0.05)
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 Finger to ﬂ oor distance mean changed score (+/- SEM klopt... zie boven), cm, after 7 days: (i) -22 
(17); (ii) -18 (13); (i) vs (ii) signiﬁ cantly lower (P< 0.05)
 Side effects: (i) 13 patients; (ii) 22 patients
Notes Methodological quality: randomization ?; treatment allocation ?; withdrawals +; co-interventions -; 
patients blinded ?; outcomes blinded ?; care providers blinded ?; intention-to-treat -; compliance ?; 
baseline similarity ?; follow-up +. Total score = 2.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 Unclear presentation of results. (mean changed score pain was extracted from the graph)
 
Study Milgrom 1993
Methods RCT. Randomization according to their military identiﬁ cation numbers.
Participants 70 male infantry recruits with over exertion back pain, 32 with thoracic and 40 with lumbar pain, 
mean age 18 years.
 Inclusion criteria: no history of back pain, no back trauma, back pain exertionally related to carrying 
loads on the back, not present or markedly improved on nonexertional activities, no sciatica, no 
sudden onset.
Interventions NSAID (i): ibuprofen 800 mg tid, 7 days (N=24).
 Reference treatment (ii): paracetamol 1000 mg tid, 7 days (N=24).
 Reference treatment (iii): no drug treatment (N=22).
Outcomes % patients cured after 10 weeks: (i) 67%, (ii) 54%, (iii) 82%. No signiﬁ cant difference. Side effects 
not speciﬁ ed.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 3.
 Clinical relevance: patients description - intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Muckle 1986
Methods CCT; double-blind. Not randomized.
Participants 50 hospitalized patients with lumbar disk syndrome, age and sex ratio unknown.
 Inclusion criteria: acute onset ﬁ rst time low back pain.
 Exclusion criteria: previous hospital admissions for back pain, marked changes in the lumbar spine 
on radiography.
Interventions NSAID (i): ﬂ urbiprofen 200 mg, 3 weeks (N=25).
 Reference treatment (ii): acetaminophen, 4 g, 3 weeks (N=25).
Outcomes No. of patients improved (physician’s assessment of pain) after 1, 2, 3 and 6 weeks: (i) 13/23, 17/18, 
7/8, 16/17, (ii) 8/22, 13/18, 8/9, 18/18. No signiﬁ cant difference. Side effects not speciﬁ ed.
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Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity -; follow-up -. Total score = 3.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Nadler 2002
Methods RCT; single-blind, multi-center study. Stratiﬁ ed randomization, allocation procedure not described.
Participants 371 patients , age 18-55 years, 216 women, 155 men.
 Inclusion criteria: acute nonspeciﬁ c low back pain; pain intensity >=2 on 6 point scale; no LBP trauma 
within 48 hours; an answer of “yes” on the question “do the muscles in your low back hurt?”; 
 Exclusion criteria: radiculopathy/ neurologic deﬁ cits; history of back surgery; ﬁ bromyalgia, diabetes 
mellitus; hypersensitivity for NSAIDs/ acetaminophen/ heat; peptic ulcer or gastrointestinal 
bleedings; renal or hepatic disorders; anticoagulant treatment; pregnancy.
Interventions NSAID (i): ibuprofen 200 mg, 2 tablets t.i.d. + 2 placebo tablets once a day , days (N= 106)
 Reverence treatment (ii): acetaminophen 500 mg, 2 tablets q.i.d., 4 days (N= 113)
 Reverence treatment (iii): heat wrap, 40 degrees centigrade, 8 hours/ day, 4 days (N= 113)
 Reverence treatment (iv): unheated wrap, 8 hours/ day, 4 days (N=19), no outcome 
measures presented
 Reverence treatment (V): placebo, 2 tablets q.i.d., 4 days (N= 20), no outcome measures presented
Outcomes Roland-Morris Back Pain Questionnaire (0-24, no- maximal disability) mean changed score after 
4 days: (i, N=101) -2.7, (ii, N=104) -2.9, (iii, N=110) -4.9; (i) vs (ii) not presented; (i) vs (iii) signiﬁ -
cantly less effective (P< 0.001)
 Pain mean changed score, 0-5 NRS, after 4 days: (i) -1.7; (ii) -2.0; (iii) -2.6; (i) vs (ii) not presented; 
(i) vs (iii) signiﬁ cantly less effective (P< 0.001); Side effects: no serious side effects occurred
Notes Methodological quality: randomization ?; treatment allocation ?; withdrawals +; co-interventions ?; 
patients blinded -; outcomes blinded +; care providers blinded -; intention-to-treat -; compliance ?; 
baseline similarity +; follow-up +. Total score = 4.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Orava 1986
Methods RCT; double-blind. Randomization procedure not described.
Participants 133 patients.
 Inclusion criteria: acute lumbago less than 2 weeks after onset, bothersome LBP and considerable 
functional disability.
 Exclusion criteria: previous use of analgesics, antiinﬂ ammatory or muscle relaxing agents for 
this episode.
Proefschrift Binnen_2.indd   101 28-12-2009   17:52:19
 102 Non-steroidal anti-infl ammatory drugs for low back pain
Interventions NSAID (i): diﬂ unisal 500 mg capsules, twice daily, 7 days (N=66).
 NSAID (ii): indomethacin 50 mg capsules, three times daily, 7 days (N=67).
Outcomes Mean difference (95% CI) pain intensity scale (100 mm VAS) at 4 weeks; (i, N= 228 vs iii, N= 223) 
-13.5 (-18.1 to -8.9); (ii, N= 224 vs iii) -13.8 (-18.5 to -9.2)
 Mean difference (95% CI) LBP bothersomeness scale over 4 weeks (4-pt Likert, 0= not at all, 
4= extremely); (i vs iii) -0.5 (-0.6 to -0.3); (ii vs iii) -0.5 (-0.7 to -0.3)
 Mean difference (95% CI) RMDQ (0- 24 pt scale) over 4 weeks; (i vs iii) -2.2 (-3.2 to -1.3); (ii vs iii) 
-2.3 (-3.3 to -1.3)
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Pena 1990
Methods Double-blind study. Randomization procedure not described.
Participants 214 patients with acute low back pain, age and sex ratio unknown.
Interventions NSAID (i): etodolac 200 mg t.i.d., 5 days (N=?).
 NSAID (ii): diclofenac 50 mg t.i.d., 5 days (N=?).
Outcomes % patients showing improvement after 5 days on pain intensity, global measure, Laseque in (i) 
50%, 65%, 66% and (ii) 55%, 60%, 74%. Side effects not speciﬁ ed.
Notes Methodological quality: randomization -; treatment 
 allocation -; withdrawals -; co-interventions -; patients blinded +; outcomes blinded +; care provi-
ders blinded +; intention-to-treat -; compliance -; baseline similarity -; follow-up -. Total score = 3.
 Clinical relevance: patients description - intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Pohjolainen 2000
Methods RCT; double-blind; double-dummy; multicentre. Randomised according to a list in permutation 
blocks, concealed allocation.
Participants 104 outpatients, 52 women, 52 men
 Inclusion criteria: age 18 to 65 years; acute LBP, onset within 30 days
 Exclusion criteria: chronic LBP, > 4 weeks; secondary cause of LBP; pain with radiation to an ex-
tremity below the knee;surgery for LBP; signiﬁ cant systematic disease; history of peptic ulceration; 
allergy to NSAIDs.
Interventions NSAID (i): nimesulide 100 mg b.i.d. + placebo once a day, 10 days (N= 52)
 NSAID (ii): ibuprofen 600 mg t.i.d., 10 days (N= 52)
Outcomes Oswestry LBP disability questionnaire pre-mean (SD), post-mean day 10 (SD): (i, N= 52) 35.8 
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(15,0), 10.0 (10.8); (ii, N=50) 35.1 (19.1), 16.5 (19.0), (i) vs (ii) signiﬁ cantly lower (P< 0.05)
 Pain, 100 mm VAS, pre-mean (SD), post-mean day 10 (SD): (i, N= 52) 57.9 (20.6), 12.8 (15.4); (ii, 
N=50) 55.2 (21.4), 18.5 (19.9), (i) vs (ii) not signiﬁ cant 
 Schobers test , cm, pre-mean (SD), post-mean day 10 (SD): (i, N= 52) 5.2 (1.8), 6.9 (1.6); (ii, N=50) 
5.4 (2.3), 6.3 (1.6); no signiﬁ cance test reported
 Side effects: (i) 7 patients (2 withdrew); (ii) 11 patients (1 withdrew)
Notes Methodological quality: randomization ?; treatment allocation +; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat ?; compliance 
+; baseline similarity +; follow-up +. Total score = 9.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Postacchini 1988
Methods RCT. Randomization procedure not described.
Participants 459 patients with LBP, aged 17 to 58 years, sex ratio unknown.
 Exclusion criteria: neoplastic or infectious disease, pregnant or nursing women, serious general 
diseases, psychiatric disturbances or medico-legal litigation.
Interventions NSAID (i): diclofenac ‘full dosage’, 10-14 days (acute patients), 15-20 days (chronic patients) (N=81).
 Reference treatment (ii): chiropractic manipulation (N=87).
 Reference treatment (iii): physiotherapy (N=78).
 Reference treatment (iv): bedrest (N=29).
 Reference treatment (v): back school (N=50).
 Reference treatment (vi): placebo (anti-oedema gel) (N=73).
Outcomes Mean improvement on combined pain, disability, and spinal mobility score (5-32) after 3 wks, 2 
and 6 months. In subgroup with acute pain (i) 3.0, 10.7, 14.0 (ii) 7.5, 9.7, 12.3 (iii) 5.0, 8.4, 10.2 
(iv) 5.4, 7.5, 7.3 (v) not included (vi) 1.8, 7.3, 11.0. Group (ii) signiﬁ cantly better than others after 
3 wks; no other differences. In subgroup with chronic pain (i) 2.6, 2.2, 4.0 (ii) 2.2, 2.6, 4.3 (iii) 3.9, 
4.2, 6.0 (iv) not included (v) 0.5, 4.6, 8.9 (vi) 0.7, 1.2, 2.0. Group (i) not signiﬁ cantly better. No 
data on side-effects reported.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions -; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity -; follow-up +. Total score = 1.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Radin 1968
Methods CCT; double-blind trial.
Participants 25 patients admitted to hospital with prolapsed discs.
Proefschrift Binnen_2.indd   103 28-12-2009   17:52:19
 104 Non-steroidal anti-infl ammatory drugs for low back pain
 Inclusion criteria: pain from the low back or buttock, radiating down the back of the leg to at least 
the heel, and either pain on straight-leg-raising referred to the contralateral thigh or back, muscular 
weakness, or sciatic nerve-tenderness, aged 18 to 53 years.
 Exclusion criteria: X-ray evidence of disease of the lumbosacral spine, history of prior back surgery, 
or upper gastrointestinal disease.
Interventions NSAID (i): phenylbutazone 100 mg capsules, six per day for two days, three per day next 8 days (N=6).
 Reference treatment (ii): placebo capsules (N=6).
Outcomes Group (i) improvement in motor weakness and painful straight leg raising. No results are reported 
for group (ii). Side effects reported in group (i) 3.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded -; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 4.
 Very small sample size, poor presentation of results.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Schattenkirchner2003
Methods RCT; double-blind; multicentre. Randomization procedure not described.
Participants 227 patients, mainly from general practices, 85 women, 142 men
 Inclusion criteria: age 20- 65 years; localised, uncomplicated acute LBP associated with degenerative 
spinal disorders; had pain without analgesic therapy during previous 24 hours and at rest at least a 
100 mm VAS score of 60
 Exclusion criteria: suspicion of serious underlying spinal condition, non-speciﬁ c back symptoms 
related to abdominal, pelvic or thoracic pathology; prior neurological deﬁ cits in lower extremities; 
surgery for LBP; lumbosacral facet syndrome; history of heamatological or bleeding disorders; severe 
cardiac, hepatic or renal insufﬁ ciency; severe hypertension; connective tissue diseases; gastrodu-
odenal ulcer; history of GI bleeding; hypersensitivity to aspirin or NSAIDs; alcohol/ drug abuse; 
pregnant/ lactating.
Interventions NSAID (i): aceclofenac 100 mg b.i.d., 10 days (N=114)
 NSAID (ii): diclofenac 75 mg b.i.d., 10 days (N=113)
Outcomes Pain mean changed score (SD), 100 mm VAS, after 10 days: (i, N=114) -62 (25); (ii, N=113) -57 (23)
 ; QBPDS change form baseline (SD) after 4 days (i, N=100) 25.5 (14.8); (ii, N=105) 20.6 (12.1) 
 Side effects: (i) 17 patients; (ii) 18 patients
Notes Methodological quality: randomization +; treatment allocation +; withdrawals +; co-interventions +; 
patients blinded ?; outcomes blinded ?; care providers blinded +; intention-to-treat +; compliance +; 
baseline similarity ?; follow-up +. Total score = 8.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
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Study Siegmeth 1978
Methods RCT; single-blind. Clinician remaining unaware of the drug treatment of individual patients who 
were allocated to the trial by an independent third person.
Participants 30 patients with radiologically conﬁ rmed lumbar osteoarthritis, age and sex ration unknown.
Interventions NSAID (i): ibuprofen, 1200 mg per day, 14 days (N=15).
 NSAID (ii): diclofenac, 75 mg per day, 14 days (N=15).
Outcomes No. of patients reporting to be improved after 1, 3, 4 weeks (i) 5, 10, 6 (ii) 5, 12, 11. No signiﬁ cant 
differences. Side effects similar: one in each group.
Notes Methodological quality: randomization -; treatment allocation +; withdrawals +; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 5.
 Clinical relevance: patients description - intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Stratz 1990
Methods RCT; single-blind, multi-center study. Randomization procedure not described.
Participants 100 patients with acute low back pain, 50 men and 50 women, aged between 16 and 78 years.
 Inclusion criteria: acute or acute onset after a long symptom-free period.
 Exclusion criteria: age less than 14 years, pregnancy or lactation, allergy, corticosteroid, other NSAID 
or anticoagulant treatment.
Interventions NSAID (i): diclofenac intramuscular 3 ml (= 75 mg), 1 to 3 injections, 1 to 3 days (N=50).
 NSAID (ii): etofenamat ml (= 1500 mg), 1 to 3 injections, 1to 3 days (N=50).
Outcomes Mean pain score (11-point NRS) at baseline and after 3-5 days: (i) 5.3, 2.7, (ii) 5.3, 2.4; physical 
examination (Schober): (i) 30, 52, (ii) 31, 59. No. of patients recovered after 3-5 days;: (i) 27/47, (ii) 
34/49. Not signiﬁ cant. Side effects: (i) 2, (ii) 0.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded -; care providers blinded -; intention-to-treat +; compliance +; 
baseline similarity -; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Sweetman 1987
Methods RCT. Randomization procedure not described.
Participants 122 Ambulant patients with acute LBP of 12 general practitioners, 65 men and 57 women, aged 15 
to 72 years.
 Inclusion criteria: current episode longer than 24 hours and less than 28 days.
 Exclusion criteria: nerve root compression, arthritis, ankylosing spondylitis, infection, malignancy, 
renal or hepatic disease, peptic ulcers, pregnant or lactating women, sensitivity to test medications.
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Interventions NSAID (i): mefenamic acid 500 mg three times per day + placebo twice daily (N=40).
 Reference treatment (ii): chlormezanone 100 mg and paracetamol 450 mg two capsules three times 
per day + placebo three times daily (N=42).
 Reference treatment (iii): ethoheptazine 75 mg and meprobamate 150 mg and aspirin 250 mg two 
capsules + placebo three times per day (N=40).
Outcomes No. of patients reporting no pain after 1 and 7 days (i) 7, 21 (ii) 12, 23 (iii) 10, 20. No. of patients 
with adverse events (i) 9 (ii) 10 (iii) 16.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals -; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 4.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Szpalski 1990
Methods RCT. Use of randomization table.
Participants 110 patients with acute low back pain treated at an outpatient department.
 Inclusion criteria: pain present < 2 weeks, asymptomatic period of at least 4 months.
 Exclusion criteria: LBP related to industrial accident covered by insurance, speciﬁ c pathology such 
as disc protrusion or trauma.
Interventions NSAID (i): tenoxicam 20 mg, 1 tablet daily, 14 days plus bed rest, 7 days strict, 7 days intermittent 
(N=49).
 Reference treatment (ii): bed rest, 7 days strict, 7 days intermittent (N=50).
Outcomes Mean % improvement (SD) between baseline and 14 days in ROM (I) 123 (24), (ii) 114 (23). 
Signiﬁ cant. 86% (i) versus 70% (ii) no need for further treatment. Side effects: 2 patients in (i).
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 2.
 Physical examination only outcome. Outcome presented as percentages, baseline values 
not presented.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Szpalski 1994
Methods RCT; double-blind, placebo-controlled. Randomization procedure not described.
Participants 73 Patients with acute LBP, 47 men and 26 women, mean age about 38 years.
 Inclusion criteria: LBP less than 2 weeks, ﬁ rst presentation after an asymptomatic 6-months period.
 Exclusion criteria: worker’s compensation, herniated disc or spinal trauma, pregnancy or lactation, 
hypersensitivity to NSAIDs, history of gastrointestinal ulceration, current use of NSAIDs, 
Proefschrift Binnen_2.indd   106 28-12-2009   17:52:20
 Non-steroidal anti-infl ammatory drugs for low back pain 107
anticoagulants, antidiabetics or lithium.
Interventions NSAID (i): tenoxicam 20 mg intramuscular injection on day one + 20 mg capsules 1 per day for 
day 2 to 14 (+ 7 days bedrest) (N=37).
 Reference treatment (ii): placebo injection + placebo capsules (+ 7 days bedrest) (N=36).
Outcomes Mean pain intensity on VAS on day 1, 8 and 15 (i) 7.4, 1.9, 0.6 (ii) 7.1, 2.8, 0.8. (i) signiﬁ cantly 
better on day 8. Side effects: one patient in group (i).
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 7.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Vetter 1988
Methods RCT; double-blind, multi-center study. Block randomization for each center.
Participants 252 patients with acute degenerative low back disorders, 131 men and 107 women, aged between 
19 and 82 years.
 Exclusion criteria: acute disk protrusion, malignancy, alcohol or drug abuse, pregnancy or lactation, 
gastrointestinal, hepatic or renal disease, hypersensitivity to study drugs.
Interventions NSAIDs (i): diclofenac 50 mg t.i.d., 14 days (N=126).
 Reference treatment (ii): diclofenac 50 mg plus vit. B1 50 mg, B6 50 mg, B12 0.25 mg, t.i.d., 14 
days (N=126).
Outcomes Mean (SEM) pain intensity (VAS) at baseline and after 3, 7 and 14 days: (i) 64.8 (2.2), 54.2 
(2.4), 45.0 (2.7), 33.8 (3.1); (ii) 66.9 (1.7), 52.9 (2.3), 39.3 (2.8), 30.5 (2.9). No. (%) of patients 
improved after 7 and 14 days: (i) 20 (19%), 27 (29%); (ii) 28 (29%), 27 (33%). Side effects: (i) 21 
patients, (ii) 21 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance +; 
baseline similarity +; follow-up -. Total score = 7.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Videman 1984a
Methods RCT; double-blind. Randomization procedure not described.
Participants 70 Outpatients with acute LBP, duration from 1 day to 30 days, 41 men and 29 women, aged 20 to 
64 years.
 Exclusion criteria: pregnant or nursing women, haematological, renal, hepatic, respiratory or circula-
tory disorders, history of peptic ulceration or gastrointestinal upset, sensitivity to narcotic analgesics 
or benzomorphan derivatives, weight less than 45 kg or more than 95 kg.
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Interventions NSAID (i): diﬂ unisal 250 mg capsule, 4 times per day, 3 weeks (N=35).
 Reference treatment (ii): meptazinol 200 mg capsule, 4 times per day, 3 weeks (N=35).
Outcomes Mean change in degree of pain on 100 mm visual analogue scale at three weeks (i) 45 (ii) 40. 
Similar improvement regarding capacity for daily tasks (data in graphs). No signiﬁ cant differences. 
Side effects similar (i) 19 (ii) 23 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Videman 1984b
Methods RCT; double-blind. Randomization procedure not described.
Participants 28 Outpatients with chronic severe LBP, 17 men and 11 women, aged 25 to 76 years.
 Exclusion criteria: pregnant or nursing women, compensation claims, haematological, renal or 
hepatic disease, peptic ulcer, intolerance to indomethacin.
Interventions NSAID (i): piroxicam 20 mg + placebo capsules, one per day + twice placebo, 6 weeks (N=14).
 NSAID (ii): indomethacin 25 mg capsules, three times per day, 6 weeks (N=14).
Outcomes Mean improvement on visual analogue scale (range 0-31) after 6 weeks (i) 8 (ii) 9. 
Similar improvement rates (data in graphs). Side effects similar (i) 13 (ii) 15.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up -. Total score = 5.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Waikakul 1995
Methods RCT. Patients were randomly allocated to 2 groups according to the last 2 digits of their hospital 
numbers.
Participants 72 hospital patients with nonsurgical low back pain, 20 men, 52 women.
 Inclusion criteria: nonsurgical low back pain including disc syndrome, spondylosis, mild spondylolis-
thesis, spinal stenosis and postural back pain, aged 15 years and older.
 Exclusion criteria: presence of digestive, haematological, hepatic and renal disorders, hypersensitivity 
to proprionic acid derivatives, long-term administration of steroids, indication for surgery.
Interventions NSAID (i): Loxoprofen 60 mg tid, 6 weeks (N=37).
 NSAID (ii): naproxen 250 mg tid, 6 weeks (N=35).
Outcomes Mean (SD) therapeutic results according to criteria of the Japanese orthopaedic Academic Society at 
baseline and after 1 and 6 weeks: (i) 16.86 (4.90), 22.27 (5.08), 27.44 (2.87) and (ii) 15.42 (5.03), 
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20.97 (6.05), 26.23 ( 3.11). Not signiﬁ cant. Side effects (i) 6 patients, (ii) 6 patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded -; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity -; follow-up -. Total score = 3.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Waikakul 1996
Methods RCT; single-blind. Randomization procedure not described.
Participants 64 ambulant patients, 16 men, 48 women.
 Inclusion criteria: non-surgical lumbago including disc syndrome, spinal stenosis, postural back pain.
 Exclusion criteria: need for surgery.
Interventions NSAID (i): indomethacin plaster twice a day, 4 weeks plus 1 mg oral vitamin B bid (N=30).
 NSAID (ii): diclofenac emulgel, 2 cm 4 times a day, 4 weeks plus 1 mg oral vitamin B bid (N=34).
Outcomes Mean (SD) score on 30-point total rating scale at baseline and after 1, 2 and 3 weeks: (i) 18.13 
(4.32), 21.43 (4.10), 24.27 (5.30), 25.87 (4.50), (ii) 18.65 (4.53), 20.46 (6.68), 24.30 (5.39), 26.33 
(4.12). Not signiﬁ cant. % of patients with good improvement, safety and usefulness after 3 weeks: 
(i) 87%, 97%, 87%, (ii) 82%, 100%, 82%. Not signiﬁ cant. Side effects: (i) 3 patients, ii) none.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions -; 
patients blinded -; outcomes blinded -; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 4.
 Clinical relevance: patients description + intervention description - outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Waterworth 1985
Methods RCT. Randomization procedure not described.
Participants 112 patients presenting with acute LBP to their general practitioners, aged 18 to 50 years, 70 men 
and 38 women.
 Inclusion criteria: sudden onset of moderate to severe LBP with or without radiation, aggravated 
by sitting or physical activity, relieved by rest, present for less than 1 month, bothersome pain and 
a considerable degree of functional incapacity.
 Exclusion criteria: established spinal disorders, pregnant women, aspirin hypersensitivity, long-term use 
of NSAIDs, steroids or anticoagulants, haematological, renal or hepatic disease, history of peptic ulcer.
Interventions NSAID (i): diﬂ unisal 500 mg capsules, 1000 mg immediately, 500 mg twice daily, 10 days (N=36).
 Reference treatment (ii): physiotherapy: local heat, ultrasound and exercises (5 weekly sessions of 
45 minutes (N=34).
 Reference treatment (iii): spinal manipulation and/or McKenzie therapy (5 sessions of 45 minutes 
weekly (N=38).
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Outcomes Mean change in pain intensity on 4-points scale after 4 and 12 days: (i) -0.9, -1.7 (ii) -0.9, -1.6 (iii) 
-1.1, -1.7. No signiﬁ cant differences in pain and mobility.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 4.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Weber 1980
Methods CCT; double-blind. Not randomized.
Participants 59 hospital patients with acute and subacute sciatica, 32 men and 27 women, aged 16 to 69 years.
 Exclusion criteria: indication for immediate surgical intervention, contra-indications for NSAIDs.
Interventions NSAID (i): phenylbutazone 200 mg capsules, 2 capsules 3 times per day for 3 days, 1 capsule 3 
times per day next 2 days, 5 days (N=28).
 Reference treatment (ii): placebo capsules (N=29).
Outcomes No. of patients reporting deﬁ nite positive effect after intervention period (i) 14 (ii) 8. No signiﬁ cant 
differences. There were no side effects reported by the patients.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance -; 
baseline similarity -; follow-up -. Total score = 6.
 Clinical relevance: patients description + intervention description + outcome measures - effect size 
- beneﬁ ts/ harms -
 
Study Weber 1993
Methods RCT; double-blind, placebo- controlled. Randomization procedure not described.
Participants 214 patients aged 18 to 75 years.
 Inclusion criteria: acute sciatica within 14 days of onset, radiating pain , L5 or S1 nerve root 
compression, with or without sensory and/or motor deﬁ cits, positive straight leg raising, reduced 
mobility of the lumbar spine in standing position, free from sciatica during past 6 months.
 Exclusion criteria: cauda equina syndrome, acute back, progressive paresis, suspected tumor or local 
infection, ankylosing spondylitis, rheumatoid arthritis, history of peptic ulcer or severe dyspepsia, 
hypersensitivity to aspirin or other NSAIDs, hematologic, hepatic, renal, pulmonary, cardiac, 
or systematic disease, severe psychiatric disease, drug addiction, alcoholism.
Interventions NSAID (i): piroxicam 20 mg capsules, 40 mg per day ﬁ rst two days, 20 mg per day next 12 days, 
14 days (N=120).
 Reference treatment (ii): placebo capsules (N=94).
Outcomes Reduction of pain in back and leg measured by visual analogue scales after 4 weeks the same in the 
two groups (data in graphs). No signiﬁ cant differences. More side effects in (i) 22 than in (ii) 13.
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Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance 
+; baseline similarity +; follow-up -. Total score = 8.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Wiesel 1980
Methods RCT. Randomization procedure not described.
Participants 45 patients admitted to a military hospital for bed rest, all men, aged 17 to 34 years.
 Inclusion criteria: no previous back pain, no radiating, normal neurologic and straight leg raising 
results, normal lumbar roentgenograms.
 Exclusion criteria: discovering entities such as spina biﬁ da on the roentgenogram.
Interventions NSAID (i): aspirin 625 mg capsules, 4 times per day, 2 weeks (N=?).
 NSAID (ii): phenylbutazone 100 mg capsules, 4 times per day (ﬁ rst 5 days), no further information (N=?)
 Reference treatment (iii): acetaminophen (dosage not given), twice daily, 2 weeks (N=?).
Outcomes Mean no. of days before return to full activity (i) 5.7 (ii) 6.5 (iii) 5.7. No signiﬁ cant differences. 
No data on side-effects given.
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded -; outcomes blinded -; care providers blinded -; intention-to-treat +; compliance -; 
baseline similarity +; follow-up -. Total score = 4.
 Clinical relevance: patients description - intervention description - outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Ximenes 2007
Methods RCT; double-blind; multicentre. Randomised according to computer generated random allocation 
table, stratiﬁ ed for pain intensity
Participants 340 patients from 31 centres, 173 female, 18 to 65 years, Patients with acute low back pain (<=72 
hours), class 1a or 2a (Quebec Task Force), VAS Pain >50 mm
Interventions NSAIDs (i): valdecoxib 40 mg per day, second dose on day 1, 7 days (N=170)
 NSAIDs (ii): diclofenac 75 mg b.i.d., 7 days (N=170)
Outcomes Mean difference (95% CI) pain intensity scale (100 mm VAS) at 7 days; (i, N=167 vs ii, N=166) 
0.26 (-3.76 to 4.28)
 Mean difference (95% CI) OLBPDQ (0 to 24 pt scale) over 4 weeks; (i vs ii) 0.02% (-3.21 to 3.16)
Notes Methodological quality: randomization +; treatment allocation +; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance -; 
baseline similarity +; follow-up +. Total score = 8.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
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Study Yakhno 2006
Methods RCT; double-blind; multicentre. Randomised according to computer generated random 
allocation table
Participants 220 patients from 6 centres, 18-55 years, Patients with acute low back pain (<5 days), 
11-point NRS Pain >5
Interventions NSAIDs (i): lornoxicam on day 1: 16 mg once a day and 8 mg once a day; day 2 to 7: 
8 mg b.i.d. (N=110)
 NSAIDs (ii): diclofenac on day 1: 150 mg once a day and 50 mg once a day; day 2 to 7: 
50 mg b.i.d. (N=110)
Outcomes Sum of pain intensity differences from baseline on day 1-6 (SE); (i, N=109) 4.2 (0.17);
 (ii, N=110) 3.8 (0.17); (i) signiﬁ cantly lower than (ii) P < 0.05
 Side effects: (i) 27; (ii) 28
Notes Methodological quality: randomization +; treatment allocation +; withdrawals +; co-interventions -; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat +; compliance 
+; baseline similarity +; follow-up +. Total score = 10.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
 
Study Zerbini 2005
Methods RCT; “ﬂ are design”; double-blind, multicentre. Randomization procedure not described.
Participants 440 patients from 62 centres, 315 female, 125 male, 19 to 85 years, with chronic low back pain, 
regular usage of analgesic medication; pain without radiation to an extremity and without neurolo-
gical signs or pain with radiation to an extremity, but not below the knee and without neurological 
signs; ﬂ are criteria after washout period; LBP intensity <= 80 on 100 mm VAS.
Interventions NSAIDs (i): etoricoxib 60 mg per day, 4 weeks (N=222)
 NSAIDs (ii): diclofenac 3 * 50 mg per day, 4 weeks (N=218)
Outcomes Mean difference (95% CI) pain intensity scale (100 mm VAS) at 4 weeks; (i, N= 222 vs ii, N= 218) 
2.51 (-1.50 to 6.51)
 Mean difference (95% CI) RMDQ (0- 24 pt scale) over 4 weeks; (i vs ii) -0.23 (-1.14 to 0.67)
 Mean difference (95% CI) LBP bothersomeness scale over 4 weeks (4-pt Likert, 0= not at all, 4= 
extremely); (i vs ii) -0.02 (-0.17 to 0.13)
 Side effects: (i) 79 patients (15 withdrew); (ii) 87 patients (13 withdrew)
Notes Methodological quality: randomization -; treatment allocation -; withdrawals +; co-interventions +; 
patients blinded +; outcomes blinded +; care providers blinded +; intention-to-treat -; compliance +; 
baseline similarity +; follow-up +. Total score = 8.
 Clinical relevance: patients description + intervention description + outcome measures + effect size 
- beneﬁ ts/ harms -
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b.i.d.  = twice a day
t.i.d.  = three times a day
q.i.d.  = four times a day
NRS  = numeric rating scale
VAS  = visual analogue scale
SEM  = standard error
SD  = standard deviation
OLBPDQ - Oswestry LBP Disability Questionnaire
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Additional tables
01 Literature search Medline
no. Queries Results
#1 (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized  1382177
controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] 
OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR 
“clinical trial” [tw] OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* 
[tw]) AND (mask* [tw] OR blind* [tw])) OR “latin square” [tw] OR placebos 
[mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] 
OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies 
[mh] OR prospective studies [mh] OR cross-over studies [mh] OR control* [tw] 
OR prospectiv* [tw] OR volunteer* [tw]) NOT (animal [mh] NOT human [mh]) 
Limits: Entrez Date from 1998/10/01
#2 (“low back pain”[MeSH Terms] OR low back pain[Text Word]) OR (“sciatica” 7982
[MeSH Terms] OR sciatica[Text Word]) Limits: Entrez Date from 1998/10/01
#3 (“non-steroidal anti-inﬂ ammatory agents”[Text Word] OR “anti-inﬂ ammatory agents, 49675
 non-steroidal”[MeSH Terms] OR “anti-inﬂ ammatory agents, non-steroidal”
[Pharmacological Action] OR Anti-Inﬂ ammatory Agents, Non-Steroidal[Text Word]) 
Limits: Entrez Date from 1998/10/01
#4 acetylsalicyl* OR carbasalaatcalcium OR diﬂ unisal OR aceclofenac OR alclofenac OR  18680
diclofenac OR indometacin OR sulindac OR meloxicam OR piroxicam OR dexibuprofen 
OR dexketoprofen OR fenoprofen OR ﬂ urbiprofen OR ibuprofen OR ketoprofen 
OR naproxen OR tiapro* OR metamizol OR phenylbutazone OR phenazone OR 
propyphenazone OR celecoxib OR etoricoxib OR nabumeton OR parecoxib 
Limits: Entrez Date from 1998/10/01
#5 #3 OR #4 Limits: Entrez Date from 1998/10/1 53000
#6 #1 AND #2 AND #5 Limits: Entrez Date from 1998/10/1 125
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02 Literature search The Cochrane Central Register of  Controlled Trials
no. Queries Results
#1 (low back pain), from 1998 to 2007 in Clinical Trials 1108
#2 MeSH descriptor Low Back Pain explode all trees 1019
#3 (#1 OR #2), from 1998 to 2007 in Clinical Trials 1108
#4 nsaid*, from 1998 to 2007 in Clinical Trials 678
#5 MeSH descriptor Anti-Inﬂ ammatory Agents, Non-Steroidal explode all trees 11115
#6 (#4 OR #5), from 1998 to 2007 in Clinical Trials 3835
#7 (#3 AND #6), from 1998 to 2007 in Clinical Trials 55
03 Literature search Embase
no. Queries Results
#1 ‘low back pain’/exp OR low-back-pain OR ‘ischialgia’/exp OR ischialgia OR sciatica  566
OR lumbago OR (‘sacroiliac joint’/exp AND (pain/de OR backache/de))
 AND
 (‘nonsteroid antiinﬂ ammatory agent’/exp OR acetylsalicyl* OR carbasalaatcalcium 
OR diﬂ unisal OR aceclofenac OR alclofenac OR diclofenac OR indometacin OR 
sulindac OR meloxicam OR piroxicam OR dexibuprofen OR dexketoprofen OR 
fenoprofen OR ﬂ urbiprofen OR ibuprofen OR ketoprofen OR naproxen OR tiapro* 
OR metamizol OR phenylbutazone OR phenazone OR propyphenazone OR celecoxib 
OR etoricoxib OR nabumeton OR parecoxib)
 AND
 ‘clinical trial’/exp OR ‘clinical study’/de OR ‘prospective study’/de OR ‘clinical article’/de 
OR ‘controlled study’/exp OR ‘major clinical study’/de OR ‘double blind procedure’/
de OR ‘single blind procedure’/de OR ‘crossover procedure’/de OR placebo/exp OR ‘
comparative study’/de OR randomization/exp OR ((singl* OR doubl* OR trebl*) AND 
(mask* OR blind*)) OR latin-square OR placebo* OR random* OR control* OR prospectiv* 
OR volunteer* OR ‘evaluation and follow up’/de
 AND 
 [01-10-1998]/sd
 NOT ([animals]/lim NOT [humans]/lim) 
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04 Operationalisation Quality Assessment
Criteria Operationalisation
A. Was the method of 
randomisation adequate? 
A random (unpredictable) assignment sequence. Examples of 
adequate methods are computer-generated random numbers 
table and use of sealed opaque envelopes. Methods of allocation 
using date of birth, date of admission, hospital numbers, or 
alternation should not be regarded as appropriate.
B. Was the treatment allocation 
concealed? 
Assignment generated by an independent person not responsible 
for determining the eligibility of the patients. This person has no 
information about the persons included in the trial and has no 
inﬂ uence on the assignment sequence or on the decision about 
eligibility of the patient.
C. Were the groups similar at 
baseline regarding the most 
important prognostic indicators? 
In order to receive a “yes,” groups have to be similar at baseline 
regarding demographic factors, duration and severity of com-
plaints, percentage of patients with neurological symptoms, and 
value of main outcome measure(s).
D. Was the patient blinded to 
the intervention? 
The review author determines if enough information about the 
blinding is given in order to score a “yes.”
E. Was the care provider blinded 
to the intervention? 
The review author determines if enough information about the 
blinding is given in order to score a “yes.”
F. Was the outcome assessor 
blinded to the intervention? 
The review author determines if enough information about the 
blinding is given in order to score a “yes.”
G. Were co-interventions 
avoided or similar? 
Co-interventions should either be avoided in the trial design or 
be similar between the index and control groups.
H. Was the compliance 
acceptable in all groups?
The review author determines if the compliance to the interven-
tions is acceptable, based on the reported intensity, duration, 
number and frequency of sessions for both the index intervention 
and control intervention(s).
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I. Was the drop-out rate 
described and acceptable? 
The number of participants who were included in the study but 
did not complete the observation period or were not included in 
the analysis must be described and reasons given. If the percen-
tage of withdrawals and drop-outs does not exceed 20% for 
immediate and short-term follow-ups, 30% for intermediate and 
long-term follow-ups and does not lead to substantial bias 
a “yes” is scored.
J. Was the timing of the out-
come assessment in all groups 
similar? 
Timing of outcome assessment should be identical for all interven-
tion groups and for all important outcome assessments.
K. Did the analysis include an 
intention-to-treat analysis? 
All randomized patients are reported/analyzed in the group to 
which they were allocated by randomization for the most im-
portant moments of effect measurement (minus missing values), 
irrespective of noncompliance and co-interventions.
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Objectives: In order to defi ne in which work conditions lumbar supports are the most 
effi cient for workers with low back pain, more insight is needed in the mechanism of  action. 
We explored the possible effect of  lumbar supports on working postures of  home care wor-
kers with ambulatory accelerometry.
Methods: In this pilot study, the rate of  occurrence and duration of  working postures of  7 
home care workers were monitored for 2 consecutive working days with an Activity Monitor. 
Randomly assigned, the workers used a lumbar support on either the fi rst or second day. 
Results: On average, the home care workers were monitored for 9 hours per day. They 
were not hampered by the Activity Monitor in performing their job. The rate of  occurrence 
and duration of  working postures above 30° trunk fl exion all tended to be less on the day the 
subjects used a lumbar support, while the rate of  occurrence and duration of  trunk postures 
up to 30° increased. However, statistical signifi cance of  the differences between the working 
day with or without lumbar support was not reached in this small sample. 
Conclusions: Lumbar supports seem to effect the working posture of  home care workers. 
In future research, there is a high potential in ambulatory measuring working postures with 
ambulatory accelerometry. 
Abstract
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Introduction
Low back pain is a widespread problem in western industrialized countries, resulting in high 
medical expenses, work absenteeism and disablement(1). Reported one-year prevalences 
in a general population range from 15 to 40%(2). For home care workers these ﬁ gures are 
even higher, ranging from 44 to 72%(3-5). 
In industry, lumbar supports/back belts are frequently used to prevent low back pain(6), 
and positive secondary preventive effects have been reported for home care workers(5), 
warehouse workers(7) and freight personnel(8). However, in order to deﬁ ne in which work 
conditions lumbar supports are the most efﬁ cient, more insight is needed in the mechanism 
of action(9). 
A possible mechanism of action could be a reminder function by the lumbar support on 
speciﬁ c working postures, and thereby reducing for example exposure to frequent or 
prolonged trunk ﬂ exion above 30°(10-12). For measuring actual working postures of home 
care professionals during their work, a non-interfering instrument is needed. The Activity 
Monitor (AM) is a validated ambulatory instrument that is able of measuring aspects of 
overt human behaviour during normal daily life, and has so far been investigated and ap-
plied in several medical ﬁ elds, such as rehabilitation, psychophysiology, and cardiology(13). 
In this pilot study, we explored the possible effect of lumbar supports on working postures 
of home care workers during working days with the activity monitor.
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Methods
In this pilot study, the working postures of 7 home care workers were monitored for 
2 consecutive working days with an Activity Monitor. Randomly assigned, the workers used 
a lumbar support on either the ﬁ rst or second day.
Subjects
The volunteers for this feasibility study were recruited among former participants of the 
control group of an RCT that investigated the effectiveness of lumbar supports for pre-
venting recurrent low back pain in home care(5). The inclusion criteria in the RCT were: 
performing medical care and/or domestic tasks as a home care worker; experiencing low 
back pain symptoms at the moment of inquiry or experienced two or more episodes (at 
least 2 consecutive days) of low back pain symptoms in the 12 months prior to the inquiry; 
not suffering from speciﬁ c low back pain e.g. due to rheumatoid arthritis or vertebral frac-
tures; not pregnant at the start of the study; not receiving medical treatment for high blood 
pressure(14). Additional inclusion criteria for this feasibility study were: ﬁ nished the one year 
follow-up period of the RCT, and working as a maternity nurse. The latter was chosen as 
these home care workers perform similar tasks for at least two consecutive days within the 
same family they are assigned to. All volunteers enrolled after giving written consent.
Activity Monitor
The technique of ambulatory accelerometry is based on prolonged monitoring of signals 
from body-ﬁ xed acceleration sensors. Based on these sensors, one-second information can 
be obtained on body postures (e.g. sitting, standing, lying), body motions (e.g. walking, run-
ning, cycling), and transitions between postures (e.g. sit-to-stand movements). Based on this, 
measures on when, how often, and for how long body postures and motions and transitions 
are performed can be calculated. Studies using video recordings as a reference method have 
shown that these postures, motions and transitions can be validly quantiﬁ ed(13, 15-18).  
The standard conﬁ guration of the AM consists of four ADXL201 (Analog Devices, Breda, 
The Netherlands, adapted by Temec Instruments, Kerkrade, The Netherlands) piezo-re-
sistive accelerometers (size 1 x 1 x 0.5 cm). The sensors are ﬁ xed on Rolian Kushionﬂ ex 
(Smith & Nephew, Hoofddorp, The Netherlands) or siliconebased stickers (Schwa-Medico, 
Ehringshausen, Germany) by double-sided tape; both materials can be ﬁ xed directly on the 
skin. One sensor is attached at the lateral side of each thigh, at the level halfway between 
trochanter major and knee joint. The sensitive axis of this uniaxial sensor is in a sagittal 
direction while subject is in the anatomical position. The third (biaxial) sensor is attached on 
the lower part of the sternum, with sensitive axes in the sagittal and longitudinal directions. 
The raw acceleration signals are expressed in g (9.81 ms-2) and are a combination of two 
Proefschrift Binnen_2.indd   122 28-12-2009   17:52:22
 The infl uence of  lumbar supports on working postures 123
Figure 1. Simplifi ed nine working postures with motion ranges of  trunk and upper legs.
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components: gravitational acceleration and accelerations due to movement(13, 19). The 
magnitude of these components depends on the extent and direction of the accelerations 
with regard to the sensitive direction. Raw acceleration signals were stored digitally on a 
40 Mb PCMCIA FlashCard (SanDisk, USA) with a sample frequency of 32 Hz. After the 
measurements, the raw data were downloaded onto a PC for analysis. 
Detection of body postures and motions was automatically done; see for detailed des-
cription Bussmann et al(13). For this study, additional analysis software was made. When a 
person does not move, and assuming good alignment of the sensors and body postures in 
the sagittal plane, accelerometers can function as inclinometers. Based on this, the sagit-
tal accelerometer signals of trunk and one leg were also converted to an angular feature, 
expressing the position of the trunk and thigh in the sagittal plane. 
Outcome measures 
Additionally to the usually reported outcome measures on body postures and motions, 
9 combinations of trunk and thigh positions were determined. These combinations were 
the result of 3*3 position ranges of trunk ﬂ exion and upper leg ﬂ exion: 0-30°; 30-60°; and 
60-90°, as illustrated in ﬁ gure 1. With SPIL routines, each second one of the nine combina-
tions was determined. Based on that, the rate of occurrence and the duration of each com-
bination could be calculated. To discriminate between sitting and active working postures 
resembling sitting, an arbitrary time limit of 60s was used: periods > 60s were interpreted as 
sitting, and equal or less than 60s as an active working posture. More sophisticated discri-
mination is possible based on logarithms of the transfer from stand to sit and vice versa, but 
were not necessary for this pilot study. Relative measures, like % time in a speciﬁ c posture 
during a total working day, were easily calculated from these raw outcomes.
Lumbar supports
All participants wore the lumbar supports on either the ﬁ rst or the second working day, 
which was randomly assigned. There was a choice between four types of lumbar supports, 
supplied by Bauerfeind B.V., Haarlem, The Netherlands: LumboTrain® and LumboTrain® 
Lady, an individually adjustable (with hook and loop fasteners), fully elastic support availa-
ble in ﬁ ve sizes for men or women; Lumboloc® and Lordoloc®, two types of more stabilizing 
supports with integrated stays in the back, individually adjustable (with hook and loop 
fasteners) and both available in six sizes. All supports were personally measured by one of 
the researchers. The choice of model was based on ﬁ t and wearing comfort. 
Measurement procedure
The researcher placed the Activity Monitor on the participants just before they left home 
for their working day, and retrieved it when they returned at the end of their working day. 
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The participants knew that the aim of the study was to investigate the mechanism of action 
of lumbar supports, but were unaware of what was actually measured. They were instruc-
ted to ignore the measurement instrument as much as possible and to perform their usual 
working routines. After removing the Activity Monitor, a short semi-structured interview 
was held to evaluate the day and potential difﬁ culties with the instrument. 
Table 1. Characteristics of  the study population.
Factor N=7
Age, years, mean (SD) 44 (6.7)
Gender, female (%) 7 (100)
BMI, mean (SD) 28 (6.4)
LBP previous week, Numeric Rating Scale (0= no pain, 10= worst pain), mean (SD) 4.1 (2.4)
Number of days with LBP past month, calendar days, mean (SD) 18 (9.0)
Functional status previous week, QBPDS (0=no disability, 100=completely disabled), mean (SD) 37 (12)
LBP related sick leave past year, calendar days, mean (SD)  5.3 (9.8)
Registration period AM/ day, hh:mm, mean (SD) 9:07’ (1:22’)
Registered activities AM/ day, hh:mm, mean (SD) 6:21’ (1:24’)
Registered sitting AM/ day, hh:mm, mean (SD) 2:46’ (1:02’)
BMI – body mass index; LBP – low back pain; QBPDS – Quebec back pain disability scale; 
AM –Activity Monitor.
Statistics
Differences and its variance in rate of occurrence and duration of the body postures 
between the working day with or without wearing the lumbar support, were estimated 
with a paired samples T Test. The obtained estimates served for explorative purposes only. 
These estimates can be used for power calculations determining which group sizes in future 
research projects are needed.
Results
The seven maternity nurses who participated in the pilot were on average 44 (SD 6.7) years 
old. Mean Body Mass Index was 28 (SD 6.4); three of them were obese (BMI > 30) and 
two overweight (BMI > 25). All 7 women had experienced an episode of low back pain in 
the previous month. The average registered working day lasted 8.9 hours (SD 1.8) on the 
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day without lumbar support and 9.3 hours (SD 1.0) on the working day with lumbar sup-
port. The measurement period included travelling time to and from their client’s address. 
Table 1 summarises the characteristics of the participants. None of the subjects was ham-
pered by the measurement instrument in their work activities and no errors had occurred in 
recording the signals. 
Table 2. Rate of  occurrence and duration working postures. 
 Posture Without Lumbar support With Lumbar support
Rate of occurence
(n/ working day)
  Upper leg Trunk mean SD mean SD Difference
  (ﬂ exion) (ﬂ exion) 
 1 0-30° 0-30° 789 304 833 264 44
 2 0-30° 30-60° 400 208 372 149 -28
 3 0-30° 60-90° 123 104 101 77,9 -22
 4 30-60° 0-30° 31,3 28,6 38,3 36,8 7.0
 5 30-60° 30-60° 10,4 7,79 5,43 1,51 -5.0
 6 30-60° 60-90° 3,43 4,04 3,71 3,77 -0.3
 7 60-90° 0-30° 118 110 99,1 100 -19
 8 60-90° 30-60° 10,7 20,8 4,29 4,99 -6.4
 9 60-90° 60-90° 0,57 1,51 0,29 0,76 -.28
 
Duration
(hh:mm:ss/ working day) 
 1 0-30° 0-30° 3:03:26 1:10:41 3:26:46 0:58:21 0:23:20
 2 0-30° 30-60° 0:21:07 0:11:25 0:21:19 0:09:40 0:00:12
 3 0-30° 60-90° 0:06:41 0:07:47 0:05:19 0:06:19 -0:01:22
 4 30-60° 0-30° 0:02:11 0:02:06 0:02:55 0:03:56 0:00:44
 5 30-60° 30-60° 0:00:15 0:00:08 0:00:13 0:00:13 -0:00:02
 6 30-60° 60-90° 0:00:07 0:00:10 0:00:06 0:00:10 -0:00:01
 7 60-90° 0-30° 0:14:10 0:14:07 0:10:32 0:10:36 -0:03:34
 8 60-90° 30-60° 0:00:33 0:01:02 0:00:08 0:00:11 -0:00:22
 9 60-90° 60-90° 0:00:00 0:00:01 0:00:00 0:00:01 0:00:00
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The number and duration of working postures above 30° trunk ﬂ exion all tended to be less 
on the day the subjects wore a lumbar support, while the rate of occurrence and duration 
of trunk postures up to 30° increased. For example, when examining working postures 
with trunk ﬂ exion above 60°, without lumbar support the mean rate of occurrence of these 
postures was 127 times per day with a mean duration of 6 minutes 48 seconds per day, and 
with lumbar support 105 times per day with a corresponding duration of 5’25’’. The mean 
rate of occurrence and duration of all working postures are plotted in ﬁ gure 2 and descri-
bed in table 2 (numbering of the working postures in this table is similar to the numbering 
in ﬁ gure 1). As expected due to the small sample size, the mean rate of occurrence and 
mean duration of the nine combinations did not show statistically signiﬁ cant differences 
between the working day with or without lumbar support. 
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Figure 2. Boxplots of  mean rate of  occurrence and mean duration of  working postures 
without and with lumbar support.
Proefschrift Binnen_2.indd   128 28-12-2009   17:52:23
 The infl uence of  lumbar supports on working postures 129
0-30°
30-60°
60-90°
30-60°
30-60°
30-60°
0
4
8
12
0
10
20
30
2 7
0
5
10
15
20
6
2
0
10
20
30
40
0
40
80
120
5
0
200
400
600
5
Mean frequencies Mean seconds 
Lumbar support 
without  with without  with 
without  with without  with 
without  with without  with 
Figure 2. Continued... 
Proefschrift Binnen_2.indd   129 28-12-2009   17:52:23
 130 The infl uence of  lumbar supports on working postures
0-30°
60-90°
60-90°
60-90°
60-90°
30-60°
55
Mean frequencies Mean seconds 
without  with 
7
7
7
7
7 7
0
20
40
60
0
1
2
3
4
0
100
200
300
400
0
60
120
180
0
1
2
3
0
1000
2000
3000
Lumbar support 
without  with 
without  with without  with 
without  with without  with 
Figure 2. Continued... 
Proefschrift Binnen_2.indd   130 28-12-2009   17:52:23
 The infl uence of  lumbar supports on working postures 131
Discussion 
For measuring working postures of home care professionals during their work, the Activity 
Monitor seems to be a capable and non-interfering instrument, although the technique has 
not been validated in working populations yet. There were neither technical obstructions 
nor practical interferences with their job when measuring a whole working day with the 
Activity Monitor. Moreover, current progress in technology resulting in smaller sensors, the 
application of other sensors such as gyroscopes, and wireless data transmission, will only 
increase the feasibility and applicability of such systems in this ﬁ eld of research. A limitation 
of the Activity Monitor as used in this pilot is that we did not measure spinal rotations nor 
lateral ﬂ exion of the trunk, whereas rotation of the trunk is considered to be a risk factor 
for low back pain(11), and rotation and lateral bending movements may have inﬂ uenced our 
recordings in the sagittal plane. As stated previously, the application of accelerometers in 
the current study was based on the fact that alignment of the sensors was optimal (i.e. their 
sensitive axis as close as possible to the actual sagittal axis while standing in the standard, 
anatomical position), and that other body postures and motions were mainly executed in 
the sagittal plane. Actual movement behaviour will also include movements outside this 
plane, and decrease the validity of accelerometers when used as inclinometers. 
The use of a lumbar support seems to effect working postures in the hypothesised direc-
tion, decreasing the rate and duration of trunk ﬂ exion above 30°. However, the within sub-
ject differences were small and a minimal clinical relevant reduction is not yet determined. 
Working in trunk ﬂ exion positions above 30° for more than 10% of the working time is 
associated with long-term absence(12), and could be used as a cut-off point for a working 
population. In our population, body positions with trunk ﬂ exion above 30° occurred on 
average 13% of the working time without lumbar support and 11% of the working time 
with lumbar support. However, these kind of dose-response relations should also be deter-
mined for other low back pain related outcomes of interest, like functional status, as earlier 
health restoration before preventing long term absence could be relevant. 
Furthermore, large numbers are needed while data gathering is time consuming. If, for 
example, we would like to reach statistical signiﬁ cance based on differences and varian-
ces in our data, the population size should have been 89 per study arm to show a 20% 
reduction of trunk ﬂ exion postures above 30°, with a signiﬁ cance level of 5% and a power 
of 80%. When more extreme and less frequent postures, like trunk ﬂ exion postures from 
60-90° are desired as outcome, even 204 subjects per study arm are needed. Albeit, when 
using our data, the weight of our subjects has to be considered. Five of the seven were 
overweight in such a way that it might have hampered trunk ﬂ exion. 
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We conclude that there is a high potential in ambulatory measuring working postures with 
ambulatory accelerometry, although a validation of measuring body postures during work 
and determining clinical relevant changes is recommended. Lumbar supports seem to effect 
the working posture of home care workers. 
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Background: In most effectiveness studies on lumbar supports for patients with low back 
pain, insuffi cient data is reported about adherence. In a secondary preventive RCT, we found 
benefi cial effects and a good adherence among home care workers with low back pain. 
To target the use of  lumbar supports on those patients who can benefi t optimally from usage, 
we need to know why people are adherent. 
Methods: We used the attitude, social support and self-effi cacy model, which is developed 
to explain health behaviour, to identify determinants for prolonged adherence to wearing a 
lumbar support in the intervention group of  the RCT. 
Results: In the multivariable model, the strongest predictor for the intention for sustained 
use of  a lumbar support was a positive attitude towards lumbar supports, explaining 41% of  
the variance (B= 1.31; p< .001). Social Support and Self  Effi cacy both explained 2% of  the 
variance, of  which only the latter was statistically signifi cant (B=0.22; p<.05). 
Conclusion: The intention for prolonged use of  workers with recurrent back pain was 
mainly explained by a positive attitude. The discomfort of  a lumbar support was outweighed 
by perceived benefi t. Reducing practical hindrances and creating suffi cient social support for 
using the support within the organisation, are factors that may help to enhance adherence 
with the use of  lumbar supports.
Abstract
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Introduction
Low back pain is a widespread medical and costly burden in industrialized countries. For 
example in the Dutch population, the one year prevalence of low back pain was 44% in 
1998 (1), whereas the total costs attributed to low back pain were estimated at €269 per 
inhabitant(2). Lumbar supports are used to prevent or cure low back pain, although there is 
moderate evidence that lumbar supports are not effective in preventing the onset of low 
back pain, and there is insufﬁ cient evidence on effectiveness in the treatment of low back 
pain(3). However, most of the studies that investigated the effectiveness of lumbar sup-
ports did not report data on adherence to wearing lumbar supports, while adherence is a 
confounding factor when studying the effectiveness. If reported, in general adherence with 
wearing lumbar supports is poor and a matter of self-selection, which makes it difﬁ cult to 
be certain of possible effectiveness(3). 
Figure 1. The Attitude, Social infl uences and Self-Effi cacy model
We found in a RCT, which studied the effectiveness of lumbar supports for home care 
workers with a history of recurrent low back pain episodes (i.e. secondary prevention), that 
the use of a lumbar support in addition to usual care reduced the number of days with low 
back pain with 45%, reduced average pain intensity with 13% and improved functional 
status with 14%(4). In this study, participants of the intervention group were instructed to 
use a lumbar support on those working days they experienced or expected to experience 
low back pain. Adherence was good, as 78% of the intervention group had used the lum-
bar support at least one third of the total calendar days they experienced low back pain(4). 
Apparently, for adherence, possible beneﬁ ts have to outweigh the discomfort of wearing 
External
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Attitude
Social influences
Self-Efficacy
Intention Behavior
Proefschrift Binnen_2.indd   137 28-12-2009   17:52:24
 138 Determinants of  the intention for using a lumbar support
such a lumbar support and we assume that experiencing recurrent low back pain or not is a 
threshold for considering and actually wearing a lumbar support. 
Besides attributing possible effects to the use of lumbar supports, it is important to gain in-
sight in determinants for adherence to target the use of lumbar supports on those patients 
who can beneﬁ t optimally from usage and to reduce barriers to enhance future adherence. 
For these purposes, the Attitude, Social inﬂ uences and self-Efﬁ cacy model (ASE-model)(5) 
can be used. The ASE-model (ﬁ gure 1.) is developed to explain health behavior, and 
evolved from the theory of reasoned action from Fishbein and Ajzen(6), and Bandura’s social 
cognitive theory(7). We explored possible determinants for the intention to prolong using a 
lumbar support with the ASE-model.  
Methods
Design
This adherence study was embedded in a randomized controlled trial(4) (ISRCTN73707379), 
and focused on the intervention group of this RCT. The intervention group received a 
lumbar support in addition to usual care, consisting of a short refresher course on healthy 
working methods provided by their employer from the start of their appointment (a yearly 
training of 2 hours, practising the most frequent handlings and a yearly played board game 
with questions on healthy working methods); primary and secondary care for the manage-
ment of low back pain was available as usual(8). 
Subjects
All participants worked for a large home care organization in Rotterdam. The inclusion 
criteria were: performing medical care and/or domestic tasks as a home care worker; expe-
riencing low back pain symptoms at baseline or experienced two or more episodes (at least 
2 consecutive days) of low back pain symptoms in the previous 12 months; not suffering 
from speciﬁ c low back pain e.g. due to rheumatoid arthritis or vertebral fractures; not preg-
nant at the start of the study; not receiving medical treatment for high blood pressure(9). 
Employees who met the inclusion criteria received detailed information about the procedu-
res of the trial and were enrolled after giving written consent. 
Lumbar supports
The participants in the intervention group were given instructions to wear the lumbar sup-
ports on those working days that they experienced low back pain or expected to experien-
ce low back pain. There was a convenience choice between four types of lumbar supports, 
supplied by Bauerfeind B.V., Haarlem, The Netherlands: LumboTrain® and LumboTrain® 
Lady, an individually adjustable (with hoop and loop fastening), fully elastic support availa-
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ble in ﬁ ve sizes for men or women; Lumboloc® and Lordoloc®, two types of more stabilizing 
supports with integrated stays in the back, individually adjustable (with hoop and loop 
fastening) and both available in six sizes. All supports were individually ﬁ tted. The choice 
of model was based on ﬁ t and wearing comfort. The expected life span of the lumbar sup-
ports was one year.
Measures 
Determinants were measured by questionnaires. The questionnaire items were derived from 
results of an earlier performed feasibility study for lumbar supports in home care(10). Lumbar 
supports are not commonly used in the Netherlands and most people are unfamiliar with 
their existence, which was conﬁ rmed in our trial. At the start of the RCT, none of the 360 
home care workers was using a lumbar support. Only 4% was aware of the existence of 
lumbar supports, and less than 1% had used one in the past. Therefore, we measured the 
attitude, social inﬂ uences and self-efﬁ cacy determinants during the trial after 3, 6, 9 and 12 
months. Attitude, social inﬂ uences and self-efﬁ cacy determinants were operationalised by 
the mean score of several statements per determinant. 
External factors
The determinants we considered as possible external factors of inﬂ uence were: self reported 
body height and a body mass index above 30, calculated from self reported weight. Body 
height was considered because for a smaller person a lumbar support is relatively tall, which 
might decrease comfort of wearing. A body mass index above 30 as obesity could also 
lower comfort of wearing. In a feasibility study a high body mass index was found to be 
associated with lower adherence(10).
Attitude 
Attitude was divided into a positive and negative subscale. Positive attitude was based on 
12 statements, for example: “Using a lumbar support facilitates me to perform my job.” 
Participants answered on a 5-point Likert-scale ranging from 0 “strongly disagree” to 4 
“strongly agree”. Internal consistency was good (Cronbach’s α= 0.93). 
Eight statements, like “Using a lumbar support is too warm.” were presented for negative 
attitude with an identical 5-point Likert scale. Internal consistency for the negative subscale 
was moderate (Cronbach’s α= 0.70). 
Social support
For measuring social support, the opinions of ﬁ ve groups of people potentially of inﬂ uence 
were stated: peer, clients, managers, colleagues and therapists. For example: “When I 
use a lumbar support, my colleagues think I pity myself.” Home care workers were asked 
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whether they disagreed or agreed on a 5-point Likert scale. With a Cronbach’s α of 0.40, 
the internal consistency was poor. 
Self-effi cacy
Four statements addressing the ability to use a lumbar support were posed to measure self-
efﬁ cacy (Cronbach’s α = 0.80). “How well do you manage to wear the lumbar support on 
warm days?” is an example. The answer categories on a 7 point Likert scale ranged from 
0 “not at all”, to 6 “very well”.
Adherence and Intention 
To measure adherence during the intervention period of the trial, the workers of the inter-
vention group were asked to keep a low back pain calendar. They could tag the days they 
experienced low back pain, and mark whether they had worn the lumbar support. These 
calendars were collected after 1, 3, 6, 9 and 12 months. As stated before, the workers were 
instructed to wear the lumbar support on those working days that they experienced or 
expected to experience low back pain. Because the number of days with low back pain was 
measured in calendar days, the minimum for adherence was predetermined arbitrarily at 
using the lumbar support on at least one third of the calendar days with low back. 
The intention to prolong the use of a lumbar support when experiencing/ expecting to 
experience low back pain was measured after the intervention period at 12 months, with a 
7 point Likert scale, 0 “never” to 6 “always”. 
Statistical analysis
All items were calculated into averaged subscale scores for analysing the inﬂ uence of At-
titude, Social support and Self Efﬁ cacy. 
To explore possible correlations, univariate Pearson correlations were calculated. Then the 
hypothesised ASE-model was ﬁ lled in with a linear regression pathway analysis. Finally, on 
the ASE-determinants contributing to the model, a principal components factor analysis 
with varimax rotation was performed to explore possible subcomponents within the scales. 
The analyses were performed with SPSS 15. 
Results
Of the intervention group in total (n=183), 143 (78%) workers had used the lumbar sup-
port for at least one third of the total number of days they reported low back pain. On 
average the supports were worn on 5.5 days per month (SD 6.1, range 0 to 27.3), which 
was 90% of the mean number of days with low back pain per month. 134 workers (73%) 
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completed the 12-month adherence questionnaire and were used in the analyses. The 
general characteristics of these 134 workers were similar to the characteristics of the total 
intervention group, and are listed in Table 1 together with the ASE-determinants scores. 
The reasons for withdrawal from the RCT were: participation was too much effort (4), 
personal circumstances (2), other health problems (10), pregnant and unwilling to ﬁ ll in fol-
low-up questionnaires (2), lumbar support was uncomfortable, not beneﬁ cial and unwilling 
to ﬁ ll in follow-up questionnaires (3) therapist advised against support (1), dismissal from 
job in home care (8), deceased (1), and unknown/ without giving a reason (11). Another 7 
workers were missing in the analyses because of incomplete adherence data.
Table 1. Characteristics of  the workers reporting adherence data (n= 134).
General 
Age, 43
Mean (sd)  (8.8)
Female, 132
n (%) (99)
Body Mass Index, 27
kg/m2, (sd)  (5.9)
Low back pain,  6.3
number of calendar days per month (sd)  (6.3)
External factors in model 
Height, 1.68
m (sd)   (0.08)
Obese, 33
n with BMI≥ 30 (%)  (25)
ASE determinants in model 
Positive attitude, 
Towards lumbar supports,  2.57
scale 0 – 4, mean (sd)  (0.77)
Negative attitude,
Towards lumbar supports,   1.85
scale 0 – 4, mean (sd) (0.66)
Social support, 
Towards lumbar supports,  2.72
scale 0 – 4, mean (sd) (0.63)
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Self efﬁ cacy,
Using lumbar supports,   3.42
scale 0 – 6, mean (sd)  (1.50)
Intention, 4.21
0 – 6, mean (sd) (1.86)
 
Adherent during study period, 105
Used lumbar support at least 1/3 of the days  (78)
with low back pain n (%)
Intention
A proportion of 7.5% reported that in the future, they would never use a lumbar support 
when experiencing/ expecting to experience low back pain; 6.7% said they would use 
a lumbar support sometimes; 18% intended to keep using it regularly; 34% most of the 
times; and another 34% intended to always keep using a lumbar support. 
Correlations
The univariate correlations revealed that from the external factors only obesity correlated 
statistically signiﬁ cantly with negative attitude. Positive attitude, negative attitude, social 
support and self-efﬁ cacy all correlated signiﬁ cantly with intention to keep using a lumbar 
support (Table 2). 
Table 2. Univariate Pearson correlations 
 Height Obese  Intention
 -0.01 0.01 Positive attitude 0,64***
 0.11 0.24** Negative attitude -0,31***
 n/a n/a Social support 0,40***
 n/a n/a Self efﬁ cacy 0,46***
 **) p< .01; ***) p< .001 (2-tailed) 
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Figure 2. Pathway analysis for intending to keep using a lumbar support.  
*) p< .05; **) p< .01; ***) p< .001
During study period
Adherence
Positive
Attitude
R2=.45
 R2=.00
 R2=.07
 B=.00
 B=.01 B=.02
 B=.36**
B=1.31***
B=.23
B=.39
B=.22*
 =.40**
Intention
Negative
Attitude
Social
Support
Height
BMI ≥ 30
Self
Efficacy
Future
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Pathway analysis
Body height and obesity did not inﬂ uence positive attitude. Body height and obesity 
explained 7% of the variance of negative attitude. In this, obesity was the only signiﬁ cant 
determinant (B= .36; 95%CI .10 to .61; p= .006) and accounted for 6% of the explained 
variance. 
For intending to keep using a lumbar support, 45% of the variance could be explained 
by the ASE-determinants. A positive attitude was the strongest predictor for intention 
(B= 1.31; 95%CI .91 to 1.71; p< .001; R2 change= .41), followed by self-efﬁ cacy (B= .22; 
95%CI .03 to .42; p= .026; R2 change= .02). Social support was not statistically signiﬁ cant, 
but accounted for 2% explained variance (B= .39; 95%CI -.05 to .82; p= .083), and none 
of the variance was explained by negative attitude (B= .23; 95%CI -.22 to .67; p= .315; 
R2 change= .00). Figure 2 summarizes the pathway analysis and contains the correlation 
(Spearman’s rho) between adherence during the RCT and intention, which was 
.40 (p< .001). 
Factor analysis
Within the positive attitude scale we found two components with initial Eigenvalues >1, 
which together explained 68% of the variance. The ﬁ rst concerned a low back pain relief 
component, consisting of items like “A lumbar support makes my low back pain more 
bearable.”, and the second a practical component, with items like “The lumbar support 
remains placed properly during my work”. Also within social support, two components 
were found, together explaining 56% of the variance. The ﬁ rst consisted of social support 
by family/ friends and managers. The second of support by clients and colleagues. Self-
efﬁ cacy yielded one practical component (63% explained variance), with items such as 
“How well do you manage to put on the lumbar support?” 
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Discussion
After one year of experience with a lumbar support, 86% of the home care workers with 
recurrent low back pain intended to keep using a lumbar support when experiencing/ 
expecting to experience low back pain. Only 7.5% was determined to never use a lumbar 
support again. A higher intention was mainly explained by positive attitude and to a limited 
extend by self-efﬁ cacy. Obesity was signiﬁ cantly related with negative attitude. However, 
the inﬂ uence of negative attitude on intention was diminished by positive attitude in the 
multivariable analysis. This diminished inﬂ uence pertained also for the role of social support. 
The correlation between adherence during the trial and the intention to keep using a 
lumbar support was lower than we would expect. We assume that this is partly caused by 
workers who were adherent because they participated in the study and no longer intend to 
continue using a support. 
We have to emphasize that administering a lumbar support as a secondary preventive 
measure is part of a behavioural change process, since workers are at least in a contem-
plation stage of change(11), or even beyond. Besides, deciding to participate in this trial, 
has been a form of preselecting; of the 668 eligible workers 46% (308) was unwilling to 
participate. Both forms of preselecting, together with 27% missing data on adherence may 
have caused that our results are too positive. However, the proportion of workers deter-
mined to never use a lumbar support again, would still only be 17%, even if we would add 
all workers who withdrew because the supports were uncomfortable and all workers lost to 
follow-up or with missing data for unknown reasons (21 in total). 
As far as we know, this is the ﬁ rst study using the ASE-Model to clarify determinants for 
lumbar support usage. A next step in identifying speciﬁ c target groups could be a Q metho-
dology study. Q methodology provides a foundation for the systematic study of subjective 
attitudes, viewpoints, opinions, or beliefs(12, 13), and originates from Stephenson’s(14) idea to 
invert a factor analysis, thus analysing correlations between subjects. Because each subject 
in a Q-study prioritises his/ her subjective attitudes, the factor analysis of these prioritised 
subjectivities generates target group proﬁ les, providing detailed information about differen-
ces and similarities in viewpoints of importance. 
From the results of this study, we conclude that the discomfort of a lumbar support has 
to be outweighed by perceived beneﬁ t. Besides concerns on effectiveness(3), offering a 
lumbar support to people as a primary preventive measure, where people are not likely to 
experience beneﬁ t from it’s usage, is bound to be a waste of scarce health-care resources 
because of a poor adherence. For workers with recurrent back pain however, reducing prac-
tical hindrances by making sure that the support remains ﬁ xed during work for example, 
and creating sufﬁ cient social support for using the support within the organisation, are 
factors that may help to enhance adherence with the use of lumbar supports. 
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Appendix
Statements about lumbar supports:
Positive attitude
- A lumbar support is comfortable to use.
- It is easy to use.
- It supports my back when I have to lift something/ someone.
- It supports my back when I have to bend.
- It reminds me of my working posture.
- Using a lumbar support facilitates me to perform my job.
- The lumbar support remains placed properly during my work.
- It makes me feel safe to move.
- It makes my low back pain more bearable.
- Because of the lumbar support, I experience less back pain.
- Because of the lumbar support, my back pain relieves faster.
- Because of the lumbar support, I experience back pain less often.
Negative attitude
- A lumbar support restricts moving too much.
- Using a lumbar support is too warm.
- The pressure of the lumbar support on my ribs is irritating.
- It irritates my skin.
- It irritates my stomach.
- It is hard to go to the toilet with a lumbar support.
- It looks odd underneath tight clothing.
- (If applicable:) A lumbar support is unpleasant during my period.
Social support
- My manager thinks it is important to use the lumbar support when I experience low 
back pain.
- When I use a lumbar support, my colleagues think I pity myself.
- My clients think it is silly to use a lumbar support.
- My family and friends think it is good to wear a lumbar support.
- (If applicable:) My therapist/ GP discourages using a lumbar support.
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Self-effi cacy
How well do you manage…
… to put on the lumbar support? 
… to mind using it?
… to bring along the lumbar support?
… to wear it on warm days?
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This thesis primarily focuses on the role of lumbar supports to manage non speciﬁ c low 
back pain in a working population of home care workers with previous low back pain. This 
chapter intends to reﬂ ect on the main results in its entirety, general methodological limita-
tions, practical implications, and implications for future research of the studies presented in 
this thesis.  
Main results in perspective
In the studies described in Chapter 2 and 3, lumbar supports were found to be feasible, 
safe and cost-effective in reducing low back pain complaints for home care workers with 
previous low back pain, when administered in addition to usual care. The average number 
of days each worker experienced low back pain was reduced by 53 days per year (95%CI 
-60 to -45). This is a clinically relevant improvement of 45% when compared with the 
control group, against a statistically signiﬁ cant annual saving in direct low back pain related 
costs of on average €235 per person (95%CI -386 to -79). 
Despite the reduced low back pain, use of lumbar supports did not statistically signiﬁ cantly 
decrease total work absenteeism (-5 days per year; 95%CI -21.1 to 6.8), and the associated 
indirect costs (€-255; 95%CI -879 to 299). 
The secondary outcome measures, functional status, severity of low back pain and self-
reported low back pain related absenteeism, were all in favour of using a lumbar support 
as a secondary preventive aid. 
The clinical results are difﬁ cult to compare with other published studies on lumbar supports. 
To our knowledge, this still is the only secondary preventive study on this topic available. 
In the recently updated Cochrane review on the effectiveness of lumbar supports which 
incorporated our randomise controlled trial(1), it was stated that the included studies were 
heterogeneous with regard to study populations, interventions and outcomes. Therefore 
the study results were not pooled in a meta-analysis. The review concluded that there was 
limited evidence that lumbar supports plus usual care reduce the number of days with LBP 
and improve functional status in the long-term better than usual care alone, but are not 
better at reducing sick leave. Adding two curative studies, which were recently published 
and (independently) conducted parallel to ours(2, 3) does not alter our solitary position. 
For the cost-effectiveness ﬁ ndings, there is no study to compare with either. A signiﬁ -
cant decrease in overall costs of medical treatment is mentioned in one publication(2) and 
another study mentioned an insigniﬁ cant effect on overall use of healthcare services(4). 
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However, these ﬁ ndings were not valorised in monetary units. 
If we compare our clinical ﬁ ndings with other studies on lumbar supports for low back pain, 
skating on thin ice, our results are remarkably positive towards administering a lumbar sup-
port. Possible explanations for this difference from other ﬁ ndings are (I) the use of calendars 
to measure low back pain, (II) the secondary preventive approach and (III) the chosen study 
population of home care workers, as these three factors may have led to clearer results, as 
explained below. 
 I) Low back pain calendars
The use of calendars, on which workers could mark daily whether they had experienced 
low back pain, was perhaps more sensitive for measuring recurrent and ﬂ uctuating low 
back pain episodes than the commonly used questionnaires, which for example ask about 
the number of episodes and number of days low back pain in the previous three months. 
With the commonly used questionnaires possible effects therefore may have been unde-
restimated because of recall bias. This assumption is supported by the measured secondary 
low back pain outcomes of the trial. For example, functional status, measured with the 
Quebec Back Pain Disability Scale at baseline, 3, 6, 9, and 12 months showed a difference 
between the control and intervention group of 14% “only”. 
 II) Secondary prevention – adherence
Offering a lumbar support as a secondary preventive intervention probably has enhanced 
adherence/ compliance to its usage in our study, in which 78% of the workers in the inter-
vention group was found to be adherent. 
Adherence may act as a strong confounder for studying the effectiveness of lumbar sup-
ports(5). If reported, adherence to the use of lumbar supports has in general been low in 
previous studies(1). A poor adherence to the intervention causes uncertainty of potential 
effects: Is effectiveness underestimated because of non-adherence? Or is the intervention 
ineffective, but can one not be certain because of non-adherence? 
The secondary preventive approach in our study has likely enhanced adherence because only 
workers with a history of previous low back pain episodes were included. This selected a 
population that could expect a potential short term health gain, which is important for consi-
dering the intervention(6). From my single case primary preventive experiment with a lumbar 
support, I must admit that I would not use one without apparent reason. Having been pain 
free until now, I would prefer to get low back pain some day, from which I am likely to suffer 
only a week or so, than preventively being bothered every day by a lumbar support. 
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In this study, the home care workers were asked to wear a lumbar support on those wor-
king days they experienced or expected to experience low back pain, instead of using one 
all the time, which was common in other studies. In this way, hindrance and discomfort 
for home care workers was kept to the minimum. Our ﬁ nding that impeding determinants 
for prolonged lumbar support usage are outweighed by perceived beneﬁ cial determinants 
(Chapter 6), supports the assumption that we might have had clearer effects because of 
sufﬁ cient adherence. Reducing practical barriers by making sure that the support remains 
ﬁ xed during work for example, and creating sufﬁ cient social support for using the support 
within the organisation, are other factors that may help to enhance adherence with the use 
of lumbar supports.
 III) Mechanism of action – chosen study population
The effects of a lumbar support on low back pain could also have been more pronounced 
because we chose to study their effect for home care workers. Apart from the high inci-
dence of low back pain among them(7-9) and the known feasibility(10), the type of work lends 
itself for the use of lumbar supports in regard to the possible mechanism of action. 
Possible mechanisms of action were studied earlier in a systematic review(11). The only 
mechanism supported by evidence was that lumbar supports restrict trunk range of motion 
(ﬂ exion, extension and lateral bending). Often quoted intra-abdominal pressure and back 
muscle force does not seem to be inﬂ uenced by a lumbar support. This pleads for usage in 
physical active working conditions, like home care, instead of in passive or static working 
conditions when studying the effectiveness of lumbar supports. A lumbar support then can 
aid as a reminder for preventing extreme working postures. However, the pilot study with 
ambulant accelerometry on the effect of lumbar supports on trunk motion during work did 
not provide evidence for this mechanism (Chapter 5). 
Usual care
The systematic review on the medical treatment of low back pain in usual care (Chapter 4), 
endorses current guidelines for the management of low back pain – i.e. consider acetami-
nophen/ paracetamol as treatment option before NSAIDs. In both the intervention and the 
control group, medication was the most frequently utilised health care resource (Chapter 
3). We found in the review that there was moderate evidence that NSAIDs are not more 
effective than acetaminophen for acute low-back pain, but acetaminophen had fewer side 
effects. NSAIDs were more effective than placebo, but differences in effect were small and 
were at cost of more side effects. The evidence that various types of NSAIDs, including the 
relative new selective COX-2 inhibiting NSAIDs, were equally effective for acute low-back 
pain was strong. COX-2 NSAIDs had statistically signiﬁ cantly fewer side-effects than tradi-
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tional NSAIDs. However, evidence from other study populations (not involving treatment 
of low back pain) have brought the safety of COX-2 NSAIDs to the attention because of 
increased risk for serious gastrointestinal and cardiovascular adverse events(12). Unfortuna-
tely, implementing guidelines also is a difﬁ cult process of changing human behaviour(13), 
and NSAIDs still seem to be ﬁ rst choice in many patients(14).
General methodological limitations
In this paragraph, general limitations are addressed for the following topics: blinding, 
measuring sick leave, and missing data. For study speciﬁ c methodological limitations, 
we refer to the discussion section of the corresponding chapter. 
Blinding
Inevitably, in a pragmatic randomised clinical trial like ours it is not possible to blind the 
participants for the treatment. Even a sham support may fulﬁ l the hypothesised mechanism 
of action, and remind workers of extreme trunk positions. The inability to blind the home 
care workers may have contributed to the observed effects because of measurement bias. 
Especially because most outcomes were self-reported measures through questionnaires, and 
before randomization most home care workers had positive expectations of using a lumbar 
support. As a result, workers in the control group may have exaggerated their complaints 
as they were disappointed about not having received a lumbar support yet. However, we 
consider it unlikely that one would over-report (when assigned to the control group), or 
under-report (when assigned to the intervention group) consequently for a whole year on 
all measured outcomes. But the lack of deﬁ nitive conclusions on the number of days total 
sick leave, the only external outcome measure, asks for carefulness when interpreting the 
self-reported outcomes. 
In future secondary preventive studies, perhaps measurement of self-reported outcomes 
over a baseline period in addition to the usual random indication of back ground variables, 
may aid in addressing blinding issues. Measuring over a baseline period would expand the 
possibilities to interpret answering tendencies before and after randomisation. On the other 
hand, prolonged measuring demands more effort from the population under study and 
therefore may increase difﬁ culties because of missing data during the follow-up period. 
Sick leave
Although it was the only outcome measure which was not self-reported, sick leave 
probably was not the most convenient outcome measure as well. Because a valid sick 
leave registration by diagnosis was lacking, only general data on total sick leave could be 
Proefschrift Binnen_2.indd   153 28-12-2009   17:52:26
 154 General discussion
gathered. This is a common issue when studying short-term absenteeism in the Nether-
lands, as Dutch workers are not obliged to specify for which health problem they report 
themselves ill. It is doubtful if total sick leave has been sensitive enough to measure the 
effects of an intervention aimed at reducing recurrent low back pain. Besides, we may have 
aimed a little high. In other studies, about 14- 23% of all sick leave is low back pain rela-
ted(15, 16). Assuming that 23% of the on average 45 days sick leave per year (SD 67 days) in 
our study was low back pain related, implies that we aimed in our power calculation on a 
70% reduction of absenteeism attributed to low back pain, by the use of a lumbar support. 
Alternatively, combining external sick leave data with self-reported diagnoses could solve 
this issue in future research. If strong cooperation with the organisation(s) under study is 
possible, the sick leave registration could be supplemented by timely in person contact with 
an email or phone call to the respondent, asking whether or not their cause for reporting ill 
was low back pain related. 
Missing data
Workers leaving the study, sloppy ﬁ lled-in questionnaires or even totally forgotten ones led 
to an other common problem related to self-reported measures with questionnaires: missing 
or incomplete data. To illustrate the issue, in total 1297 reminder letters were sent, an aver-
age of 3.6 per worker, and for the low back pain calendars for example, on average data 
was collected for 8.7 out of a possible 11 months (delays in the in-company postal service 
and delays in measuring the participants for the right size of lumbar support shortened the 
actual follow up period). All data were collected with paper questionnaires, which were di-
gitised and processed by a computer, and we lacked manpower to pursue incomplete data. 
However, from the sensitivity analyses on complete cases, worst case scenarios and multiple 
imputed data sets(17) we assume that missing data has not distorted the results. The missing 
data neither caused a problem with the statistical power of the analyses. 
New studies with limited resources like ours can proﬁ t from technological advances. Nowa-
days in home care for example, portable devices like personal digital assistants and smart-
phones are common logistic aids. The potential of using these in scientiﬁ c research is great 
when you think of electronic reminding, real time feed back on incomplete or impossible 
answers and so on. 
Practical implications and (remaining) implications for research
The studies in this thesis have shown that lumbar supports as a secondary preventive aid 
probably are a valuable addition to the usual management options available for low back 
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pain in an occupational setting. At present, lumbar supports may well be used in home 
care: they are likely more effective at lower costs, safe and feasible. However, at this 
moment evidence is limited to one single study in a predominantly female population. 
Preferably, additional secondary preventive studies in mixed/ male populations(18, 19) and 
other physical active working situations should be conducted to provide more evidence. On 
the other hand, there are no arguments not to prescribe a lumbar support for the secondary 
prevention of low back pain in other physical active settings as well.
Furthermore, clarity is needed about the effect of lumbar supports on trunk postures during 
work. Especially now the sensors technically are advancing and have become available 
by mass production for the computer game industry, ambulatory measurement has high 
potential. We recommend to validate the measurement of body postures during work and 
determine clinical relevant changes ﬁ rst.
Finally, more in general this thesis has shown secondary prevention seems to be feasible. 
For the needed paradigm shift towards an integrated preventive health care system, as 
promoted by the World Health Organisation(20), secondary preventive interventions should 
be considered whenever preventive interventions involve great changes in individual health 
behaviour, and the health issue at matter, for example in terms of reversibility, makes 
secondary prevention possible and sensible. This might help saving scarce health care 
resources for the upcoming greying decennia(21), otherwise spend on patronizing interventi-
ons hardly affecting the general population. 
What this thesis adds.
-  For home care workers with recurrent low back pain, a lumbar support is a cost-effective 
secondary preventive intervention in addition to usual care. 
-  Guidelines for the treatment of non-speciﬁ c low back pain are endorsed regarding the medical 
treatment options: consider acetaminophen/ paracetamol before prescribing NSAIDs. 
-  The effect of lumbar supports on trunk postures during work should be further explored. 
Ambulatory measurements are feasible and have high potential. 
-  Perceived beneﬁ t is the strongest predictor for prolonged use of lumbar supports as a secondary 
preventive aid, and outweighs impeding determinants. 
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Low back pain is a common disorder in industrialised countries. The chance that someone 
may experience low back pain during her/ his life is 49 to 70%. In most cases (80-95%) 
there is no identiﬁ able pathophysiological origin, which is often labelled as non-speciﬁ c 
low back pain. The prognosis for non-speciﬁ c low back pain is usually good, as complaints 
improve rapidly within weeks, but recurrences are common. Guidelines on the management 
of non-speciﬁ c low back pain recommend to: reassure that the low back pain is likely to 
resolve rapidly; advise to stay active and continue daily activities; if necessary, supported by 
prescribing analgesics. When complaints persist over six weeks, guided activating therapies 
are considered. 
Certain working populations, like health care workers, suffer even more often from low 
back pain. To prevent low back pain, workers can use lumbar supports. However, lumbar 
supports seem not effective as primary preventive intervention. Secondary analyses from 
primary preventive studies suggest beneﬁ t among workers with previous low back pain, 
but deﬁ nitive studies on the effectiveness of lumbar supports for the secondary prevention 
of low back pain were lacking.
To determine the secondary preventive effectiveness of lumbar supports for low back pain, 
a randomised controlled trial was conducted (Chapter 2). 360 home care workers with self-
reported history of low back pain received usual care, comprising a short course on healthy 
working methods, with or without patient-directed use of one of four types of a lumbar 
support. Primary outcomes were the number of days of low back pain and sick leave over 
12 months. Over 12 months, participants in the lumbar support group reported an average 
of 52.7 days (95%CI, −59.6 to −45.1 days) fewer days with low back pain than partici-
pants who received usual care only. However, the total sick days in the lumbar support 
group did not decrease statistically signiﬁ cantly (−5 days; 95%CI, −21.1 to 6.8 days). Limi-
tations of the study were unblinding of the participants, incomplete or missing data and the 
lack of objective data on sick days due to low back pain. From the results of the randomised 
controlled trial it was concluded that patient-directed use of lumbar supports may reduce 
the number of days on which low back pain occurs, but not overall work absenteeism, 
among home care workers with previous low back pain. There is a need for more evidence 
to conﬁ rm these ﬁ ndings, also in other working populations.
Apart from the physical complaints, low back pain is an economical burden to society. 
To assess the cost-effectiveness of wearing a lumbar support for home care workers with 
recurrent low back pain, an economic evaluation (Chapter 3) from a societal perspective 
was conducted alongside the previously mentioned 12-month randomised controlled trial. 
For this cost-effectiveness study, direct costs, indirect costs and quality of life (EuroQol) 
were measured by means of cost diaries in addition to the self-reported days with low back 
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pain and calendar days sick leave in general. Differences in mean costs between groups, 
cost-effectiveness, and cost-utility ratios were evaluated, and cost-effectiveness planes 
and acceptability curves presented by applying non-parametric bootstrapping techniques. 
During the intervention period direct costs were € 235 lower (95% CI -386 to -79) for the 
home care workers using a lumbar support in addition to usual care. Indirect costs were not 
statistically signiﬁ cantly lower (€-255; 95% CI -879 to 299). There were no differences in 
quality of life. In conclusion, lumbar support seem a cost-effective addition to usual care for 
home care workers with recurrent low back pain. For estimating the indirect costs it would 
have been more precise when an objective measure for low back pain related sick leave 
would have been available. 
In the study population of the randomised controlled trial described in chapter 2 and 3, 
medication was the most common treatment option within usual care. Non-steroidal anti-
inﬂ ammatory drugs (NSAIDs) are the most frequently prescribed medications worldwide 
and account for 80% of the prescriptions for patients with low-back pain. We performed a 
systematic Cochrane review (Chapter 4) to assess the effectiveness of NSAIDs and selective 
COX-2 inhibitors currently available and used for patients with low-back pain. Therefore 
the MEDLINE and EMBASE databases and the Cochrane Central Register of Controlled 
Trials were searched up to and including June 2007 if reported in English, Dutch or German. 
We also screened references given in relevant reviews and identiﬁ ed trials. Randomised 
trials and double-blind controlled trials of NSAIDs in non-speciﬁ c low-back pain with or 
without sciatica were included. In total, 65 trials (total number of patients = 11,237) were 
included in this review. Twenty-eight trials (42%) were considered high quality. Statistically 
signiﬁ cant effects were found in favour of NSAIDs compared to placebo, but at the cost of 
statistically signiﬁ cant more side effects. There was moderate evidence that NSAIDs are not 
more effective than paracetamol for acute low-back pain, but paracetamol had fewer side 
effects. There was moderate evidence that NSAIDs are not more effective than other drugs 
for acute low-back pain. There was strong evidence that various types of NSAIDs, including 
COX-2 NSAIDs, are equally effective for acute low-back pain. COX-2 NSAIDs had statisti-
cally signiﬁ cantly fewer side-effects than traditional NSAIDs. The evidence from the 65 trials 
included in this review suggests that NSAIDs are effective for short-term symptomatic relief 
in patients with acute and chronic low-back pain without sciatica. However, effect sizes 
are small. Furthermore, there does not seem to be a speciﬁ c type of NSAID which is clearly 
more effective than others. The selective COX-2 inhibitors showed fewer side effects com-
pared to traditional NSAIDs in the RCTs included in this review. However, in recent studies 
COX-2 inhibitors are associated with increased serious cardiovascular risks in speciﬁ c patient 
populations.
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Returning to the lumbar support, another aspect of it was explored. Currently, the potential 
mechanisms of action of lumbar supports are still under debate. We explored the possible 
inﬂ uence of lumbar supports on working postures of home care workers with ambulatory 
accelometry (Chapter 5). In this pilot study, the rate of occurrence and duration of working 
postures of seven maternity nurses were monitored for two consecutive working days with 
an Activity Monitor. Randomly assigned, the workers used a lumbar support on either the 
ﬁ rst or second day. On average, the working postures were monitored for 9 hours per day. 
They were not hampered by the Activity Monitor in performing their job. The rate of occur-
rence and duration of working postures above 30° trunk ﬂ exion all tended to be less on the 
day the subjects used a lumbar support, while the rate of occurrence and duration of trunk 
postures less than 30° increased. Statistical signiﬁ cance of the differences between the 
working day with or without lumbar support was not reached in this small sample. Thus, 
lumbar supports seem to inﬂ uence the working posture of home care workers. In future 
research, there is a high potential in ambulatory measuring working postures with ambula-
tory accelerometry. 
Implementing a lumbar support as a secondary preventive aid, involves behavioural change 
of its users. To target the use of lumbar supports on those persons who can beneﬁ t opti-
mally from usage, we need to know why people are adherent. We used the attitude, 
social support and self-efﬁ cacy model, which is developed to explain health behaviour, to 
identify determinants for prolonged adherence to wearing a lumbar support in the interven-
tion group of the randomised controlled trial (Chapter 6). In the multivariable model, the 
strongest predictor for the intention for sustained use of a lumbar support was a positive 
attitude towards lumbar supports, explaining 41% of the variance (B= 1.31; p< .001). 
Social support and self efﬁ cacy both explained 2% of the variance, of which only the lat-
ter was statistically signiﬁ cant (B=0.22; p<.05). In conclusion, the intention for prolonged 
use of a lumbar support for workers with recurrent back pain was mainly explained by a 
positive attitude. The discomfort of a lumbar support was outweighed by perceived beneﬁ t. 
Reducing practical hindrances and creating sufﬁ cient social support for using the support 
within the organisation, are factors that may help to enhance adherence with the use of 
lumbar supports.
Finally, Chapter 7 reﬂ ects on the described studies in this thesis. Results, limitations, practi-
cal implications, and implications for future research of the described studies are integrated, 
and put in the context of other research in this area. In this, amongst others the following 
topics are addressed: low back pain calendars to measure low back pain; measuring sick 
leave; missing data; blinding; secondary prevention and health behaviour; and home care 
as research setting.
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De behandeling van lage rugpijn met ruggordels en medicatie
Lage rugpijn is een veelvuldig voorkomend probleem in geïndustrialiseerde landen. De 
kans dat iemand gedurende zijn leven een episode van lage rugpijn doormaakt is 49-70%. 
Meestal (80-95% van de gevallen) is er geen sprake van een pathofysiologische oorzaak, 
ook wel aspeciﬁ eke lage rugpijn genoemd. De prognose voor aspeciﬁ eke lage rugpijn is 
meestal goed, daar de klachten over het algemeen binnen enkele weken verbeteren, maar 
de klachten keren vaak terug. Richtlijnen voor de behandeling van aspeciﬁ eke lage rugpijn 
adviseren om: de patiënt gerust te stellen met het feit dat de klachten over het algemeen 
snel verminderen; de patient te stimuleren actief te blijven en dagelijkse werkzaamheden zo 
veel mogelijk voort te zetten; en zo nodig pijnstillende medicatie aan te bieden. Wanneer 
de klachten aanhouden over een periode van zes weken, worden begeleidende activerende 
therapievormen overwogen. 
Bepaalde beroepsgroepen, bijvoorbeeld in de zorg, lopen een verhoogd risico op lage 
rugpijn. Ter preventie van deze rugpijn kunnen ruggordels gebruikt worden. Echter, rug-
gordels lijken niet effectief als primair preventief hulpmiddel. Secundaire analyses uit primair 
preventieve studies lieten wel gunstige effecten zien bij werknemers met terugkerende lage 
rugpijn, maar onderzoek gericht op de secundaire preventie van lage rugpijn ontbrak. 
Om de secundair preventieve effectiviteit van ruggordels te bepalen is er een gerandomi-
seerd en gecontroleerd experiment uitgevoerd (Hoofdstuk 2). 360 thuiszorgmedewerkers 
met zelfgerapporteerde lage rugpijn ontvingen de standaard beschikbare zorg, welke 
ondermeer een arbeidsomstandigheden training omvatte over gezonde werkhoudingen, 
met of zonder gebruik van een van de vier beschikbare typen ruggordel. Primaire uitkomst-
maten waren het aantal dagen met rugpijn en ziekteverzuim over 12 maanden. Gedurende 
de 12 maanden rapporteerden de deelnemers met een ruggordel gemiddeld 52,7 dagen 
(95%BI, -59,6 tot -45,1) minder lage rugpijn dan de deelnemers die alleen de standaard 
beschikbare zorg ontvingen. Het aantal dagen ziekteverzuim daalde niet statistisch signi-
ﬁ cant (-5 dagen; 95%BI, -21,1 tot 6,8 dagen). Beperkingen van de studie waren: het niet 
geblindeerd zijn van de deelnemers, onvolledige of missende gegevens, en het ontbreken 
van objectieve gegevens voor lage rugpijn gerelateerd ziekteverzuim. Volgens de resultaten 
van het gerandomiseerde en gecontroleerde experiment lijkt het dragen van een ruggordel 
door thuiszorgmedewerkers met recidiverende lage rugpijn het aantal dagen met rugpijn 
te verminderen, maar heeft dit geen invloed op het totale ziekteverzuim. Deze resultaten 
zouden verder onderzocht moeten worden, ook in andere beroepsgroepen. 
Naast het persoonlijke fysieke ongemak drukt lage rugpijn een grote economische stempel 
op de maatschappij. Om de kosteneffectiviteit te onderzoeken van het dragen van ruggordels 
Proefschrift Binnen_2.indd   164 28-12-2009   17:52:28
 Samenvatting 165
door thuiszorgmedewerkers met recidiverende lage rugpijn, is parallel aan het hierboven 
genoemde gerandomiseerde en gecontroleerde experiment een economische evaluatie 
vanuit een maatschappelijk perspectief (Hoofdstuk 3) uitgevoerd. Voor deze kosteneffec-
tiviteitstudie werden met kostendagboeken aanvullend de directe kosten, indirecte kosten 
en kwaliteit van leven (EuroQol) gemeten. Verschillen in gemiddelde kosten tussen de 
groepen, kosteneffectiviteit en kostenutiliteit ratio’s werden geëvalueerd en kosteneffectivi-
teitgraﬁ eken en aanvaardbaarheid curven werden gepresenteerd op basis van niet parame-
trische bootstrap technieken. In de interventieperiode van 12 maanden waren de directe 
kosten €235 lager (95%BI, -386 tot -79) voor de thuiszorgmedewerkers die als aanvulling 
op de standaard beschikbare zorg een ruggordel droegen. Indirecte kosten waren niet 
statistisch signiﬁ cant lager (€-255; 95%BI, -879 tot 299). Er was geen verschil in kwaliteit 
van leven. Concluderend, lijken ruggordels een kosteneffectieve aanvulling op de standaard 
beschikbare zorg voor thuiszorgmedewerkers met recidiverende rugklachten. Voor het 
schatten van de indirecte kosten zou het meer accuraat zijn wanneer er een objectieve maat 
voor lage rugpijn gerelateerd ziekteverzuim voorhanden was geweest.
In de studiepopulatie van de in hoofdstuk 2 en 3 beschreven gerandomiseerde en gecon-
troleerde studie, was medicatie de meest toegepaste behandeloptie binnen de standaard 
beschikbare zorg. NSAIDs (non-steroïde ontsteking remmende medicijnen) zijn wereld-
wijd de meest voorgeschreven medicijnen en vormen ook voor lage rugpijn 80% van de 
voorgeschreven medicatie. We hebben een systematische Cochrane review (Hoofdstuk 
4) uitgevoerd om de effectiviteit van NSAIDs en selectieve COX-2 remmers te onderzoe-
ken die momenteel beschikbaar zijn en gebruikt worden door patiënten met lage rugpijn. 
Daarvoor zijn de MEDLINE en EMBASE databases en het Cochrane Central Register of 
Controlled Trials doorzocht op publicaties tot en met juni 2007, in Engels, Nederlands of 
Duits. Daarbij zijn ook de literatuurlijsten van relevante reviews en geïdentiﬁ ceerde stu-
dies gescreend. Gerandomiseerde en dubbel blind gecontroleerde studies naar NSAIDs 
voor aspeciﬁ eke lage rugpijn met of zonder ischias werden geïncludeerd. In totaal werden 
65 studies (totaal aantal patiënten = 11.237) geïncludeerd in deze review. Achtentwintig 
daarvan (42%) werden van hoge kwaliteit beschouwd. NSAIDs waren statistisch signiﬁ cant 
effectiever dan placebo’s, echter ten koste van statistisch signiﬁ cant meer bijwerkingen. Er 
was matig sterk bewijs dat NSAIDs niet effectiever zijn dan paracetamol tegen acute lage 
rugpijn, maar paracetamol had minder bijwerkingen. Met matig sterke bewijskracht lijken 
NSAIDs niet effectiever dan andere medicijnen tegen acute lage rugpijn. Er was sterk bewijs 
dat de verschillende typen NSAIDs, inclusief de COX-2 NSAIDs, even effectief zijn tegen 
acute lage rugpijn. De COX-2 NSAIDs hadden statistisch signiﬁ cant minder bijwerkingen 
dan de traditionele NSAIDs.
Het bewijs uit de 65 geïncludeerde studies suggereert dat NSAIDs voor de korte termijn 
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effectief de symptomen verlichten van patiënten met acute of chronische lage rugpijn zon-
der ischias, maar de grootte van de effecten is echter klein. Daarbij lijkt er niet een speciﬁ ek 
beter type NSAID te zijn dat zich onderscheidt van andere. De selectieve COX-2 inhibitors 
vertoonden binnen de studies uit deze review minder bijwerkingen dan de traditionele 
NSAIDs. Echter, in recent onderzoek zijn COX-2 inhibitors geassocieerd met een verhoogde 
kans op ernstige cardiovasculaire bijwerkingen in speciﬁ eke patiënten populaties. 
Terugkerend naar de ruggordel, werd hiervan in het volgende hoofdstuk het werkings-
mechanisme verkend. Op dit moment staat het werkingsmechanisme van ruggordels nog 
ter discussie. We hebben de mogelijke invloed van ruggordels op de werkhouding van 
thuiszorgmedewerkers verkend met ambulante accelerometrie (Hoofdstuk 5). In deze pilot 
studie werd de frequentie en duur van werkhoudingen van zeven kraamhulpen gedu-
rende twee opeenvolgende dagen geregistreerd met een Activiteiten Monitor. Door het lot 
bepaald, droegen de medewerkers de eerste of de tweede dag een ruggordel. Gemiddeld 
werden de werkhoudingen negen uur per dag geregistreerd. Ze werden niet in hun werk-
zaamheden gehinderd door de Activiteiten Monitor. De frequentie en duur van werkhou-
dingen met meer dan 30° ﬂ exie in de romp neigden te verminderen wanneer de ruggordel 
gedragen werd, terwijl de frequentie en duur van werkhoudingen met minder dan 30° 
buiging vermeerderden. Statistische signiﬁ cantie voor het verschil tussen de dag met of 
zonder ruggordel werd in deze kleine steekproef niet bereikt. De ruggordels lijken dus de 
werkhouding te beïnvloeden. Ambulante accelerometrie heeft veel potentie voor het meten 
van de werkhoudingen. 
Het implementeren van ruggordels als secundair preventief hulpmiddel vraagt om gedrags-
verandering van de gebruikers. Om de ruggordels bij de juiste doelgroep te implementeren 
is het noodzakelijk om te weten waarom men therapietrouw is aan het gebruik ervan. 
We hebben het attitude, sociale steun en eigeneffectiviteit (ASE-)model, dat ontwikkeld 
is voor het verklaren van gezondheid gerelateerd gedrag, gebruikt om de determinanten 
voor blijven dragen van de ruggordel te onderzoeken (Hoofdstuk 6). Dit onderzoek werd 
uitgevoerd in de interventiegroep van het eerder beschreven gerandomiseerde experiment. 
In het multivariabele model was een positieve attitude naar de ruggordel de sterkste voor-
speller, welke 41% van de variantie verklaarde (B= 1,31; p< ,001). Sociale steun en eigen 
effectiviteit verklaarden beiden 2% van de variantie, waarvan alleen de laatste 
statistisch signiﬁ cant was (B=0,22; p<,05). Uit dit onderzoek kan geconcludeerd worden 
dat het voornemen om de ruggordel te blijven gebruiken door werknemers met terugke-
rende lage rugpijn voornamelijk werd bepaald door een positieve attitude. Het ongemak 
van de ruggordel werd door de ervaren voordelen overschaduwd. Het reduceren van 
praktische ongemakken en het creëren van voldoende sociale steun op de werkvloer, 
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zijn factoren die de therapietrouw voor het dragen van een ruggordel zouden 
kunnen verhogen. 
Tot slot reﬂ ecteert Hoofdstuk 7 op de in dit proefschrift beschreven studies. Resultaten, 
beperkingen, praktische implicaties, en implicaties voor vervolgonderzoek van de beschre-
ven studies worden geïntegreerd en in de context van andere onderzoeksresultaten op dit 
gebied geplaatst. Hierin worden ondermeer de volgende onderwerpen aangekaart: lage 
rugpijn kalenders voor het meten van lage rugpijn; het meten van ziekteverzuim; missende 
data; blindering; secundaire preventie en gezondheid gerelateerd gedrag; en de thuiszorg 
als onderzoekssetting.
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Als kind genoot ik al van het onderzoeken van alles in mijn omgeving, al werden de resul-
taten niet altijd in dank afgenomen. Ook het onderzoek dat heeft geleid tot dit proefschrift 
heeft mijn nieuwsgierigheid bevredigd. Zelfs toen ik een deel in eigen tijd heb moeten 
uitvoeren. Het was inspirerend om meermaals te ervaren hoe gezamenlijke inspanningen 
boven de individuele bijdragen uitstegen. Daar wil ik veel mensen voor bedanken. 
Bedanken voor hoe en wat precies is vaak minder belangrijk, maar strekt in mijn dankwoord 
van directe inhoudelijke inbreng of faciliteren tot noodzakelijke aﬂ eiding of relativeren. 
Echter kan de volgorde van namen in het meest bekeken deel van menig proefschrift als 
heikel punt opgevat worden. Daarom mijn gerandomiseerde dankwoord (de namen staan 
er op willekeurige volgorde in; de spreadsheet is bij mij thuis in te zien) waarin onverhoopt 
namen zullen ontbreken: 
Natuurlijk. Er zaten ook minder leuke kanten aan. Het vervelendste was een gebrek aan 
aandacht/ toewijding voor andere belangrijke dingen in het leven. Iedereen die mij daar 
ruimte voor gegeven heeft, nogmaals dank!
Pepijn
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